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The introduction of antibiotics in medicine revolutionised the treatment of common 
bacterial infections. However, bacteria have overcome the obstacles imposed by these 
compounds via several mechanisms. As a consequence, they are rapidly becoming 
resistant and we are now entering a post-antibiotic era, whereby all clinically used 
antibiotics will soon become obsolete. A group of pathogens, known as the ESKAPE 
pathogens, have been identified as those that give rise to the most infections in hospitals 
and effectively “escape” the effects of antibacterial drugs. Patients that are 
immunocompromised and in the intensive care units are most at risk. There is now a 
dire need for new antibiotics with unexplored mechanisms of action. 
The process of bacterial DNA replication is a vital function for bacterial survival that 
has many unexploited targets for new antibiotics. One such target is the bacterial !2-
sliding clamp. This is a toroid protein that encircles DNA, and slides along the DNA 
during the replication and repair processes. It is a protein-protein interaction hub that 
acts as a mobile tether for polymerases to synthesise the nascent complementary DNA 
strands prior to cell division. Without the DNA replicated, bacteria are unable to divide 
and cannot propagate. 
The mechanism of the protein partners interacting with the sliding clamp has been 
extensively characterised using the Escherichia coli !2-sliding clamp. Each partner 
protein contains a conserved amino acid sequence, QLx1Lx2F/L (S/D preferred at x1; x2 
may be absent) that binds a specific pocket on the sliding clamp surface. This pocket is 
a target for the development of new antibiotics, and using fragment-based screening, 
lead scaffolds have been identified. To date, our knowledge of the structure and 
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function of the !2-sliding clamp from other bacterial homologues is poor. There are 
homologues of the !2-sliding clamp found in humans and bacteriophages. While these 
are structurally and functionally similar to bacterial !2-sliding clamps, there are 
variations amongst the number of protomers, and the interaction with respective binding 
partners; particularly, the linear motif recognised by protein binding partners and the 
structure of the interaction site. It is therefore hypothesised that any inhibitor developed 
for the bacterial !2-sliding clamp will not inhibit the function of the human homologue. 
This Thesis reports on the structure and function of !2-sliding clamps from a subset of 
the ESKAPE pathogens, and demonstrates their high degree of conserved peptide 
binding and inhibition with the lead inhibitor scaffolds. The crystal structure of !2-
liding clamps from Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter 
cloacae, and Enterococcus faecium have been determined and the binding pockets and 
dimerization interfaces have been characterised. Fluorescence polarization and 
molecular dynamics simulations have determined that the conserved linear motif, 
QLDLF, interacts with the pocket using the same mechanism of interaction as with the 
E. coli !2-sliding clamp. Fluorescence polarization also showed that the lead scaffolds 
were able to inhibit the linear motif-!2-sliding clamp interaction and did not interact 
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1.1!EMERGENCE OF “SUPERBUGS” 
 
The idea of a “magic bullet” to selectively target disease-causing microbes was first 
introduced by Paul Ehrlich.1,2 Together with Alfred Bertheim and Sahachiro Hata, the 
compound Arsphenamine (a derivative of the toxic drug Atoxyl) was derived that cured 
syphilis-infected rabbits.1,3 The systematic screening approach used by Ehrlich was 
employed by Bayer chemists who, along with Gerhard Domagk, identified the first 
active antibacterial drug in 1935, the sulfonamide antibiotic Prontosil.4 Alexander 
Fleming discovered the antibacterial activity of Penicillin in 19285 and in doing so, 
identified a new method of screening using inhibition zones in bacterial lawns on agar 
plates.6 The synthesis and purification protocol developed by Howard Florey and Ernest 
Chain in 19407 eventually lead to mass production and distribution of Penicillin by 
1945. Since then, several classes of antibiotics have become commercially available that 
target different essential bacterial cellular processes, such as cell wall synthesis and 
protein synthesis.8 However, antibiotic resistance is an ever-increasing worldwide 
phenomenon and since the introduction of antibiotics, multi-drug resistant strains of 
bacteria, termed “superbugs”, have emerged.  
 
 
1.1.1! ESKAPE pathogens 
The presence of multi-drug and pan-drug resistant bacteria in the hospital environment 
has lead to the infection of compromised patients in intensive care units, threatening 
patient health, increasing the lengths of hospital stays and increasing hospitalisation 
costs. The bacterial species of greatest concern have become known as the ‘ESKAPE’ 
pathogens, comprising of Enterococcus faecium, Staphylococcus aureus, Klebsiella 
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pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter spp.9-11 These pathogens cause nosocomial infections, such as bacteremia, 
sepsis and pneumonia, and comprise approximately 40% of clinically isolated bacteria 
from patients.9 They are able to escape common antibacterial treatments to survive in 
the hospital environment through a variety of mechanisms (Table 1.1).12  
Several of the ESKAPE pathogens are Gram-negative bacteria, for which new classes of 
antibiotics to treat these infections have not been introduced in over 40 years.13 These 
bacteria are rapidly becoming pan-drug resistant and multi-drug resistant, and 
community-acquired infections from these pathogens are on the rise.14 Conversely, 
there have been four classes of antibiotics introduced since 2000 targeting 
Gram-positive bacteria: oxazolidinones, lipopeptides, mutilins and fidaxomicin.15 This 
was after a 50 year “innovation gap” where no new classes of antibiotics were 
introduced. Unfortunately, resistance to these new classes has been observed. 
 
 
1.1.2! Evolution of resistance of ESKAPE pathogens  
Resistance in bacteria has occurred due to selective pressure from antibiotic use. The 
most common targets of antibiotics fall into five classes: cell wall synthesis, protein 
synthesis, RNA polymerase (RNAP) and DNA gyrase, folate metabolism and 
membrane structure. Resistance to these antibiotic targets occurs through a variety of 
mechanisms (Figure 1.1).16 For example, Gram-negative bacteria have developed 
resistance to the !-lactam classes of cell wall synthesis inhibitor by producing extended-
spectrum !-lactamases. These !-lactamases catalyse the degradation of the !-lactam 
ring in !-lactam-based inhibitors, such as carbapenems, cephalosporins and penicillins, 
 
  Table 1.1: Major mechanisms of resistance by ESKAPE pathogens identified for the different antibiotic classes. 
Inhibition Target/ 
Antibiotic Class 






















Tet family efflux pump 
MexAB-OprM efflux pump 
MLS B efflux pump 
AcrA efflux pump 
erm genes encode for 
enzymes that modify domain 
V of 235s rRNA 
 
E, S, K, A, P, Ent. 




S, K, Ent. 
 




















Modification of target site 
 
 





mecA encodes for foreign 
cPBP with reduced affinity 
to penicillins 
vanA operon mutates 
 
S, K, A, P, Ent. 
S, K, A, P, Ent. 






dipeptide form D-Ala-D-Ala 
















Point mutation in ParC 
subunit of Topisomerase IV 
and GyrA subunit of DNA 
Gyrase 
NorA  efflux pump 













Modification of target site 
 












OprH efflux pump 
 
S, K, A, P, Ent. 
 aE, E. faecium; S, S. aureus; K, K. pneumoniae; A, A. baumannii; P, P. aeruginosa; Ent., Enterobacter spp.; bESBL, extended-spectrum 
β-lactamases encoded by plasmid-mediated enzymes such as TEM-1 and SHV-1; cPBP, penicillin-binding proteins.  Information from 
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Figure 1.1: Schematic diagram identifying the four main mechanism of resistance and 
the main antibiotic targets. The antibiotic classes for each target are listed. Adapted 
from Chellat et al.16 
 
 
preventing the !-lactam from irreversibly inhibiting the enzyme transpeptidase —which 
is essential for cell wall synthesis.18,19 Bacteria can have genes introduced that encode 
efflux pumps, for example the MexAB-OprM complex in Pseudomonas aeruginosa, 
that physically remove antibiotics from cells.20 A third example is the mechanism for 
vancomycin resistance in Staphylococcus aureus and Enterococcus faecium. 
Vancomycin binds to the carboxy-terminal (C-terminal) D-Ala-D-Ala of the 
pentapeptide precursors of peptidoglycan, inhibiting the essential cross-linking step in 
cell wall synthesis and leading to cell lysis. Both Staphylococcus aureus and 
Enterococcus faecium contain the vanA operon that gives rise to a modified cell wall 
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glycopeptide (D-Ala-D-Lactate) for which vancomycin has a lowered affinity, allowing 
cross-linking to occur.21,22 Multi-drug resistant strains of the ESKAPE pathogens are 
prevalent in the clinical setting and pan-drug resistant strains have been identified in 
many Gram-negative bacteria including K. pneumonia, A. baumannii, and 
P. aeruginosa.23-28 
As the current situation stands, we are on the cusp of a “post-antibiotic era”, where the 
creation of new antibiotics is being far outweighed by the development of resistance to 
existing classes of antibiotics. Consequently, there is an urgent need for the 
development of antibiotic compounds with novel mechanisms of action, in particular 





1.2.1! DNA replication in Escherichia coli 
An underexploited group of drug targets are found among the bacterial DNA replication 
proteins that produce identical copies of a parental chromosome prior to cell division. 
Each daughter cell will then contain double-stranded DNA (dsDNA) comprised of one 
parental strand and one complementary nascent strand.29 An Escherichia coli 
chromosomal DNA molecule is comprised of ~4.6 million base pairs (Mbp),30 with the 
dsDNA molecule arranged as an antiparallel helical structure.31,32 To replicate this 
molecule requires a multitude of carefully orchestrated weak and strong interactions 
from a multiprotein machine known as the replisome.33-35 Prior to chromosomal 
replication, the initiation process must take place to establish the replication forks. 
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1.2.1.1!Initiation 
DNA replication is initiated by the DnaA protein, which recognises the origin of 
replication (oriC) site on the circular chromosome and unwinds the duplex DNA. 
Multiple molecules of DnaA bind to an A-T rich region near the oriC, and separate the 
dsDNA into the two template strands (Figure 1.2).36,37 Two copies of the primosome 
complex (consisting of the DnaB helicase, DnaC helicase loader and DnaG primase) are 
then recruited to the two single-stranded DNA (ssDNA) templates.38 The DnaB-DnaC 
complexes encircle the two templates,39 and the DnaC helicase loaders dissociate upon 
association of DnaG primase to the DnaB helicase.40 The DnaB helicase, a RecA-type 
ATPase molecular motor, unwinds the parental duplex DNA and the primase 
synthesises the short RNA primers, one for the leading strand and one for each Okazaki 
fragment synthesised on the lagging strand.41-44 The primed DNA allows for recruitment 
of the replisome to begin the elongation of DNA, which is bidirectional.45 The 




The E. coli replisome has been extensively studied and contains thirteen types of 
proteins (Figure 1.3): the catalytic core (DNA polymerase III (Pol III) ", # and θ 
subunits), protein-interaction hubs (DNA Pol III !2-sliding clamp, SC, and ssDNA-
binding protein, SSB), clamp loader complex (CLC; consisting of Pol III τ/γ, δ, δ$, ψ 
and χ subunits in a stoichiometry of (τ/γ)3δδ$ψχ), and the primosome (DnaB helicase, 
DnaG primase and the DnaC helicase loader).41,46,47  
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Figure 1.2: Initiation of DNA replication at the oriC. The initiator protein, DnaA 
(green), coats the oriC and melts the duplex DNA to the ssDNA templates. The 
primosome assembles on each ssDNA strand prior to the introduction of the DNA 
polymerase III replisome. Firstly, the DnaB helicase (yellow) is loaded by the DnaC 
helicase loader (blue) and then the DnaG (red) associates. The arrows indicate the 




1.2.1.2.1 Catalytic core and SCs 
Each replication fork contains two catalytic cores, each with one SC, for simultaneously 
replicating the leading and lagging strands.48,49 Both cores are tethered to DNA by SCs 
and the cores are coupled to the CLC. The leading strand (5$–3$ polarity) is synthesised 
continuously in the direction of the fork movement, while the lagging strand (3$–5$ 
polarity) is synthesised discontinuously in the opposite direction of the fork 
movement.43,45 To overcome the discontinuity of lagging strand synthesis, Okazaki 




Figure 1.3: Schematic diagram of E. coli replisome at the replication fork. As the DnaB 
helicase translocates along the lagging strand of DNA in the 5’–3’ direction, it unwinds 
duplex DNA. The CLC loads the SC onto the primed DNA (indicated in red, formed by 
the DnaG primase), which then recruits the core polymerase. During the elongation 
stage, the two core polymerases replicate each strand simultaneously and in the same 
direction (indicated by the arrow) as the helicase movement through the interaction with 




fragments are synthesised.50,51 The replication forks can move at rate close to 1000 
nucleotides per second, copying the chromosome in ~40 min.52-54 
The core is recruited to the primed sites on DNA by the SC. SCs are comprised of two 
Pol III ! subunits in a ring that surrounds dsDNA, acting as mobile tethers to confer 
processivity to the replicase (detailed in section 1.3). The catalytic core consists of three 
subunits in a 1:1:1 stoichiometry: the Pol III " subunit (the polymerase), the Pol III # 
subunit (a 3$–5$ proofreading exonuclease), and the Pol III θ subunit (stabilises Pol III # 
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subunit).55,56,57 The catalytic cores synthesises nascent DNA strands complementary to 
the parental leading and lagging strands.58 
  
 
1.2.1.2.2 CLC and SSB 
The CLC is comprised of five different subunits: Pol III τ or γ, %$, %, ψ and χ subunits. 
Its primary function is to load SCs onto the primed DNA of the leading and lagging 
strands.59,60 The secondary function is to couple the catalytic cores at the replication 
forks. The Pol III τ and γ subunits are expressed from the same dnaX gene. The Pol III τ 
subunit is the full-length protein while Pol III γ subunit is a truncated protein resulting 
from ribosomal frame-shift during translation.61 It is Pol III τ subunit that interacts with 
the Pol III " subunit of the core through its C-terminal domain (absent in Pol III γ 
subunit) to keep the replication forks coupled.33,62,63 The Pol III τ/γ subunits comprise 
an ATPase-powered motor, that uses ATP hydrolysis to load SC onto DNA. The Pol III 
%$ subunit undergoes a conformational change to initiate the interaction between the Pol 
III % subunit with the protein-binding pocket of the SC.59,64,65,66,67 Upon binding, the Pol 
III % subunit traps one of the SC monomers in a conformation to induce the opening of 
the dimer interface.68 The complex can also unload the SC from DNA.69 The two 
proteins, Pol III ψ and χ subunits, are not essential for the clamp loading activity of the 
CLC, but rather contact the SSB proteins that coat and protect ssDNA. 
Many of protein-protein and protein-DNA interactions within the replisome that govern 
the cellular process of DNA replication are highly conserved amongst bacterial species. 
However, not all are conserved across pathogenic bacteria.47,70,71 While the essential 
nature of DNA replication makes it an attractive target for antibacterial agents, the 
target must be conserved across a range of pathogenic bacteria if a broad-spectrum 
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antibiotic is to be developed. The protein-protein interaction hub of the SC is essential 
for the DNA replication process due to the conserved nature of its interactions; it is a 
prime target for the discovery of new antibacterial agents.72-76 
 
 
1.3!THE SC AS AN ANTIMICROBIAL TARGET 
 
The SC forms interactions with several proteins not only in DNA replication, but also 
recombination and repair. Bacterial SCs are homodimeric, toroid-shaped proteins. 
Crystal structures revealed that the two SC monomers are arranged in a head-to-tail 
fashion, giving rise to two distinct faces: the amino-terminal (N-terminal) and 
C-terminal faces (see Chapter 3). 77,78 Each monomer contains three copies of the 
DNA-clamp domain (Figure 1.4).  
Within the realm of the replisome, the Pol III " and # subunits of the catalytic core and 
the Pol III % subunit of the CLC interact with the SC. The catalytic core must remain 
stably associated with the DNA during chromosomal replication in order to achieve 
high processivity. Interaction with the SC confers this processivity by tethering the 
complex to the DNA.77,79 SCs encircle the DNA and can freely diffuse along it in a 
sequence-independent manner.77,79 The inner channel of SCs are lined with positively 
charged residues that interact electrostatically with the DNA backbone.78  
The SC has interactions with the other DNA polymerases that are involved in DNA 
replication and repair (Pols I, II, IV and V),81-84 the mismatch repair proteins MutS and 
MutL,85-87 and the cell-cycle regulating protein Hda.38,85 Remarkably, all these proteins 
interact at the same region of the SC, the protein-binding pocket (details in Chapter 4). 
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As there are two binding pockets, one on each monomer, a maximum of two proteins 
can interact with the SC at any given time. In the elongation stage of DNA replication, 
 
 
Figure 1.4: Structure of the E. coli SC (SCEco; Protein Data Bank (PDB) entry 4K3S). 
Monomers are shown in blue and red colours, with the C-terminus face visualised.80 
The N-terminal and C-terminal ends of the monomer are labeled. The circles indicate 
the two sub-sites for the interaction with protein partners: sub-site I (yellow circle) and 
sub-site II (red circle).  
 
it appears that both Pol III " and # subunits interact with the SC, one with each binding 
pocket.52,88 The pocket has two separate sub-sites. Sub-site I is wide and shallow, while 
sub-site II is deep and narrow. Both are lined with predominately hydrophobic 
residues.89 These residues are highly conserved across bacterial SCs as well as the 
binding region from the protein partners.75,90,91 
 
1.3.1! Conserved linear motifs (LM) from SC protein partners 
Interactions with the SC occur at a hydrophobic protein-binding pocket located on the 
C-terminal face. Each partner protein has LM sequence, usually found in loops or 
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disordered regions, which interact with the protein-binding pocket. In the bacterial SCs, 
the conserved LM is QLx1Lx2F/L (S/D preferred at x1; x2 may be absent).90,91 The 
corresponding LMs in the binding partners of SCEco are listed in Table 1.2.  
Interactions between SCs and binding partners are transient, whereby the protein partner 
will readily associate/dissociate from the SC protein-binding pockets. This is a feature 
of highly dynamic systems such as the replisome. Yin and colleagues (2013) recently 
elucidated the mechanism of interaction between the representative LM peptide 
AcQLDLF, and the SCEco binding pocket using a combination of X-ray crystallography, 
biophysical and functional assays.80 Briefly, the LF dipeptide interacts in sub-site I and 
the QL in sub-site II, with the D residue spanning the border; and sub-site I must be 
occupied for the Q to bind into sub-site II (details in Chapter 4).  
 
Table 1.2: Binding partners of SCEco and their consensus LMs. 
Protein Protein function LM Reference 
Pol III " 
subunit/PolC 
Replicative synthesis QADMF 79,89,92,93 
Pol III # subunit Exonuclease 
proofreader 
QTSMAF 52 
Pol III % subunit Clamp opener QAMSLF 94,95 
MutS Mismatch repair QMSLL 87 
MutL Mismatch repair QPLLIP 87 
Hda Initiation regulator QLSLPL 38,96 
DNA Pol I/PolA DNA replication Not reported 86 
DNA Pol II/PolB DNA replication QLGLF 89,97 
DNA Pol IV/DinB Translesion synthesis QLVLGL 95,98 
DNA Pol V/UmuCD  Translesion synthesis QLNLF 99,100 
DNA ligase I Okazaki fragment 
maturation 
Not reported 86 
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1.3.2! Comparison with other SC homologues 
 
There are bacterial SC homologues in other organisms that have the same function. The 
human homologue, the proliferating cell nuclear antigen (hPCNA) and the T4 
bacteriophage homologue gp45 have a strikingly similar resemblance to the bacterial 
SC, despite low sequence similarity. All these proteins have the six structurally distinct 




Figure 1.5: Structure of SC homologues. Cartoon representations of (a) SCEco (PDB 
entry 4K3S), (b) hPCNA (PDB entry 1U76), and (c) gp45 (PDB entry 1CZD) with 
circles superimposed to represent each domain. The protomers are labelled inside the 
structures interior channel, coloured according to the respective monomer. Domains are 
labelled outside the structure, coloured according to the corresponding domain. Adapted 
from Oakley (2016).103 
 
 
The overall shape of the gp45 homologue is slightly triangular, whereas the other two 
are circular.101,102 The distinction between the three lies in the number of monomers. 
While the bacterial SC has two monomers comprising of three domains, PCNA and 
gp45 both have three monomers comprised of two domains. The PCNA and gp45 also 
function as tethers for accessory proteins acting on DNA. These protein partners are 
also involved in DNA replication and repair and cell-cycle regulation.104,105 
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1.3.3! The SC as an antimicrobial target 
The bacterial SC is a promising target for novel antibiotics. Blocking the binding sites 
would disrupt several essential cellular processes. The probability of simultaneously 
accumulating point mutations in the SC binding pockets and LM sequences of protein 
partners to prevent inhibitor binding and maintaining partner binding is vanishingly 
small. The interaction and binding sequences are reportedly conserved across bacterial 
species, appealing to the potential for developing a broad-spectrum antibiotic.106,107  
Several groups have investigated natural products, peptidomimetics and utilised 
high-throughput screening (HTS) to discover inhibitors of interactions involving the 
bacterial protein-binding pocket. Yin and colleagues utilised fragment-based screening 
(FBS) to identify a tetrahydrocarbazole (THC) scaffold that interacts in sub-site I of the 
SCEco binding pocket.72 Since then, a series of THC-derivatives have been developed 
that have increased the affinity for the binding pocket from 74 µM to 15 µM (described 
in more detail in Chapter 5).73 Subsequently, all THC-derivatives were found to inhibit 
in vitro DNA replication assays, and the THC-scaffold had antibacterial activity. These 
are promising SC inhibitors from which further generations are being produced to 
increase the potency to the sub-micromolar range. Georgescu and colleagues utilised 
HTS to identify the compound, RU7, that inhibited the interactions between SCEco and 
the Pol III " subunit LM (of the catalytic core). RU7 also inhibited the interaction of the 
S. pyogenes SC (SCSpy) with the Pol C replicase LM in fluorescence anisotropy assays.89 
The co-crystal structure with SCEco revealed the RU7 binds into sub-site I, and the 
authors indicated that the compound would be a starting scaffold for drug design, 
potentially building into sub-site II. Wolff and co-workers used incorporated unnatural 
amino acids into the AcQLDLF LM to improve the affinity of the peptide for the SCEco 
binding pocket by 2 orders of magnitude and were able to out-compete DNA Pol IV for 
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the binding pocket.76 The peptides were able to interact similarly with SCPae, and to a 
lesser extent Mycobacterium tuberculosis SC (SCMtu); however, the SC from Bacillus 
subtilis and S. aureus (SCBsu and SCSau, respectively) interacted more weakly with the 
peptides.75 The authors suggested that subtle amino acid substitutions in the highly 
conserved binding pockets of the Gram-positive SCs (with respect to SCEco) have a 
dramatic affect on the interaction with the LM and LM-derived peptides (detailed in 
Chapters 4 and 5; see section 3.1, Table 3.1 for more details on sequence similarities 
between bacterial SC and solved SC structures). These peptides inhibitors have not been 
assayed for antibacterial acivitity. 
 
1.4!AIMS OF PROJECT 
The work described in this thesis is directed to address the following aims: (i) to 
ascertain the overall structure of SCs from the ESKAPE pathogens; (ii) probe the 
conserved LM mechanism of interaction with the ESKAPE SCs; and (iii) to test the 
THC-derivatives as potential ESKAPE SC inhibitors. 
 
1.5!STUDYING PROTEIN STRUCTURE AND FUNCTION 
 
1.5.1! X-ray crystallography 
X-ray crystallography is a tool for determining molecular structures. Essentially, a 
crystal of a molecule of interest is irradiated with X-rays to produce a diffraction pattern 
from which the positions of atoms in the crystal can be determined in three-dimensions. 
With respect to macromolecules such as proteins, the rate-limiting step of the process is 
often the production of crystals that diffract to sufficient resolution for structure 
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determination. A crystal is a periodic arrangement of the target molecule in three 
dimensions. The smallest unit of a crystal, referred to as the asymmetric unit, contains 
all the structural information of the molecule. It can contain the whole molecule, 
oligomers of the molecule, or parts of the molecule. The unit cell is the smallest group 
of atoms of a molecule that has the symmetry of a crystal of that molecule, and from 
which the crystal lattice can be built up by translation in three dimensions. It is 
comprised of asymmetric unit(s) related to each other by the symmetry operations 
rotation and translation. A space group is a symmetry group of a configuration in space, 
and determines the arrangement of asymmetric units in the unit cell. In macromolecular 
crystals, crystalline order is maintained through a plethora of weak, noncovalent 
interactions. Once a crystal is obtained, it is exposed to X-rays (at different angles) and 
a series of diffraction patterns are recorded. The electron density map of all the atoms in 
the molecule can be calculated and a model of the molecule built. The process is 
outlined in Figure 1.6. 
 
1.5.1.1!Crystallisation process 
Growing diffraction-quality crystals is often the most difficult step in macromolecular 
structure determination by X-ray crystallography. The conditions for crystallisation of a 
previously unstudied macromolecule cannot be predicted. Additionally, crystals need to 
be of size and quality sufficient to produce useful diffraction. If the crystal is not 
sufficiently large with respect to a given X-ray source and detector, the diffraction spots 
signal-to-noise ratio will not be sufficiently high for accurate structure determination. 
When a molecule is being crystallised, the molecules associate with one another to form 
an ordered lattice in the solid state108 while releasing water molecules from the 
molecular surface at the places where crystal contacts form. This is an entropy- driven 
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Figure 1.6: The process of X-ray crystallography from crystal growth to structural 
determination.  
 
For macromolecules to crystallise, they must be of high purity, structurally 
homogeneous, and the physical conditions (temperature, solution ionic strength, etc.) 
must promote crystal growth and not precipitation.111 Due to the multitude of variables 
that collectively contribute to crystallisation, there is no known way to predict these 
conditions. For biomolecule crystallisation, important variables include: biomolecule 
Amy E. McGrath  20 
concentration, precipitant type and concentration, buffer type and pH, the presence of 
salt, temperature, crystallisation technique, and the inclusion of chemical additives. A 
popular crystallisation technique is vapour-diffusion, whereby a drop containing the 
crystallisation condition and the biomolecule to be crystallised is suspended over a 
reservoir containing higher reagent concentration. To reach equilibration, water vapour 
diffuses from the drop to the reservoir, ensuring supersaturation of the biomolecule and 
promoting crystal nucleation and growth. Two examples of vapour-diffusion 
experiments are sitting-drop and hanging-drop experiments (Figure 1.7). 
So-called “sparse matrix” screens have been developed that typically contain 96 
conditions of varying buffer, pH, precipitant type and concentration, and different salts. 
Attempts to determine protein crystallisation conditions typically commence with these  
 
 
Figure 1.7: Schematic diagrams of protein crystallisation techniques. (a) Sitting-drop 
vapour diffusion and (b) hanging-drop vapour diffusion are two techniques utilised for 
growing protein crystals. Both require the vapourisation of water from the crystal drop 
to the reservoir, direction indicated by the arrows, driven by the concentration of the 
precipitant in the reservoir. This forces the protein into a supersaturated state and 
enables for spontaneous nucleation to form protein crystals. Examples of protein 
crystals formed by (c) sitting-drop vapour diffusion and (d) hanging-drop vapour 
diffusion.  Drops are approximately 2 mm in diameter. 
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sparse matrix screens, with the trays incubating at different temperatures in order to 
promote crystal growth. Once a ‘hit’ is identified, the conditions can be further refined 
(e.g. by screening pH versus precipitant concentration) to achieve crystals of sufficient 
quality for X-ray diffraction experiments. 
 
1.5.1.2 Bragg’s Law and determining the structure of crystals 
Wilhelm Conrad Röntgen discovered X-rays in 1895, after he observed radiation 
emanating from a cathode-ray tube. Seventeen years later, Friedrich, Kipling and von 
Laue projected an X-ray beam through a copper sulfate crystal and recorded the first 
diffraction pattern.112,113 This was the first evidence that X-rays are electromagnetic 
waves, i.e. having an electric field vector and a magnetic field vector and that the atoms 
in a crystal have a repeating arrangement that creates an interference (diffraction) 
pattern of X-rays.114 Within a year of this discovery, W.H. and W.L Bragg interpreted 
diffraction spots as resulting from reflections off discrete lattice planes, formulating 
what is now known as Bragg’s Law (eq. 1; Figure 1.8). They further used this 
relationship to solve the crystal structures of NaCl and ZnS.114-116 
 
!" = 2%&'( sin ,---………………………………………………………………  (eq 1.) 
 
where n is an integer, λ is the wavelength of the incident X-ray beam, dhkl is the distance 
between a set of reflecting planes with Miller index hkl and θ is the incident and 
scattering angle of the reflected X-ray beam. 
The field of X-ray crystallography has extended from chemical compounds and small 
molecules to large biomolecules and complexes over the last 100 years since the 
description of Bragg’s Law.  
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Figure 1.8: Graphical representation of Bragg’s Law that describes diffraction spots as 
reflections of discrete lattice planes. An incoming X-ray beam of a particular 
wavelength (λ) enters the crystal and is reflected by an atom (green circle) at an angle 
(θ). The scattered X-ray beam from reflecting planes, with a certain interplanar distant 
corresponding to Miller indices hkl (dhkl), interacts constructively. This produces a 
diffraction spot of a relating intensity.  
 
 
1.5.1.2!From diffraction pattern and electron density to solved structure 
An X-ray diffraction pattern contains spots resulting from many reflections (of planes 
that satisfy Bragg’s Law at a given crystal orientation) with various intensities. Two 
pieces of information from each diffraction spot are needed for structure solution: a 
structure factor amplitude and phase angle. The structure factor amplitudes can be 
measured directly and are proportional to the square roots of the intensities of the 
diffracted X-ray spots. However, the phase angles cannot be determined directly from 
the diffraction pattern; this is known as the phase problem. The amplitude and phase of 
diffracted X-rays are vital for calculating the electron density in the unit cell. The most 
frequently used indirect method to overcome the phase problem in macromolecular 
crystallography is molecular replacement.117,118 The requirement of this method is that a 
high quality structure closely related to the one being determined is available. There are 
software programs, such as Phaser,117,119 that perform molecular replacement using 
maximum likelihood methods.119,120 Briefly, molecular replacement proceeds by 
calculating rotation and translation functions to determine the orientation and position 
of the model in the unit cell. The phase angles calculated from the correctly placed 
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model are then used to calculate the electron density map. From here, the molecule can 
be built into the density manually or automatically (e.g. using PHENIX Autobuild),121 
and iteratively refined before the final crystal structure is determined. These programs 
improve the fit of the model into electron density while maintaining accurate geometry 
(bond lengths, bond angles, etc.). 
 
1.5.2! Using fluorescence polarization (FP) to study protein-peptide interaction 
FP is a sensitive technique that was first described by Perrin.122 Fluorescent molecules 
that are oriented parallel to the electric field of the linearly polarized light are able to 
absorb a photon, and re-emit the photon parallel to the excitation plane (assuming the 
molecule remains static). However, if the molecule is small it has a rapid tumbling rate 
in solution and consequently will rotate out of the plane once excited. As a result, the 
emitted light from the excited fluorescently-labelled molecule is depolarised. A 
fluorescent tracer, for example, a fluorescently-labelled peptide < 1,500  Daltons (Da), 
will tumble rapidly in solution and emit depolarized light. When the tracer is bound to a 
receptor (e.g. a protein > 10,000 Da), the tumbling rate decreases and the emitted light 
retains a greater degree of polarization. A schematic of this process is outlined in 
Figure 1.9. 
The polarization (P) of the emitted light is quantified from two emission measurements 
through polarizers that are oriented parallel (vertical) and perpendicular (horizontal) to 
the excitation polarizer (eq. 2).124 This is a ratio of intensities that is multiplied by 






  ………………………………………………………………………  (eq. 2) 
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where 4∥  and 45are the emission intensities at the vertical and horizontal orientations 
with reference to the excitation plane, respectively. A low polarization means that the 
tracer is rapidly tumbling freely in solution, while a high polarization means the 





Figure 1.9: Diagram of a typical FP assay. The fluorophore-labelled peptide rapidly 
tumbles in solution and the emitted light is depolarized. Once the tracer associates with 
a comparatively larger molecule, shown as protein here, the overall tumbling rate slows 
down and the emitted light remains polarized.  The fluorescence emission intensity is 
measured in horizontal and vertical planes, respective to the excitation plane, and a ratio 




1.5.2.1 Applications of FP 
This technique is versatile in the different types of interactions that can be assessed. 
These include DNA-DNA, DNA-protein, protein-peptide, and small molecule-protein 
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interactions. FP can be used for direct binding assays and competition assays. FP can be 
used in a microplate and a plate reader format for HTS, making it a useful tool in drug 
discovery.  
Binding assays involve labelling a small molecule, e.g. peptide, chemical compound, or 
DNA, with a fluorophore (i.e. the tracer) and acquiring a saturation curve by titration of 
the receptor (e.g. a protein) at different concentrations. These data are used to determine 
the KD of the interaction. The most important part of designing the tracer is the choice 
of fluorophore and the position of attachment on the ligand of interest, as it can 
contribute or detract from the interaction through electrostatic repulsion, steric 
hindrance or non-specific interactions. Typical fluorophores used include fluorescein, 
rhodamine, and BODIPY.123,125 The size difference between the tracer and receptor 
must be significant enough to measure a reasonable change in polarization.126 
In competition assays, the tracer and receptor concentration are kept constant with the 
inhibitor titrated in at varying concentrations. The receptor concentration used is based 
on the KD of the interaction with the tracer, determined by the binding assay.127 The KD 
of the tracer-receptor interaction limits the tightest interaction that can be measured by 
FP competition assays.128 If the inhibitor appears to have an affinity that is higher than 
the tracer, then either a tracer of higher affinity will need to be used or another 
biochemical assay technique will need to be explored. Assuming the exact location of 
the tracer-binding site on the receptor is known, the advantage of these FP competition 
assays is in knowing the identification of the inhibitor-binding site. This can be a 
powerful HTS technique for drug discovery.128 
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1.5.3 Mass spectrometry  
Mass spectrometry is an analytical technique that ionises chemical species and sorts the 
resulting ions based on their mass-to-charge ratio (m/z). A mass spectrometer (MS) 
generally consists of three main sections: an ion source, a mass analyser and a detector 




Figure 1.10: General arrangement of a quadrupole time-of-flight (Q-ToF) MS used for 
studying proteins and protein complexes. Ions generated in the Z-spray source are 
transferred to the quadrupole via the hexapole lens. Ions are separated based on m/z 
ratio in the quadrupole, where selected ions can also be subjected to collision-induced 
dissociation. The ions are then accelerated to the pusher in the ToF analyser, which will 
direct the ion beam to the reflectron. The ions are separated by reflections in a flight 
tube prior to the detection. The blue line indicates the ion path through the MS. 
 
ionisation. The ions are then separated according to their m/z, producing a mass 
spectrum whereby each ion is detected as a peak.  
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For large biomolecules and protein complexes, electrospray ionisation (ESI) is a 
revolutionary ion source that provides the mild ionisation needed to prevent 
fragmentation of proteins and allowing weak, noncovalent interactions of complexes to 
be detected.129-131 The process of ESI involves spraying a solution containing the dilute 
biomolecule through a fine, electrostatically charged needle to produce charged droplets 
(Figure 1.11). Each droplet contains molecular ions with multiple charges, and as the 
solvent evaporates (with the aid of a nebulizing gas), the droplet size decreases 
(retaining the same charge) until Coulombic fission of the droplets occurs. At this point, 
known as the Rayleigh limit, the charge is able to overcome the surface tension.132-134 
This continues until the ions are free of solvent. Further development of ESI sources 
have lead to nanospray ESI (nanoESI).135 The sample, reduced to 1–2 µL from the 
traditional 100–200 µL, is loaded directly into a gold-coated capillary. The advantage of 
nanoESI is the resulting generation of smaller droplets that assist the desolvation 
process, and require much milder conditions compared to traditional ESI.129 Smaller 
droplets have a higher surface area-to-volume ratio, increasing the number of analyte 
molecules available for desolvation.135 
The ions are passed into the mass analyser in a high vacuum. The ions are then 
accelerated so they all have the same kinetic energy. They are then deflected by a 
magnetic field according to their masses and the net number of positive charges on the 
ion (if in positive mode) — the lighter and more charged they are, the more they are 
deflected. By coupling ESI with Q-ToF mass filter, the possible m/z detection range is 
increase significantly from 2,000–4,000 m/z with standard quadrupole mass analysers, 
to > 4,000 m/z.136,137 
Since its inception, nano-electrospray ionisation mass spectrometry (nanoESI-MS) has 
been used for many different applications due to its speed, high sensitivity and 
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accuracy, ability to elucidate subunit stoichiometry of multi-subunit proteins and 




Figure 1.11: Schematic diagram of the electrospray ionisation process. In positive ion 
mode, the capillary tip becomes enriched with positively charged ions. Positively 
charged droplets are discharged from the Taylor cone. These droplets contain numerous 
positively charged molecules that move towards the negatively charged detector. The 
droplets become increasingly smaller, due to Coulombic fission evaporation, and 
eventually form free gas phase ions (represented here as single charges).  Adapted from 
Kebarle, 2000.133  
 
 
technique as it is used to elucidate stoichiometry, dynamics, and specificity of proteins 
and protein-protein complexes.138 The structural organisation and stoichiometry of 
protein complexes can be obtained when each protein has a different mass and 
associated charge state distribution, and the complex would then have another mass and 
charge state associated.138 Direct measurement of the mass of the complex allows 
identification of the stoichiometry of the complex.130,139 Subunit exchange can be 
conducted in native mass spectrometry in order to understand the dynamics and 
properties of protein complexes in real time. ESI-MS has previously been used to 
monitor the subunit exchange of small heat shock proteins from pea and wheat,137 [N14] 
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and [N15] labelled E. coli glucosamine-6-phosphate synthase,140 and wild-type and 
mutant variant of transthyretin.141 
 
1.6 SCOPE OF THESIS 
 
As the SCEco structure-function relationship has been well characterised, determining 
the structure of closely (structurally and functionally) related proteins can provide 
invaluable insights into their functions. While there are SC structures from several 
different bacteria in the PDB, only one ESKAPE SC structure has been solved 
(P. aeruginosa; SCPae).75 Chapter 3 describes the use of X-ray crystallography to 
determine the structure of the ESKAPE SCs. The solution dynamics of the ESKAPE 
SCs were explored using mass spectrometry to observe subunit exchange between the 
ESKAPE SCs and SCEco.  
Chapter 4 explores the LM interaction through an alanine scan of the LM to identify 
the residues important for interaction with the ESKAPE SCs pockets. LM peptides were 
modelled into the binding pockets of the SC crystal structures determined in Chapter 3 
to probe the stability and specific interactions required for protein-binding pocket 
interaction. 
The attractiveness of the SC as a target for developing antimicrobials is the potential 
simultaneous disruption of multiple cellular processes through blocking one site, the 
protein-binding pocket. The THC-derivatives have proven to directly bind into the 
SCEco protein-binding pocket to inhibit in vitro DNA replication and have antibacterial 
activity. However, these compounds have not been tested for cross-interaction with 
other bacterial SCs. Additionally, they have not been tested for interaction with 
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hPCNA. Chapter 5 will ascertain the potential broad-spectrum bacterial SC activity of 
the THC-derivatives by determining if they can compete for the protein–binding 
pockets in a FP competition assay with the LM. The compounds will be further assessed 















GENERAL MATERIALS AND METHODS
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This chapter contains the general methods and resources used throughout this study. 
Methods that were used for specific studies are described in the corresponding chapters. 
 
2.1 CHEMICALS AND MATERIALS 
 
MilliQ™ water, used throughout all experimental procedures, was purified to resistivity 
of 18.2 MΩ.cm-2 using a Millipore (USA) MilliQ™ system. Tryptone, yeast extract 
were obtained from Bacto Laboratories (USA). Chloramphenicol, tetracycline, 
kanamycin, glycine, ammonium bicarbonate, cesium iodide, Coomassie brilliant blue 
R250, imidazole, spermidine trihydrochloride, sodium chloride (NaCl), bromophenol 
blue sodium salt, sodium acetate trihydrate, tris(hydroxymethyl)aminomethane (Tris), 
2-(N-morpholino)ethanesulfonic acid (MES), ethylenediamine-tetraacetic acid disodium 
salt dihydrate (EDTA), "-lactose monohydrate, D-(+)-glucose, citric acid, nonidet-P40, 
polyethylene glycol (PEG) of variable molecular weights (MW), !-mercaptoethanol, 
dimethyl sulfoxide (DMSO), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) and boric acid were purchased from Sigma-Aldrich (USA). Glycerol and 
ammonium acetate were obtained from Chem-supply (Australia). Hydrated magnesium 
sulfate, potassium dihydrogen orthophosphate (KH2PO4), disodium hydrogen phosphate 
dihydrate (Na2HPO4.2H2O), sodium dihydrogen orthophosphate (NaH2PO4), glacial 
acetic acid, hydrochloric acid (HCl), isopropanol, methanol and calcium chloride 
(CaCl2) dihydrate were purchased from Ajax Finechem (AUS). Dithiothreitol (DTT), L-
arabinose and Isopropyl !,D-1-thiogalactopyranoside (IPTG) was obtained from Astral 
Scientific (USA). The QIAquick miniprep and Gel extraction kits were purchased from 
QIAGEN (Germany). Magnesium chloride (MgCl2) and formic acid were obtained from 
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Fluka (USA). Sodium dodecyl sulfate (SDS) and phenylmethylsulfonyl fluoride 
(PMSF) was purchased from Amresco (USA). The Precision Plus Protein Dual Color 
MW standards and Miniprotean TGX™ gels were obtained from Bio-Rad (USA). 
Ampicillin was purchased from Roche Life Science (USA). Agarose was purchased 
from Bioline (UK). The purity of all chemicals and reagents were of at least molecular 
biology grade.  
 
2.1.1 Custom oligonucleotides 
Oligonucleotide primers were obtained from GeneWorks (Australia). Oligonucleotide 
primers were routinely dissolved in MilliQ™ water to a stock concentration of 100 µM 
and stored at –20 °C. 
 
2.1.2 Custom peptides 
Custom peptides (e.g. fluorescein-labelled and acetylated) were obtained from 
Mimotopes (Australia) and GL Biochem (China). Peptides labelled with fluorescein 
were dissolved in ammonium bicarbonate or MilliQ™ water and stored in the dark at –
20 °C. Acetylated peptides were routinely dissolved in DMSO to a concentration of 100 
mM and stored at –20 °C. Peptides were purified by reverse-phase HPLC. The 
composition and purity were validated using ES-MS. 
 
2.2 PLASMIDS, STRAINS AND GROWTH MEDIA 
2.2.1 Plasmid vectors 
Two vectors were used as scaffolds into which target genes were cloned. Vector 
pND706 contains the bacteriophage λ promoters pR and pL arranged in tandem upstream 
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of a strong ribosome binding site (RBS).142 The bla confers ampicillin resistance. The 
clts857 gene encodes the λ repressor, which represses transcription from pR and pL at 
low growth temperatures (30 °C). Once cells have reached an appropriate density, 
high-level transcription of the protein of interest is induced upon shifted temperature to 
42 °C. This denatures the thermolabile repressor, enabling it to dissociate from the λ pR 
and pL promoter/operators. The unique NdeI site (CATATG) downstream of the RBS 
contains an ATG start codon that enables in-frame gene fusion.142,143 This system 
allows for stringent control of gene expression and is appropriate for expression of toxic 
proteins.  
Vector pETMCSIII144 utilises the bacteriophage T7 transcription to produce high levels 
of expression of the protein of interest. The plasmid contains a T7 ϕ10 promoter 
upstream, and Tϕ transcription terminator downstream of the multiple cloning site 
(MCS), with the target genes inserted into the MCS region. To overproduce the gene of 
interest, a chromosomal expression of T7 RNAP is required for transcription from the 
ϕ10 promoter.  Proteins are expressed with a 6×histidine tag (His6) at the N-terminal.144 
Derivatives of the host strains BL21 (λDE3) were used for work reported above.  
 
2.2.2 Bacterial strains 
During plasmid construction, E. coli strains DH5"™ [F– Φ80lacZΔM15 Δ(lacZYA-
argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi–1 gyrA96 relA1]145 
and SURE 2 [e14– (McrA–) Δ(mcrCB-hsdSMR-mrr)171 endA1 gyrA96 thi–1 supE44 
relA1 lac recB recJ sbcC umuC::Tn5 (KanR) uvrC [F– proAB lacIqZΔM15 Tn10 (TetR) 
Amy CamR]] (Stratagene, USA) were used as a cell host. DH5"™ was the preferred 
strain, while SURE 2 was used when DH5"™ failed to produce positive clones. SURE 
2 has mutations that ensure the removal of secondary structures in the plasmid DNA. 
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For protein expression, plasmids were transformed into either E. coli strain BL21 
Star™(DE3) [F– ompT hsdSB (rB–mB–) gal dcm rne131 (DE3)] (Invitrogen, USA), 
BL21-AI™(DE3) [F– ompT hsdSB (rB–mB–) gal dcm araB::T7RNAP-tetA] (Invitrogen) 
or E. coli BL21(λDE3)recA/pLysS [F– ompT lon hsdSB (rB–mB–) recA srlA Tn10].146-148 
The λ prophage carries the T7 RNAP gene under the lacOP operator-promoter control 
and the pLysS plasmid directs expression of the phage T7 lysozyme and confers 
chloramphenicol resistance. 
 
2.2.3 Growth media 
2.2.3.1 Lysogeny broth (LB) liquid medium 
Unless specified otherwise, E. coli cell strains were grown in LB149,150 medium 
containing 10 g L–1 tryptone, 5 g L–1 yeast extract and 10 g L–1 NaCl, supplemented 
with appropriate antibiotics [100 µg mL–1 ampicillin (Ap100) for DH5"™ and BL21 
Star™ (DE3); Ap100 and 34 µg mL–1 chloramphenicol (Cam34) for 
BL21(λDE3)recA/pLysS; Ap100, Cam34, 20 µg mL–1 tetracycline (Tet20) and 50 µg mL–1 
kanamycin for SURE 2; Ap100 and Tet20 for BL21-A1™(DE3)]. For expression of genes 
under the control of the tandem bacteriophage λ pR and pL promoters, strains were 
grown at 30 °C then heated to 42 °C to induce expression.  
 
 
2.2.3.2 LB agar medium 
E. coli cells containing pND706- or pETMCSIII-derived vectors were grown on LB 
agar plates [15 g L–1 agar in LB media with appropriate antibiotics (section 2.2.3.1)] in 
an incubator (Thermo Fisher Scientific) at 30 °C (pND706) or 37 °C (pETMCSIII) 
overnight (~18 h). 
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2.2.3.3 LB autoinduction medium 
Auto-induction is an alternative method for overproducing a protein of interest in 
BL21(λDE3) and derivatives. Auto-inducing media requires the presence of lactose, 
glucose and glycerol, to collectively produce high-density and fully induced cultures. 
Glucose is the primary source of carbon and energy for the bacteria, preventing the 
uptake of lactose and allowing high-density growth of cells. When glucose is depleted, 
lactose can be taken up by lactose permease, the product of the lacY gene. The lactose is 
converted to allolactose, which is the natural inducer of T7 RNAP. This initiates high-
level expression of the gene of interest under the control of the T7 promoter.146,151 Basal 
expression can sometimes be detected and may make it difficult to maintain toxic genes 
in T7 promoter vectors.147 
LB auto-induction medium151 contained 372 mL of XY [10 g L–1 tryptone and 5 g L–1 
yeast extract], 20 mL 20 × NPS [1 M Na2HPO4.2H2O, 1 M KH2PO4, and 0.5 M 
(NH4)2SO4], 8 mL 50 × 5052 [0.5% (w/v) glycerol, 0.05% (w/v) glucose, 0.2% (w/v) 
"-lactose monohydrate] and 400 µL 1 M MgSO4, and appropriate antibiotics required. 
For the BL21(λDE3)recA/pLysS cells with the pETMCSIII-derived vectors, starter 
cultures (20 mL) were grown for 4 h at 37 °C then reduced to 25 °C for 24 h, with 
constant orbital shaking at 250 rpm. 
 
2.2.3.4 Terrific broth (TB) medium 
TB is an enriched medium that promotes an extended growth phase.152 The large 
amount of tryptone and yeast extract present in the medium allows for higher plasmid 
yield. Glycerol is added as an additional carbon and energy source. TB medium 
contained 12 g L–1 tryptone, 24 g L–1 yeast extract, 0.004% (v/v) glycerol, 1 × TB 
phosphate [0.17 M KH2PO4, 0.72 M K2HPO4] and the appropriate antibiotic. For 
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expression of proteins in the BL21-A1 strain, starter cultures (30 mL) were grown for 
14 h at 25 °C before inoculating 1 L TB medium. Cultures were incubated at 32 °C until 
an optical density at 600 nm of 0.6 was reached, and then protein expression was 
induced following addition of 0.2% (v/v) L-arabinose and 1 mM IPTG. Incubation 
continued at 32 °C for 4 h, with constant orbital shaking at 180 rpm. 
 
2.3 MOLECULAR GENETIC TECHNIQUES 
2.3.1 Plasmid preparation 
Plasmid preparations from E. coli DH5" cells or SURE 2 cells were obtained by 
overnight growth in 5–10 mL LB medium supplemented with the appropriate antibiotic 
at 30 °C, and constant orbital shaking at 180 rpm. Plasmids were extracted and purified 
from cells using the QIAprep spin Miniprep kit (QIAGEN). Plasmid preparations were 
subsequently used for transformation into competent cells, polymerase chain reaction 
(PCR) amplification and restriction enzyme digest, as required. 
 
2.3.2 DNA purification 
2.3.2.1 Extraction from agarose gels 
Following separation of DNA fragments on an agarose gel (section 2.3.5), required 
DNA bands were excised using a scalpel blade. DNA was extracted from the gel using 
the QIAquick® gel extraction kit (QIAGEN), according to the manufacturers 
instructions. The concentration of the DNA fragment was measured as outlined in 
section 2.3.3.  
 
Amy E. McGrath  38 
2.3.2.2 Extraction by spin column 
For polymerase chain reaction (PCR) purification and plasmid preparation using the 
QIAquick PCR Purification kit (QIAGEN) and QIAquick mini prep kit (section 2.3.1) 
respectively, according to the manufacturers instructions. 
 
2.3.2.3 Ethanol precipitation from solution 
This was typically used for preparing DNA products for sequencing (section 2.3.4.4). 
The sequencing reaction (10 µL) was mixed with 2 µL of 3 M sodium acetate, pH 4.5 
and 50 µL of 95% (v/v) ethanol prior to incubation on ice for 10 min. Precipitated DNA 
was pelleted by centrifugation [14,00 × g, 30 min]. Following aspiration of supernatant, 
the pellet was rinsed with 250 µL of 70% (v/v) ethanol and air-dried for 20–30 min.  
 
2.3.3 Determining DNA concentration 
The concentrations of purified plasmids were determined using a Nanodrop 2000c 
(Thermo Fisher Scientific). This spectrophotometrically quantifies the concentration of 
DNA in a sample by measuring absorbance at 260 nm (A260). The DNA purity was 
judged by the A260/A280 (A280, absorbance at 280 nm) ratio; pure DNA has a ratio of 1.8–
2.0 and protein-contaminated DNA has a ratio of < 1.8. 
 
2.3.4 Gene amplification by PCR 
All PCR experiments were performed using Thermal cycler C1000™ (Bio-Rad). 
Thin-walled flat cap PCR tubes (Axygen, Corning, USA) were used to carry out all 
reactions.  
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2.3.4.1 Cloning PCR 
Cloning PCR was used to clone a particular gene from a template plasmid into an 
optimal expression plasmid. Reaction mixtures for Pfu Turbo Ultra DNA polymerase 
(Agilent Technologies, USA) contained 1 × reaction buffer, 0.35 µM each of the 
designed forward and reverse primers, 0.6 mM dNTPs, ~6 ng of plasmid template, and 
2.5 U Pfu Turbo Ultra DNA polymerase. The typical reaction volume was 50 µL total. 
General PCR cycling conditions were used as a basis to develop primer/template 
specific PCR parameters, if needed (Table 2.1). 
 
Table 2.1: General PCR parameters with Pfu Turbo Ultra polymerase. 
Step Temperature Duration No. of Cycles 
Initial denaturation 95 °C 3 min 1 
Denaturation 95 °C 30 s  
30 
 
Annealing 60 °C 30 s 
Extension 72 °C 1.5 min 
Final extension 72 °C 10 min 1 
 
2.3.4.2 Gradient PCR 
A temperature gradient PCR was performed to determine the optimal primer annealing 
temperature to plasmid template. This was used when an annealing temperature of 5 °C 
below the melting point of the primer pair resulted in no PCR product. The reaction 
mixture is as outlined in section 2.3.4.1. Following PCR protocol (Table 2.2), the 
reaction mixtures were analysed on an agarose gel (section 2.3.5) to ascertain the 
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Table 2.2: Parameters for gradient PCR with Pfu Turbo Ultra. 
Step Temperature Duration No. of Cycles 
Initial denaturation 95 °C 3 min 1 
Denaturation 95 °C 30 s  
30 
 
Annealing 50, 52, 54, 56, 58, 
60 °C 
30 s 
Extension 72 °C 1.5 min* 
Final extension 72 °C 10 min 1 
*Extended by 10 s/cycle 
 
2.3.4.3 Colony PCR 
Transformants were screened for presence of dnaN gene ligated into another plasmid 
using PCR. Selected bacterial colonies are resuspended in nuclease-free MilliQ™ water 
(50 µL). Bacteria are diluted 10-fold with 9 µL BIOTAQ Red PCR mixture [1 × NH4 
buffer, 2.5 mM MgCl2, 2 mM dNTP mix, 0.5 µM each of the designed forward and 
reverse primers, BIOTAQ™ Red DNA polymerase] prior to PCR protocol (Table 2.3). 
Bacterial colonies were plated on LB agar plates supplemented with appropriate 
antibiotic and incubated overnight. The reaction mixtures were analysed on an agarose 
gel (section 2.3.5) to identify positive clones. The corresponding bacterial colony was 
streak purified prior to long-term storage in LB medium containing 7% (v/v) DMSO at 
–80 °C. 
 
Table 2.3: Parameters for colony PCR. 
Step Temperature Duration No. of Cycles 
Initial denaturation 95 °C 3 min 1 
Denaturation 95 °C 30 s  
30 
 
Annealing 55 °C 30 s 
Extension 72 °C 1.5 min 
Final extension 72 °C 10 min 1 
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2.3.4.4 Sequencing PCR 
Sequencing PCR was used to determine the nucleotide sequence of the gene of interest 
following cloning experiments. Using the ABI BigDye Terminator v3.1 (Life 
Technologies, USA). The reaction mixtures (10 µL) contained 1x sequencing buffer, 0.2 
µM of either the designed forward or reverse primer, 0.5 µL BigDye Terminator v3.1 
mix and ~200 ng template plasmid. Following the PCR protocol (Table 2.4), reaction 
mixtures were cooled to 10 °C. Sequencing extension products were purified to remove 
unincorporated dye terminators prior to capillary electrophoresis, using ethanol 
precipitation (section 2.3.2.3). Dried DNA pellets were then submitted to the 
sequencing facility at the School of Biological Sciences, University of Wollongong for 
analysis using a 3130xI Genetic Analyzer (Applied Biosystems, USA). The resulting 
chromatograms were base-called using the program Sequencer Analysis 5.2 (Applied 
Biosystems). The nucleotide sequences were assembled with 4Peaks (v1.7.1, 
http://nucleobytes.com), Serial Cloner (v2.6.1,http://serialbasics.free.fr), or 
ChromasPro® software (http://www.technelysium.com.au/chromas.html), and 
compared with the target sequence obtained from UniProtKB (http://www.uniprot.org/). 
 
Table 2.4: Parameters for PCR using BigDye Terminator v3.1. 
Step Temperature Duration No. of Cycles 
Initial denaturation 95 °C 2 min 1 
Denaturation 95 °C 10 s  
30 
 
Annealing 50 °C 5 s 
Extension 60 °C 4 min 
 
2.3.5 Agarose gel electrophoresis and isolation of DNA fragments 
Samples were mixed with 1xDNA loading dye [0.005% (w/v) bromophenol blue, 0.1% 
(w/v) glycerol, 100 mM Tris-HCl pH 7.6, 25 mM EDTA pH 8.0] before loading. 
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Analytical gels were run at 90 V until the desired fragment resolution was achieved. 
Preparative fragment separation gels were run at 50 V for 3 h or until the desired 
fragment resolution was achieved. DNA fragments were visualised using the UV 
transilluminator of a GelDoc XR+ system (Bio-Rad) for analytical gels, or under a 
small UV lamp for preparative separation gels. To isolate fragments from gels, 
individual bands were excised and DNA recovered (as outlined in section 2.3.2.1). The 
sizes of fragments were estimated by comparison with the GeneRuler 1 Kb Plus DNA 
ladder (Thermo Fisher Scientific). All experiments were performed in 1 × TBE buffer 
[89 mM Tris-HCl, pH 7.6, 89 mM Boric acid, 2 mM EDTA]. 
 
2.3.6 Restriction digestion and ligation of plasmids 
New England Biolabs (NEB, USA) supplied all restriction enzymes and appropriate 
buffers. Plasmids were double digested with EcoRI and NdeI. Digestions were 
undertaken at 37 °C for 4 h and enzymes heat inactivated for 20 min at 65 °C. Products 
were 5$-dephosphorylated by addition of shrimp alkaline phosphatase (Fermentas, USA) 
followed by incubation for a further 1 h at 37 °C. Fragments were separated by agarose 
gel electrophoresis and isolated from the gels as described in section 2.3.5.  
 
2.3.6.1 Ligation reaction using molar ratios 
The traditional method of ligation using molar ratios insert DNA to vector (see eq. 3) 
was initially conducted. The molar ratios used were 3:1, 5:1 and 10:1. Vector DNA, 
insert DNA, 10 × Ligase buffer, T4 DNA Ligase (NEB) and nuclease-free MilliQ™ 
water were added to a microfuge tube in the quantities outlined by Table 2.5. 
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Table 2.5: List of ligation methods and molar ratios used 
in this work. 
Reagent Volumes 
NdeI/dnaN/EcoRI (8.25 ng) ax  µL 
NdeI/vector/EcoRI (10ng) 1.2 µL 
10 × Ligase buffer 1 µL 
T4 DNA Ligase 1 µL 
Nuclease-free MilliQ™  up to 10 µL 
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 ………(eq. 3) 
 
2.3.7 Transformation of chemically competent E. coli cells 
The general protocol for each plasmid and ligation transformation involved 5 µL of 
plasmid DNA/ligation mixture being added to a 100 µL aliquot of chemically 
competent E. coli cells before incubation on ice for 1 h. Cells were then heat-shocked 
by incubation at 42 °C for 1 min. The transformation mixture was incubation at 37 °C 
for 1 h, without shaking, following addition of 500 µL LB medium.  Cells were 
harvested by centrifugation [3,494  × g, 3 min], and resuspended in 200 µL LB medium, 
plated on selective LB agar plate and incubated overnight at 30 °C or 37 °C. For 
plasmids derived from the pND706 vector, the heat-shock occurred at 30 °C for 2 min, 
as heating at 42 °C may induce protein expression. For cloning, transformants were 
screened for potential positive clones using colony PCR (section 2.3.4.3). 
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2.4 PROTEIN PURIFICATION AND QUANTIFICATION 
 
2.4.1 Fast protein liquid chromatography (FPLC) purification of proteins 
Proteins were purified by chromatography through various columns of different 
characteristics using FPLC techniques. ÄKTA™ systems (ÄKTApurifier™ or 
ÄKTAFPLC™, GE Healthcare, USA) equipped with fraction collector Frac-950 or 
Frac-920, were controlled by UNICORN™ software (GE Healthcare), which allows 
real-time manual control or programmed methods control for protein purification. 
Protein elution from the columns was monitored by absorbance at a particular 
wavelength (A280 for protein) and conductivity. The protein composition of collected 
fractions was routinely assessed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) (section 2.4.2) and Nanodrop 2000c (section 2.4.4). All 
the FPLC purifications of proteins were carried out at ~4 °C in a cold room. 
 
2.4.2 SDS-PAGE 
Protein gels run at 150 V for approximately 50 min or until the dye front reached the 
base of the gel in 1 × Running Buffer solution [192 mM glycine, 0.1% (w/v) SDS, 25 
mM Tris-HCl, pH 8.3]. Proceeding electrophoresis, the gels were rinsed twice with 
MilliQ™ water and stained with Coomassie blue staining solution [0.2% (w/v) 
Coomassie brilliant blue R250, 40% (v/v) methanol, 10% (v/v) glacial acetic acid] for 10 
min, following brief heating.  Gels were destained with a Destain solution [10% (v/v) 
glacial acetic acid, 30% (v/v) methanol] until the background stain was removed. The 
Precision Plus Protein™ Dual Colour Protein Standards (Bio-Rad) were used as MW 
markers. 
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2.4.3 Dialysis of proteins 
Protein dialysis procedures were performed using SpectraPor dialysis membrane 
molecular weight cut-off (MWCO) of 12–14 kiloDalton (kDa) (Spectrum Laboratories). 
Protein samples were dialysed in three changes of 1 L of buffer, or as specified, with the 
changes typically occurring after 5 h and the entire procedure lasting for 18 h. All 
dialyses were conducted at ~4 °C in a cold room. 
 
2.4.4 Concentrating protein and determining protein concentrations 
Protein samples were concentrated using Amicon Ultra-4 centrifuge filters, with a 
MWCO of 10 kDa (Millipore). The filters were rinsed thrice with 5 mL MilliQ™ water 
prior to use of the 15 mL filter, 2 mL for the 4 mL filter or 400 µL for the 500 µL filter. 
The 4 and 15 mL filter samples were centrifuged for 15 min at 3,000 × g in a Labogene 
ScanSpeed 1248R centrifuge using a GRS-G-r250-4 swing rotor  (Labogene, Denmark). 
The 500 µL filter samples were centrifuged for 5–10 min at 9,100 × g in a MicroCL 
21R microcentrifuge (Thermo Fisher Scientific). Samples were mixed thoroughly using 
repeated pipetting after centrifugation to prevent protein aggregation. 
Protein concentrations were determined with a Nanodrop 2000c (Thermo Fisher 
Scientific) using the Protein A280 application. The tryptophan and tyrosine residues or 
cysteine-cysteine disulfide bonds in purified proteins will exhibit (A280), using the 
extinction coefficient and protein MW to calculate the concentration of the protein in 
the sample. Theoretical extinction coefficients and protein MW were estimated using 
the ExPasy ProtParam tool based on the number of tryptophan and tyrosine residues in 
the protein sequence.153 An A260/A280 ratio of 0.5–0.6 indicates pure protein and > 0.6 
indicates DNA contamination. 
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2.5 MASS SPECTROMETRY 
 
2.5.1 Preparation of protein for mass spectrometry 
Proteins were dialysed overnight at 4 °C against 2 L of the appropriate buffer (specified 
for individual experiments), changed four times prior to mass spectrometry 
experiments. Samples were centrifuged briefly immediately prior to mass spectrometry 
experiments. 
 
2.5.2 Identification of purified protein 
The accurate molecular mass of purified protein was analysed after purification using 
the nanoESI-MS function on a Waters SYNAPT MS, which can be accurate to < 0.01% 
of the total molecular mass of protein. The MS was calibrated using 10 mg mL–1 cesium 
iodide in 70% (v/v) isopropanol. The proteins were dialysed against 0.1 (v/v) formic 
acid in concentrations of 1 to 10 µM. The proteins were injected into a gold-coated 
capillary needle. The capillary voltage was 1.5 kV, the cone voltage was 35 V and RF 
lens was 175 V. Data were collected over the mass range 600–10000 m/z (50–150 
acquisitions, 2 s each). The spectra were analysed using Masslynx™ (Waters, USA) and 










PRODUCTION AND STRUCTURAL 
ELUCIDATION OF ESKAPE SC
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3.1 INTRODUCTION 
 
The SC protein, encoded by the dnaN gene,154 has homologues in all kingdoms of life 
and is essential for DNA replication and repair. These proteins recruit replication and 
repair proteins and tether them to DNA. In doing so, the proteins coordinate the 
activities of many enzymes and accessory proteins at specific regions of DNA. An 
important interaction is with the DNA polymerase III (Pol III " subunit of the catalytic 
core), the protein responsible for nucleotide synthesis of the chromosomal nascent DNA 
strand. The SC secures the Pol III " subunit to DNA, increasing the enzymes lifetime 
on DNA, conferring high processivity of nucleotide polymerisation > 100-fold.58,67,79,155 
The biochemistry and structural biology of the SCEco has been studied extensively. The 
structure was first solved by Kong et al. in 1992 and was found to be a ring-shaped 
homodimer, with each monomer consisting of three structurally similar domains 
(Figure 3.1).77 The domains comprise of two !-sheets and two "-helices, orientated so 
the "-helices line the centre of the ring forming a central channel and the !-sheets 
forming the exterior of the protein. Each !-sheet has four antiparallel !-strands arranged 
in a Greek key motif (Figure 3.1), linked by the "-helices. The domains are connected 
through hydrogen bonds (H-bond(s)) of the adjacent !-strands, forming a continuous !-
sheet across the monomer, and interconnecting domain loops. The central channel is 
sporadically lined with positively charged residues, particularly Lys and Arg, that form 
topological interactions with dsDNA.77,156 The circular channel has a diameter of ~35 
Å, thereby large enough to hold dsDNA (~20 Å). 
 
Amy E. McGrath  49 
 
 
Figure 3.1: Structural arrangement of the SCEco monomer. Schematic diagram of the 
secondary structure elements with "-helices are shown as swirls and !-strands as 
arrows. Each domain has two-fold symmetry. Cartoon diagram of one monomer with 
the "-helices and !-strands labelled.  Adapted from Kong et al.77 
 
 
Thus far SC crystal structures from eleven bacterial species have been solved (Table 
3.1). Despite the varying sequence identity with respect to SCEco (varying between 20–
57%), the overall structures are conserved. The main difference between the SCs is the 
shape of the central channel. The Gram-positive structures appear to have a slightly  
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elliptical shaped channel, as opposed to the circular channel of the Gram-negative SCs. 
SCMtu, whose Gram classification is controversial, has a circular channel.159 
Electrostatic complementarity plays a significant role in dimerisation. The N-terminus 
of one monomer contains several negatively charged residues that complement the 
positively charged residues near the C-terminus of the other monomer.77 This 
electrostatic distribution facilitates the head-to-tail association of dimers and contributes 
to the high stability of the SC dimer.  
A co-crystal structure of a short primer-template DNA fragment bound directly to SCEco 
has been solved.156 The duplex DNA, which contains a 5$ ssDNA extension, was found 
to pass through the central channel at an angle of 22° from the two-fold rotational axis 
of the SC (Figure 3.2). The 5$ end of the duplex portion makes specific contact with a 
loop region between helix "1$ and strand !2$ of domain II (residues 148–152; the DNA-
binding loop, DB-loop; detailed more in Chapter 5). It has been postulated that this 
loop can assist the SC to distinguish between DNA polymerase V-dependent translesion 
DNA synthesis and DNA replication.161 
An important interaction that is vital for the replication and repair process is the SC and 
clamp loader (comprised of Pol III %, %$ and three copies of γ or τ subunits; sometimes 
called the “γ complex”) interaction. During DNA replication, the SCs remain bound to 
the leading strand for continuous DNA replication. However, SCs must be continuously 
loaded onto primed DNA sites of the lagging strand for the Okazaki fragments synthesis 
by the catalytic core.162 Consequently, the clamp loader will continuously unload SCs 
from the DNA for reuse at primed sites upstream of the next Okazaki fragment.94,162 
The CLC traps one SC monomer in a conformation that is unfavourable for ring closure, 
putting strain on the dimer and leading to the opening of the adjacent dimer interface.65 
Crystal structures of the SC in complex with the Pol III % subunit reveal that a loop from 
Amy E. McGrath  52 
the Pol III % subunit binds into the peptide-binding pocket of SC monomer (the pocket 
and the interactions is explained in great detail in Chapter 4), bringing the CLC to the 




Figure 3.2: Co-crystal structure of DNA in complex with SCEco (PDB entry 3BEP).156 
The SCEco is represented as surface view with each domain coloured differently: domain 
I, grey; domain II, white; and domain III, purple. The two strands of the duplex DNA 
are represented as yellow and green sticks with the 5$ and 3$ ends labelled. The angle 
and direction the DNA passes through the centre of the SC from the rotational axis is 
shown on the side view of the structure (right).  
 
 
the weaker interactions outside the pocket with the other clamp loader subunits to 
stabilise the monomer.59,60 The helix "1$$ of domain III is distorted from ideal geometry 
in the wild-type SC, but the distortion disappears upon binding of the Pol III % subunit, 
disrupting the capabilities of the helix packing against helix "2 of the adjacent domain 
I.59,65 Due to the high degree of structural conservation, it is predicted that the overall 
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function and interactions within the DNA replisome is conserved with respect to the 
well-characterised E. coli system. 
 
3.1.1 Aims of this Chapter 
This chapter describes attempts to elucidate the crystal structures of ESKAPE SCs to 
ascertain whether the overall structures are conserved with respect to those previously 
solved. The solution dynamics and dimeric interface of the ESKAPE SCs will be 
observed using mass spectrometry. Specifically, the ability of the ESKAPE SCs to 
exchange subunits with SCEco will be probed. This ability to form heterodimers will 
showcase the similar structural and chemical environment of the interfaces.  
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Construction of ESKAPE SC plasmids 
The dnaN genes from E. faecium DO (accession no. YP_006374608), S. aureus subsp. 
aureus N315 MRSA/VSSA (accession no. WP_000969811), A. baumannii ATCC 
19606 (accession no. EEX01755), A. baylyi ADP1 (accession no. CAG66987), 
P. aeruginosa PAO1 (accession no. NP_064722) and E. cloacae EcWSU1 (Genbank 
accession no. AEW71442) were used for this study. Klebsiella pneumoniae SC was not 
considered in this study as the sequence identity was 98% to SCEco. Instead, SCEcl was 
investigated as the sequence identity to SCEco was the lowest (95%) out of the 
Enterobacter spp. Our laboratory is focusing on two strains of Acinetobacter spp. for 
understanding DNA replication, therefore this study will also examine the SC from 
A. baumannii (SCAbm) and A. baylyi (SCAby). There have been cases of 
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community-acquired and a hospital-acquired infection with these two species, however, 
A. baumannii is considered the more pathogenic of the two.163-165 
The A. baumannii and A. baylyi dnaN genes were cloned from genomic DNA into 
pETMCSIII vectors by Dr Fay Dawes and Dr Andrew Robinson, respectively, 
producing pFD1592 and pAR1349 (see Figure A.1, Appendix). The dnaN genes for 
P. aeruginosa, E. cloacae, S. aureus and E. faecium were obtained from DNA 2.0 
(USA) in the T7-based expression vector pJ434. The genes were codon optimised for 
expression in E. coli. E. faecium dnaN was cloned into a low-copy-number cloning 
vector, pJ251. All genes had an NdeI restriction site (CATATG) at the 5$ end of the 
gene sequence, with the ATG of the restriction site encoding the start codon for Met. An 
EcoRI restriction site (GAATTC) follows the stop codon in the gene (for plasmid maps 
see Figure A.1, Appendix). The corresponding restriction sites are located in the 
multiple cloning site of the vector plasmids used in this study such that the gene of 
interest will be cloned in the correct orientation. All plasmids were transformed into 
chemically competent DH5" cells (section 2.3.7) and grown in an overnight culture of 
LB with the appropriate antibiotic to produce lots of plasmid for sub-cloning. 
E. faecium and S. aureus plasmids were transformed into chemically competent SURE 
2 cells, as the DH5" cells would not grow in an overnight culture (section 2.3.1). The 
plasmids were extracted from cells by spin column (section 2.3.2.2). 
 The A. baumannii, A. baylyi, P. aeruginosa, E. cloacae and S. aureus dnaN genes were 
subcloned into the λ-based pND706 expression vector. For the pJ434 plasmids 
(P. aeruginosa, S. aureus and E. cloacae), the dnaN genes were PCR amplified (section 
2.3.4.1) using vector primers pJ434_F and pJ434_R (Table A.1, Appendix) located 60–
100 base pairs (bp) downstream and upstream from the gene of interest. The pJ434 
plasmid is a low-copy-number T7 promoter, and it was necessary to amplify the gene 
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before subcloning. The E. faecium dnaN gene underwent gradient PCR amplification 
(section 2.3.4.2) using NED674 and NED675 primers (Table A.1, Appendix) as 
following the general rule of using an annealing temperature of 5 °C below the primer 
pair melting point resulted in no PCR product. 
All amplified genes were then purified using the QIAquick PCR purification kit 
(section 2.3.2.2). The PCR amplified genes and the pFD1592 and pAR1349 plasmids 
were restriction digested with NdeI and EcoRI (section 2.3.6). DNA fragments were 
separated by agarose gel electrophoresis (section 2.3.5) and the fragment of interest – 
dnaN gene – was extracted and purified (section 2.3.2.1). The dnaN genes from 
A. baumannii, A. baylyi, P. aeruginosa, E. cloacae and S. aureus were ligated into the 
digested λ-based expression vector pND706 (section 2.3.6.1; Figure 3.3) and 
E. faecium and S. aureus were ligated into the digested T7-based expression vector 
pETMCSIII (Figure 3.4). To assess the presence of the insert, ligation mixtures were 
transformed into chemically competent DH5" cells (section 2.3.7) and the resulting 
colonies from an overnight agar plate culture were subjected to colony PCR (section 
2.3.4.3). Once a positive clone was identified, the insert was sequenced (section 2.3.4.4) 
using the vector primers (P9 and P10 for pND706; P3 and P4 for pETMCSIII (Table 
A.1, Appendix)). Newly constructed plasmids with confirmed sequences were then 
transformed into chemically competent E. coli expression strains for overproduction of 
the SC proteins (section 3.2.2). The list of the plasmids constructed for this study are in 








Figure 3.3: Plasmids constructed during this study in the λ-based expression pND706 
vector. The P. aeruginosa, E. cloacae and S. aureus dnaN genes were PCR amplified, 
and the A. baumannii and A. baylyi dnaN genes were restricted enzyme digested from 
the parental plasmids (see Figure A.1, Appendix). The inserts were ligated into the 
digested and dephosphorylated pND706 expression vector using the T4 DNA ligase. 
Constructed plasmids were routinely sequenced prior to expression trials. Plasmid maps 
made by Dr Fay Dawes using Vector NTI.166  
 
 




Figure 3.4: His6 tag plasmids constructed during this study in the T7-based expression 
pETMCSIII vector. The dnaN inserts were PCR amplified from the parent plasmid (see 
Figure A.1, Appendix) and ligated into the restriction enzyme digested and 
dephosphorylated pETMCSIII expression vector using the T4 DNA ligase. Constructed 
plasmids were routinely sequenced prior to expression trials. Plasmid maps made by Dr 




3.2.2 Overproduction and purification of ESKAPE SC  
SCs under the control of the tandem bacteriophage λ pR and pL promoters (SCAbm, 
SCAby, SCPae, and SCEcl) were expressed as described in section 2.2.3.1. Overproduction 
of SCAbm-His6 and SCAby-His6 were conducted as outlined in section 2.2.3.3. SCEfu-His6 was 
expressed as described in section 2.2.3.4.  
 
3.2.2.1 Purification of Un-tagged SCs 
 The SCs purified in this study were SCSau, SCAbm, SCAby, SCPae and SCEcl. The 
purification procedure for all proteins is outlined below, unless specified. The purity of 
the proteins samples was assessed after each purification step using SDS-PAGE gels 
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(section 2.4.2). The final purified samples were then confirmed using denatured mass 
spectrometry (section 2.5), and the experimentally determined MWs compared to the 
theoretical MW calculated using the ExPasy ProtParam tool.153 
 
3.2.2.1.1 Cell lysis and ammonium sulfate precipitation 
Cells were resuspended in Lysis buffer [50 mM Tris-HCl, pH 7.6, 1 mM EDTA, 1 mM 
DTT, 500 mM NaCl, 10% (v/v) glycerol], with PSMF added to a final concentration of 
0.5 mM once the cells were fully suspended. Cells were lysed by passage three times 
through a chilled French press at 11,000 psi. Lysate was clarified by centrifugation 
[F21-8x50y rotor, 30,438 × g, 30 min, 6 °C]. Ammonium sulfate was slowly added to 
the soluble fraction at a concentration of 0.4 g mL–1 to precipitate the SCs. Sample was 
then clarified by centrifugation [F21-8x50y rotor, 30,438 × g, 30 min, 6 °C], and 
supernatant was discarded. Pellet was collected for further purification. Samples of 
whole cell, soluble and insoluble fractions were analysed directly by SDS-PAGE 
(section 2.4.2). 
 
3.2.2.1.1.1 Refolding of SCSau 
SCSau was > 90% insoluble after cell lysis (see section 3.2.2.2.1), therefore refolding of 
insoluble SCSau protein in the inclusion bodies was attempted. Cell pellet from 
expression was resuspended in Refolding Lysis buffer [25 mM Tris-HCl pH 7.6, 1 mM 
EDTA, 2 mM DTT]. Cells were lysed by passage two times through a chilled French 
press at 11,000 psi. Lysate was clarified by centrifugation [F21-8x50y rotor, 30,438 × g, 
30 min, 6 °C]. The insoluble pellet was washed (wash 1) by resuspension in Refolding 
Lysis buffer supplemented with 1 M NaCl for 45 min at 4 °C. The sample was 
homogenised by passage two times through a chilled French press at 11,000 psi. Lysate 
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was collected and clarified by centrifugation, as before. The pellet was washed a second 
time (wash cycle 2) by resuspenion in Refolding Lysis buffer without NaCl, followed 
by French press and centrifugation, as before. Wash cycle 1 was repeated with the pellet 
before the resulting pellet was resuspended in the smallest volume of Refolding Lysis 
buffer possible. A sample from each wash cycle was analysed by SDS-PAGE gel 
(section 2.4.2) for the presence of SCSau.  
 
3.2.2.1.2 Diethylaminoethyl  (DEAE) flowthrough 
Pellets were resuspended in 30 mL of DEAE buffer IA [50 mM Tris-HCl pH 7.6, 1 mM 
DTT, 1 mM EDTA, 150 mM NaCl, 10% (v/v) glycerol] and dialysed overnight against 
2 L of DEAE buffer IA (section 2.4.3). Following dialysis, the sample was filtered 
through a 0.22 µM syringe filter prior to loading onto the column. The column (2.5 × 15 
cm) of Toyopearl TSK DEAE-650M anion-exchange resin was pre-equilibrated with 
DEAE buffer IA. The sample was applied to the column at 0.8 mL min–1 via a 50 mL 
SuperloopTM 1/16$$ (GE Healthcare), and continually washed with the same buffer until 
the protein eluted in the flowthrough. 
 
3.2.2.1.3 DEAE binding 
Pooled fractions from the previous purification column were dialysed against DEAE 
buffer IIA [50 mM Tris-HCl pH 7.6, 1 mM DTT, 1 mM EDTA, 10% (v/v) glycerol], as 
specified in section 2.4.3. The sample was loaded onto the DEAE column, 
pre-equilibrated in DEAE buffer IIA, at 0.8 mL min–1. The column was washed with 
150 mL DEAE buffer IIA before a gradient of 0 to 1 M NaCl was applied over 500 mL 
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to elute the protein. SCs eluted at with a sharp peak ~100 mM NaCl. SCEcl protein was 
pure after this step, the others required further purification. 
 
3.2.2.1.4 Hydroxyapatite 
Pooled fractions from DEAE binding were dialysed extensively against three changes of 
2 L Hydroxyapatite buffer A [10 mM sodium phosphate pH 6.5, 1 mM DTT] (section 
2.4.3). In most cases, the samples were greater than 200 mL. As the eluted protein 
becomes quite dilute, the samples were concentrated (see section 2.4.4) to < 50 mL 
prior to loading onto the CHTTM Ceramic Hydroxyapatite column (Bio-Rad) to observe 
a clearly visible peak. The sample was loaded onto pre-equilibrated column of 
Hydroxyapatite buffer A at 0.7 mL min–1. Highly pure SC protein was eluted in a linear 
gradient of 15 to 100 mM sodium phosphate pH 6.5 over 270 mL. 
 
3.2.2.2 Purification of SCHis6 
The SCHid6 purified in this study were SCEfu-His6, SCAbm-His6, SCAby-His6 and SCEco-His6. The 
purification procedure for all the proteins is outlined below, unless specified. 
 
3.2.2.2.1 Cell lysis 
Cells were resuspended in Lysis buffer and lysed as described in section 3.2.2.1.1. The 
soluble fraction was collected for further purification. 
 
3.2.2.2.2 Immobilised metal anion chromatography 
The samples were dialysed against two changes of 2 L of HiTrap (HT) buffer [50 mM 
Tris-HCl, pH 7.6, 1 mM DTT, 10 mM Imidazole, 10% (v/v) glycerol, 500 mM NaCl] 
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(section 2.4.3). The samples were filtered through a 0.22 µM syringe filter prior to 
loading onto a 1 mL HiTrap HP column (GE Healthcare Life Sciences) connected to an 
ÄKTApurifier system (GE Healthcare Life Sciences) at 1 mL min–1. The column was 
washed with 20 mL HT buffer and SCHis6 proteins were eluted with HT buffer 
containing imidazole along a linear gradient of 10 to 350 mM imidazole over 30 mL 
(typically between 120–150 mM imidazole).  
 
3.2.2.2.3 MonoQ 
Pooled fractions of SCAbm-His6 and SCAby-His6 were dialysed against three changes of 2 L 
of MonoQ (MQ) buffer A [50 mM Tris-HCl pH 7.6, 1 mM DTT, 1 mM EDTA, 10% 
(v/v) glycerol] (section 2.4.3). Samples were centrifuged through a 0.22 µM syringe 
filter prior to loading onto a pre-equilibrated MonoQ 8 mL column (GE Healthcare) via 
a 50 mL SuperloopTM 1/16$$ at 1 mL min–1. SCHis6 were eluted in a linear gradient of 
MQ buffer A with 0 to 120 mM NaCl over 200 mL, typically with a sharp peak at 100 
mM NaCl.   
 
3.2.2.2.4 Hydroxyapatite 
SCEco-His6 was purified according to published work.52,78 SCEfu-His6 was purified as 
outlined in section 3.2.2.1.4, with the linear gradient of 15 to 200 mM sodium 
phosphate pH 6.5 over 270 mL. Highly pure SC protein eluted with a sharp peak at 110 




Amy E. McGrath  62 
3.2.3 X-ray crystallography 
3.2.3.1 Protein preparation 
Pure proteins were dialysed against three changes of 2 L of X-ray crystallography buffer 
[20 mM Tris-HCl pH 7.6,  1 mM EDTA, 1 mM DTT, 20 mM NaCl] (section 2.4.3) to 
eliminate glycerol from the buffer. Samples were then concentrated to 5–10 mg mL–1. 
 
3.2.3.2 Protein crystallisation and optimisation 
All crystals initially grew at 21 °C, except SCEfu-His6 which was grown at 12 °C, using 
the vapour diffusion method. Initial screens were conducted using the PEGs, PEGs II 
and JCSG+ screens (QIAGEN); 50 µL of screening condition was dispensed into the 
reservoirs of CrystalEX Second Generation plates (Corning) and equal volumes of 
protein and reservoir solution were mixed (total volume of 2 µL). After initial 
conditions were identified (Table 3.2), crystals for X-ray diffraction were grown using 
the hanging drop vapour diffusion method with VDXm plates (Hampton Research,  
 






SCAbm-His6 10  PEGs C12: 0.1 M MES pH 6.5, 15% (w/v) PEG 
20,000 
SCAby-His6 10 JCSG+  B8: 0.2 M MgCl2, 0.1 M Tris pH 7.0, 10% 
(w/v) PEG 8,000 
SCPae 6.8 JCSG+  B6: 0.1 M phosphate-citrate pH 6.0, 40% 
(v/v) ethanol, 5% (w/v) PEG 1,000 
SCEcl 7.0 PEGs G8: 0.2 M MgSO4, 20% (w/v) PEG 3,350 
SCEfu-His6 10 JCSG+  A6: 0.2 M LiSO4, 0.1 M phosphate-citrate 
pH 4.2, 20% (w/v) PEG 1,000 
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USA); 1 µL of protein were mixed with an equal volume of reservoir solution on a 
siliconised coverslip (total volume of 2 µL) prior to suspension over reservoirs 
containing 1 mL of condition (varying precipitant concentration and pH). 
 
3.2.3.2.1 Optimisation  
In order to optimise crystals obtained from screens, individual components of the 
conditions were screened. For example, ranges of buffers with different pH values, 
precipitant concentration, temperature and protein concentration were varied in an 
attempt to produce single large crystals that diffracted beyond 3 Å resolution. 
SCAbm-His6 crystals were initially grown from 0.1 M MES pH 6.5, 15% (w/v) PEG 
20,000. Crystals that were formed by microseeding (undiluted stock) in 0.1 M Tris-HCl 
pH 7.6, 0.1 M MgCl2, 7.5% (w/v) PEG 3,350 and 1% (v/v) DMSO with the initial 
protein concentration of 10 mg mL–1 gave resolution < 3 Å.  
SCPae crystals were initially produced in 0.1 M phosphate-citrate pH 6.0, 40% (v/v) 
ethanol, 5% (w/v) PEG 1,000 and could not be reproduced. SCEcl crystals were 
optimised by microseeding in 0.1 M citrate pH 6.0, 0.15 M MgSO4, 10% (w/v) PEG 
3,350 with a seed stock dilution of 1x10–4, protein concentration of 7 mg mL–1.  
SCAby-His6 crystals initially grew from condition B8 of the JCSG+ suite [0.2 M MgCl2, 
0.1 M Tris-HCl pH 7.0, 10% (w/v) PEG 8,000]. Optimisation of crystals that improved 
the resolution to < 3 Å involved streak seeding from a well containing 12.5% (w/v) PEG 
3,350 to 7.5% (w/v) PEG 3,350 (both also containing 0.1 M MgCl2, 0.2 M Tris-HCl pH 
7.0 and 0.05 M EDTA). While the resolution improved to ~2.8 Å and the data could be 
indexed, the integration and scaling of the data gave poor statistics (low completeness in 
both low resolution and high resolution bins, high Rmerge of 22.8%).  
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SCEfu-His6crystals originally grew from the JCSG+ suite condition A6 [0.2 M LiSO4, 0.1 
M phosphate-citrate pH 4.2, 20% (w/v) PEG 1,000]. Optimisation of the condition to 
produce crystals that diffracted < 3 Å included additive screening. Eventually, the 
crystal that diffracted to 2.8 Å resolution, and could be solved by Phaser, was grown in 
the condition 0.2 M LiSO4, 0.1 M phosphate-citrate pH 4.3, 15% (w/v) PEG 1,000 and 
1% (v/v) DMSO at 21 °C. 
 
3.2.3.3 Diffraction and data collection 
Crystals were cryoprotected by incrementally increasing the concentration of the PEG 
in the mother liquor to 25% (w/v) using 5% increments with 2 min soaking at each 
increment. All crystals were mounted onto MiTeGen™ loops (MiTeGen, USA) on pins 
with magnetic caps. For data collection in-house, the crystals were flash-frozen to 100 
K using an Oxford Cryo-stream. Diffraction data were collected with a MAR345 
desktop beamline using Cu K" X-rays from a Rigaku 007HF rotating anode generator 
with Varimax optics. Frames were collected for each crystal with 1° oscillation and an 
exposure time of 20 min.  
For synchrotron data collection, the mounted crystals were flash-frozen in liquid 
nitrogen and placed in SAM cassettes. The SSRL automated mounting system was used 
and data were collected at 100 K with either MX1 or MX2 beamlines at the Australian 
Synchrotron, using Blue-Ice.167 
 
3.2.3.4 Data processing, structural solution and refinement 
Data sets were integrated, merged and scaled with HKL2000. Structures were solved by 
molecular replacement either with PHASER in the CCP4 suite168 or PHENIX;169 the 
SCEco coordinates from PDB ID 4K3S80 was used as the search model for the 
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Gram-negative SC, the SCBsu coordinates from PDB ID 4TR675 was used as the search 
model for SCEfu-His6. Initially models were built manually with COOT,170 and refined 
using REFMAC5 in the CCP4 suite;171 5% of randomly selected reflections were set 
aside for cross validation (Rfree) refinement statistics. PHENIX autobuild was used to 
build and refine the initial models. Iterative model building and refinement, including 
non-crystallographic symmetry-based restrained refinement, was conducted using 
COOT, PHENIX and REFMAC5. For SCAbm-His6 and SCEfu-His6, intensity based twin 
refinement was selected in REFMAC5 refinement as the X-ray data was twinned. 
Electron density maps (2mFo-DFc and mFo-DFc) were calculated using structure factor 
amplitudes and phase angles derived from REFMAC5. Molecular visualisation and 
structure illustrations were performed using VMD172 and PYMOL.173 
 
3.2.4 Subunit exchange by mass spectrometry 
Subunit exchange was investigated between SCEco dimer and the SC dimers from the 
subset of ESKAPE pathogens using nanoESI-MS. In the following, all concentrations 
refer to SC as a dimer, and all dialysis steps were performed at 4 °C. SC samples were 
extensively dialysed against 2 L Buffer F [0.2 M ammonium acetate pH 7.6, 1 mM 
!-mercaptoethanol] changed four times (section 2.4.3).  ESI-mass spectra were 
acquired in positive ion mode using nanoESI on a Waters Synapt HDMS spectrometer 
with a Z-spray source. Spectra were acquired over range of 500–10,000 m/z. Between 
100 and 150 acquisitions were combined and spectra were baseline subtracted and 
smoothed using the Savitzky-Golay algorithm.174,175 
From initial experiments, where native state spectra of each SC were collected, it was 
determined that the conditions listed in Table 3.3 were optimal for each SC dimer in 
200 mM ammonium acetate pH 7.6. For subunit exchange, equal amounts of protein 
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(5 µM) were mixed and incubated at 30 °C. Samples of 3 µL were taken hourly for the 
first 7 hours then at 24 hours, each time point analysed on the MS. The time from 
sample extraction to measurement was < 1 min. In the case of SCPae, SCEcl and SCEfu-
His6, SCEco-His6 was used for the subunit exchange experiment to increase the MW 
difference for peak separation. 
 
Table 3.3: Typical instrumental parameters used for nanoESI-MS to analyse subunit 
exchange between different SC dimers 
MS Parameter  
Capillary voltage (V) 1500 
Sampling cone (V) 150 
Nano flow (µL/min) 0.00–0.08 
Scan time (s) 2 
ToF (V) 9100 
MCP detector voltage (V) 1800 
Source temperature (°C) 50 
Desolvation temperature (°C) 100 
Backing pressure (mbar) 3–3.5 
 
3.2.4.1 Subunit exchange in the presence of 1 M NaCl 
Subunit exchange was conducted in the presence of 1 M NaCl to determine the 
importance of the electrostatic interactions for the formation of SC dimers. In the 
following, all concentrations refer to SC as a dimer. Equal amounts of protein (2.5 µM) 
were mixed and incubated at 30 °C in Buffer G (30 mM Tris-HCl pH 7.6, 1 M NaCl, 10 
mM MgCl2, 1 mM DTT). Samples of 50 µL were taken at the time points 3.5, 7 and 11 
h and dialysed extensively against 2 L Buffer F (see sections 2.4.3 and 3.2.4) changed 
four times at 4 °C. Samples of 3 µL were analysed on the mass spectrometer. The time 
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from sample extraction to measurement was < 1 min. The pairwise subunit exchange 
combinations were as per section 3.2.4. 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 Producing the ESKAPE SCs 
Plasmids were constructed to direct overproduction of the different ESKAPE SCs. The 
purity of the isolated proteins was verified by SDS-PAGE and mass spectrometry. 
Coomassie blue stained SDS-PAGE gels of the purified ESKAPE SCs are shown in 
Figure 3.5, with 10 µg of protein loaded. Purified proteins used in this study were 
judged to be > 95% pure from the SDS-PAGE gels, with the positions of the bands 
consistent with the size of the protein as judged by the standards. Accurate masses of all 
proteins were further determined by nanoESI-MS following dialysis into 0.1% (v/v) 
formic acid (Figure 3.5). The majority of the masses were in agreement with the 
calculated masses with less than ± 0.01% error. SCAbm-His6, SCAby-His6 and SCEfu-His6 had 
one Met added to the 5$ end of the sequence (Met-His-His-His-His-His-His). Native 
state nanoESI-MS showed that all the SCs were dimers in solution (Figure C.1, 
Appendix). 
 
3.3.1.1 Expression and purification of SCSau 
The SCSau protein overexpressed well in E. coli BL21 cells, to approximately the same 
level of expression as observed for other ESKAPE SCs. After lysis by French press in 
the initial lysis buffer [50 mM Tris-HCl, pH 7.6, 1 mM EDTA, 1 mM DTT, 500 mM 
NaCl, 10% (v/v) glycerol, 0.5 mM PMSF], > 90% of the protein was insoluble. 
Attempts were made to purify the soluble fraction using the same protocol for the un-
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tagged SCs. While the purified protein had a mass of ~42 kDa based on SDS-PAGE, the 
protein could not be confirmed by mass spectrometry even after attempts to optimise the 
chemical conditions.  
It is important to note that usually the SCs will show two protein bands (corresponding 
to monomeric and dimeric SCs) on an SDS-PAGE gel if the sample is not heated at 95 
°C for 10 min prior to running the sample. When SCSau was analysed in this manner, no 
protein bands corresponding to the SC dimer were observed. To assess whether the lysis 
buffer was causing SC protein to precipitate, the buffer conditions were changed, 
omitting NaCl, glycerol, PMSF and including 10 mM Spermidine. The resulting protein 
yield was higher, however, the MW of the protein could not be confirmed by mass 
spectrometry. The lack of mass spectra and solubility issues suggested that SCSau 
monomer was incorrectly folded. Attempts to refold the insoluble fraction from the 
initial lysis were undertaken. Pure protein corresponding to ~42 kDa MW was observed 
from SDS-PAGE analysis; however, mass spectrometry again could not confirm the 
MW of the protein. The SCSau protein samples from all purification efforts were used in 
crystallisation trials but no quality crystals were obtained. 
The SCSau-His6 protein overexpressed quite well in E. coli BL21 cells using both 
auto-induction and arabinose induction expression systems, however, the protein was 
completely insoluble after French press lysis with the initial lysis buffer [50 mM 
Tris-HCl, pH 7.6, 1 mM EDTA, 1 mM DTT, 500 mM NaCl, 10% (v/v) glycerol, 
0.5 mM PMSF]. The gene was ordered codon optimised for expression in E. coli and 
the DNA sequence was correct after sequencing, using both vectors and S. aureus dnaN 
primers (NED640–NED643; Table A.1, Appendix). The decision was then made to 
discard the protein and focus on the rest of the ESKAPE SCs. 
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Figure 3.5: Denatured mass spectra of purified SC protein. Determined MW of protein 
samples is labelled in blue. The charge states of the ionic peaks for each sample are 
shown above peaks in the spectra. SDS-PAGE analysis of purified protein sample 
(right), from Coomassie blue solution stain. The protein molecular weight markers are 
labelled to the left of the gels. 
 
 
3.3.2 Crystallisation and structural determination of SCAby and SCAby-His6  
Attempts were undertaken to crystallise SCAby and SCAby-His6. No crystals were obtained 
with SCAby. Crystals were obtained from SCAby-His6 initially in the condition B8 from the 
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JCSG+ suite [0.2 M MgCl2, 0.1 M Tris-HCl pH 7.0, 10% (w/v) PEG 8,000] and 
diffracted to 4.0 Å resolution. Optimising this condition lead to an improved resolution 
of 2.8 Å, collected at the Australian Synchrotron on MX2. The data was indexed, 
refined, integrated and scaled, however, the completeness was low at low resolution and 
therefore the structure could not be solved. The Rmerge was high (22.8%). The unit cell 
dimensions were large (74 × 149 × 328 Å), with the result that the diffraction spots 
were close together and overlapping with each other at low resolution, resulting in 
poorly estimated intensities. Additionally, there appeared to be two lattices in the 
diffraction pattern. While one lattice had a stronger diffraction pattern, overlapping 
spots are a likely source of perturbation in measured intensities. Several crystals of 
SCAby-His6 were subjected to X-ray diffraction, and all had more than one lattice present 
in the diffraction pattern. As such, SCAby was the only purified SC protein whose 
structure remained unsolved. 
 
3.3.2 Structure of SCAbm-His6  
Much like SCAby-His6, the SCAbm-His6 crystals were difficult to work with. The crystals 
required cryoprotection, however, they dissolved in every cryosolution except 
increasing the PEG 3350 concentration from 12.5 to 25% (w/v) in 2.5% increments and 
soaking for 4 min in each solution. Every crystal had multiple lattices in the diffraction 
patterns, and overlapping diffraction spots due to the large unit cell dimensions (72.71 
Å × 328.60 Å × 147.50 Å). Individual spots were resolved using the MX2 beamline at 
the Australian Synchrotron, and the crystal structure was solved to 2.95 Å resolution 
(Table 3.4). The protein crystallised with eight dimers in the asymmetric unit (Figure 
3.6b). As the data was twinned, intensity based twin refinement in REFMAC5 was 
utilised to improve refinement and clarity of the density maps.  
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The overall architecture was very similar to that of SCEco (Figure 3.6a), despite a 
moderate sequence identity of 44%. There are 382 residues comprising the SC 
monomer, and with the His6 tag comes to 388 residues. The protein is a ring-shaped 
head-to-tail dimer. There are three domains of identical structure, !-"-!-!-!-!-"-!-!-! 
(Figure B.1a, Appendix), all connected by large loops. The circular central channel is 
formed by twelve "-helices and is lined with positive charged residues, such as Arg and 
Lys, enabling electrostatic interactions with the negatively charged phosphate backbone 
of DNA. The central channel is ~35 Å in diameter, large enough to accommodate 
dsDNA.77,156 Along with the interconnecting domain loops, there are hydrogen-bonding 
networks between the !-sheets of each domain that creates an extended !-sheet to keep 
the domains rigid.  Six H-bonds connect !4 of domain I and !8$ of domain II, seven 
H-bonds between !4$ and !8$$ of domains II and domain III, respectively and five 
between !4$$ of domain III and !8 of domain I at the interface. SCAbm-His6 has fifteen 
additional residues compared to SCEco. These are found in the loop regions of the 
!-strands in the domains, in particular between !4$ and !5$ of domain II. Density for 
either one or two His residues of the His6 tag were seen and built into the electron 
density map for each monomer. Likewise, the density for many of the loop regions was 
weak, and thus some loop regions of the eight dimers were not built. 
The N-terminal face of SCAbm-His6 is predominately negatively charged (Figure 3.6c, left 
panel), particularly domains II and III, and domain I is more hydrophobic. The dimer 
interface (indicated by the arrows in Figure 3.6c) has hydrophobic, positively and 
negatively charged residues. The C-terminal face (Figure 3.6c, right panel) has patches 
of negatively charged residues on domains I and II while being predominately 
hydrophobic. Furthermore, the interface is still composed of hydrophobic, positively
  




Figure 3.6: Structure of the SCAbm-His6. (a) Cartoon representation of the SCAbm-His6 
structure, with the C-terminal face shown. (b) Asymmetric unit contained eight dimers, 
represented here in cartoon. (c) Computed electrostatic surface of the dimer, N-terminal 
face on the left, and C-terminal face on the right, generated using COOT. Blue – 
positive, red – negative and white – hydrophobic residues. The dimer interface is 
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Table 3.4. Crystallographic data for SCAbm-His6. 















Resolution (Å) 50.00–2.95 
a(3.06–2.95) 
bRmerge (%) 11.5 
No. of unique reflections 144290 (14388) 
Mean I/σI 12.8 (2.3) 
Completeness (%) 99.8 (99.9) 
Redundancy 4.6 (4.6) 
Resolution (Å) 2.95 
cRwork/Rfree (%) 21.5/28.6 
Bond lengths (Å) 0.013 
Bond angles (°) 1.488 
Planes (°) 0.008 
Chiral volumes (Å3) 0.069 
Mean B value (Å2) 48.90 
            Ramachandran Plot  
Favoured (%) 96.16 
Allowed (%) 3.32 
Outliers (%) 0.52 
aNumber in parentheses refer to the highest resolution bin. 
bRmerge = 4 ℎMN − 4 ℎMN >>&'( |/ 4 ℎMN >>&'( -where 4 ℎMN >  is the 
intensity of the ith measurement of reflection with index ℎMN-. 
cR = ( |S? ℎMN&'( − SJ ℎMN |/ |S? ℎMN&'( | , where S?  and SJ  are the 
observed and calculated structure factors, respectively. 
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and negatively charged residues. The solvent-accessible area for chain B of the interface 
is 1069 Å2 with 32 residues involved and for chain A 1081 Å2 with 31 residues, 
according to the PDBePISA server.176-178 
3.3.3 Structure of SCPae 
The SCPae crystal was obtained from the JCSG+ suite condition B6 (0.1 M 
phosphate-citrate pH 6.0, 40% (v/v) ethanol, 5% (w/v) PEG 1,000) and could not be 
reproduced during optimization process. The crystal diffracted to 2.39 Å resolution on 
the MX1 beamline at the Australian Synchrotron and crystallised the in P1 space group 
(Table 3.5). The structure was solved by molecular replacement with Phaser using the 
SCEco structure (PDB entry 4K3S) as a search model. The protein crystallised with two 
dimers in the asymmetric unit (Figure 3.7b). Each monomer contains 367 residues and 
has a sequence identity of 58% to SCEco.  
The overall structure is similar to those of SCEco and SCAbm-His6 (Figure 3.7a). There are 
three structurally identical domains, with the same secondary structural arrangement as 
SCEco and SCAbm-His6 (see section 3.3.2 and Figure B.1b, Appendix). The central 
channel is circular and approximately 35 Å in diameter, lined with positively charged 
residues. There are six H-bonds each between !4 of domain I and !8$ of domain II, !4$ 
and !8$$ of domains II and domain III and !4$$ of domain III and !8 of domain I at the 
interface. 
The electrostatics mapped to the surface of SCPae are quite similar to SCAbm-His6 (Figure 
3.7c).  The N-terminal face is predominately negatively charged and the C-terminal face 
is predominately hydrophobic. Domains I is negatively charged at the tips on both faces, 
while domains II and III have hydrophobic tips. Much like SCAbm-His6, the dimer 
interface is lined with hydrophobic, positive and negatively charged residues on both 
Amy E. McGrath  75 
faces. The solvent accessible area of both chains at the interface is approximately 1242 




Figure 3.7: Structure of SCPae. (a) Cartoon representation of the SCPae structure, with 
the C-terminal face shown. (b) Asymmetric unit contained two dimers, represented here 
in cartoon. (c) Computed electrostatic surface of the dimer, N-terminal face on the left, 
and C-terminal face on the right, generated using COOT. Blue – positive, red – negative 
and white – hydrophobic residues. The dimer interface is indicated by the black arrows.   
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Table 3.5: Crystallographic data of SCPae 















Resolution (Å) 50.00–2. 39 
a(2.46–2.39) 
bRmerge (%) Eec_Eec_ 
No. of unique reflections 56764 (2760) 
Mean I/σI 14.2 (2.4) 
Completeness (%) 94.0 (90.2) 
Redundancy 3.4 (2.9) 
Resolution (Å) 2.39 
cRwork/Rfree (%) 24.4/28.3 
Bond lengths (Å) 0.012 
Bond angles (°) 1.724 
Planes (°) 0.006 
Chiral volumes (Å3) 0.104 
Mean B value (Å2) 36.64 
Ramachandran Plot   
Favoured (%) 98.54 
Allowed (%) 1.46 
Outliers (%) 0.00 
aNumber in parentheses refer to the highest resolution bin. 
bRmerge = T UVW − T UVW XXUVW |/ T UVW XXUVW -where T UVW X  is 
the intensity of the ith measurement of reflection with index UVW-. 
cR = ( |YZ UVWUVW − Y[ UVW |/ |YZ UVWUVW |, where YZ  and Y[  are 
the observed and calculated structure factors, respectively. 
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3.3.4 Structure of SCEcl 
The SCEcl is the most closely related to SCEco of all the ESKAPE SCs, with a sequence 
identity of 95% and only fourteen (conservative) substitutions. The structure was solved 
using our home X-ray source to 2.60 Å resolution in space group P1 (Table 3.6), using 
the SCEco (PDB entry 4K3S) as the search model for molecular replacement. The 
protein crystallised with two dimers in the asymmetric unit (Figure 3.8b). Each 
monomer of the dimer had the architecture as seen with the SCAbm-His6 and SCPae, 
however, an extra !-strand was observed in domain III termed !4a$$ (Figure B.1c, 
Appendix).   
Much like SCPae and SCEco, there are six H-bonds between the neighbouring !-strands 
of the domains to create an extended !-sheet across the exterior of the dimer, to 
reinforce the orientation of the domains and keep the monomer in its conformation. 
The electrostatic surface appears different to the previous two SC structures described. 
Every domain on the N-terminal face has patches of negatively charged and polar 
residues. The interface has concentrated area of negatively charged residues.  The 
C-terminal face is quite similar, excluding the hydrophobic area that extends from 
between domains II and III to the dimer interface (Figure 3.8c). Additionally, charged 
residues are scattered around the interface. The solvent accessible surface area of chain 
B at the interface is 1290 Å2 and 1264 Å2 for chain A. 
 
 




Figure 3.8: Structure of the SCEcl. (a) Cartoon representation of the SCEcl structure, 
with the C-terminal face shown. (b) Asymmetric unit contained two dimers, represented 
here in cartoon. (c) Computed electrostatic surface of the dimer, N-terminal face on the 
left, and C-terminal face on the right, generated using COOT. Blue – positive, red – 
negative and white – hydrophobic residues. The dimer interface is indicated by the 
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Table 3.6: Crystallographic data for SCEcl 















Resolution (Å) 50.0–2.60 
a(2.67–2.60) 
bRmerge (%) 11.1 
No. of unique reflections 41704 (1923) 
Mean I/σI 18.0 (1.8) 
Completeness (%) 96.1 (86.5) 
Redundancy 3.8 (2.8) 
Resolution (Å) 2.67 
cRwork/Rfree (%) 25.3/29.5 
Bond lengths (Å) 0.011 
Bond angles (°) 1.565 
Planes (°) 0.006 
Chiral volumes (Å3) 0.085 
Mean B value (Å2) 58.81 
   Ramachandran Plot  
Favoured (%) 98.92 
Allowed (%) 1.08 
Outliers (%) 0.00 
aNumber in parentheses refer to the highest resolution bin. 
bRmerge = T UVW − T UVW XXUVW |/ T UVW XXUVW - where T UVW X  is the 
intensity of the ith measurement of reflection with index UVW-. 
cR = ( |YZ UVWUVW − Y[ UVW |/ |YZ UVWUVW | , where YZ  and Y[  are the 
observed and calculated structure factors, respectively. 
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3.3.5 Structure of Gram-positive SCEfu-His6 
The crystal structure of SCEfu-His6 was solved at 2.8 Å resolution. The crystal contained 
one dimer in the asymmetric unit with the unit cell dimensions of 82.50 × 82.50 × 97.16 
Å in the P31 space group (Table 3.7). The protein crystallised as a dimer, with the same 
head-to-tail monomer arrangement as the other ESKAPE SCs to produce a ring-shaped 
dimer (Figure 3.9a). Furthermore, the three domains of the monomer are structurally 
similar to the Gram-negative SCs; however, the interior channel is more elliptical 
compared to the circular shape of the other structures. There are six H-bonds between 
!4 of domain I and !8$ of domain II, !4$ and !8$$ of domains II and domain III and !4$$ 
of domain III and !8 of domain I. The overall dimension of the outer ring is 79 Å × 90 
Å and the central channel is 35 Å × 42 Å. These dimensions and the elliptical central 
channel are similar to those observed in other Gram-positive SCs structures.75,160 
The electrostatic surfaces of the two faces are distinct (Figure 3.9b). The N-terminal 
face is predominately lined with negatively charged and polar residues, with a 
particularly concentrated area between domains I and II. There is a positively charged 
residue patch at the interface, closer to the central channel. The C-terminal face 
conversely is predominantly hydrophobic, with charged residues located at the interface 
and tips of the domains. The solvent accessible area of both chains at the interface is 
approximately 1122 Å2. Pertinent to the function of the SC, the central channel is lined 
with positively charged residues, particularly Arg and Lys, for interactions with DNA. 
Despite a low sequence identity to SCEco of 27%, the proteins are structurally similar. 
 




Figure 3.9: Structure of SCEfu-His6. (a) Cartoon representation of the SCEfu-His6 structure, 
with the C-terminal face shown. (b) Computed electrostatic surface of the dimer, N-
terminal face on the left, and C-terminal face on the right, generated using COOT. Blue 
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Table 3.7: Crystallographic data for SCEfu-His6 















Resolution (Å) 50.00–2.80 
a(2.98–2.80) 
bRmerge (%) 6.6 
No. of unique 
reflections 
17185 (1210) 
Mean I/σI  
Completeness (%) 99.7 (99.0) 
Redundancy  
Resolution (Å) 2.80 
cRwork/Rfree (%) 20.0/26.0 
Bond lengths (Å) 0.012 
Bond angles (°) 1.696 
Planes (°) 0.011 
Chiral volumes (Å3) 0.085 
Mean B value (Å2) 52.33 
Ramachandran Plot  
Favoured (%) 97.77 
Allowed (%) 2.23 
Outliers (%) 0.00 
aNumber in parentheses refer to the highest resolution bin. 
bRmerge = T UVW − T UVW XXUVW |/ T UVW XXUVW -where T UVW X  is the 
intensity of the ith measurement of reflection with index UVW-. 
cR = ( |YZ UVWUVW − Y[ UVW |/ |YZ UVWUVW |, where YZ  and Y[  are the 
observed and calculated structure factors, respectively. 
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3.3.6 Comparisons to known bacterial SC structures 
Several structures of bacterial SCs have been solved (see Table 3.1). The solved 
ESKAPE SC structures were structurally aligned to SCEco and SCBsu (chosen as 
representatives of the Gram-negative and Gram-positive SCs) to assess the overall 
structural conservation. As predicted, the Gram-negative SCs (SCAbm-His6, SCPae and 
SCEcl) aligned better with SCEco than SCBsu (Table 3.8). Between the SCEco and SCBsu 
alignments, there was little difference between the root-mean-square-deviation (RMSD) 
values obtained with SCPae and SCEcl (0.201 and 0.277 Å), while there was a larger 
difference of 0.557 Å RMSD in SCAbm-His6. The number of residues aligned with SCBsu 
was less than with SCEco across the SCs. Conversely, SCEfu-His6 has a lower RMSD with 
SCBsu than SCEco.  
The most obvious feature that separates the Gram-negative and Gram-positive classes is 
the shape of the interior channel. The Gram-negative SCs have a circular channel on the 
C-terminal face while the Gram-positives have an elliptical channel. There must be 
some differences in the positioning of the secondary elements that lead to this shape 
change, particularly the arrangement of the "-helices that line the channel. 
 
 
Table 3.8: RMSD values from structural alignment of the subset of ESKAPE SCs with 
SCEco and SCBsu. 
Reference SC SCAbm-His6 SCPae SCEcl SCEfu-His6 
SCEco 1.192 Å a(587) 1.049 Å (640) 1.005 Å (686) 2.005 Å (624) 
SCBsu 1.749 Å (580) 1.250 Å (574) 1.282 Å (566) 1.398 Å (641) 
aValues in brackets refer to the number of aligned C" atoms. 
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3.3.6.1 Domains I and III 
Domain I is the N-terminal domain of the SC monomer. All Gram-negative SCs align 
closely in this region and the only structural differences are in the loop regions (Figure 
3.10b). This is unsurprising, as these regions are typically flexible. The Gram-positive 
SCEfu-His6 has the most difference in comparison to SCEco. The "-helices are in slightly 
different positions, with helix "2 of SCEfu-His6 displaced 2.2 Å with respect to SCEco, and 
helix "1 displaced 1.6 Å with respect to the corresponding helix in SCEco (Figure 
3.10a). The angle formed by the helices is similar. In addition, one of the !-sheets has 
an extra !-strand between strands !4 and !5, denoted here as !4a, forming a 5-stranded 
!-sheet, in contrast to the 4-stranded !-sheets usually associated with SCs. 
The degree of structural similarity in domain III of Gram-negative SCs is very high 
(Figure 3.11b). The main difference is the arrangement of strand !4$$ in SCAbm-His6, 
which is sloping upwards towards the N-terminal face. There is a noticeable difference 
in the "-helices of domain III between SCEco and SCEfu-His6. The "2$$ helix is shifted 
upwards by 1.8 Å and helix "1$$ is shifted towards the left by 1.8 Å. Another feature is 
the sloping of the C-terminal end of strand !4$$ towards helix "1$$ (Figure 3.11a). 
Domain III of the Gram-negative SCs, by contrast, has no significant changes (Figure 
3.11b). 
 
3.3.6.1.1 Dimeric interface between domains I and III 
The dimerization between SC monomers occurs at the interface between domains I and 
III. The interaction involves strand !8 and helix "2 of domain I and strand !4$$ and 
helix "1$$ of domain III. The structural alignment of SCEco, SCBsu and SCEfu-His6 shows 
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that there are variations in the positions of the two "-helices and strand !4$$ at the 




Figure 3.10: Comparison of the structural arrangement of domain I. (a) 
Superimpositions of SCEfu-His6 (blue) with SCEco (grey, PDB entry 4K3S) on the left and 
with SCBsu (cyan, PDB entry 4TR6) on the right. Arrows indicate the direction of SCEfu-
His6 movement and the distance. (b) Superimpositions of Gram-negative SCs (SCAbm-His6, 
magenta; SCPae, green and SCEcl, purple) with SCEco (grey) on the left and with SCBsu 
(cyan) on the right. The overall domain and the "-helices from front and side view are 
shown. 
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Figure 3.11: Comparison of the structural arrangement of domain III. (a) 
Superimpositions of SCEfu-His6 (blue) with SCEco (grey, PDB entry 4K3S) on the left and 
with SCBsu (cyan, PDB entry 4TR6) on the right. Arrows indicate the direction of SCEfu-
His6 movement and the distance. (b) Superimpositions of Gram-negative SCs (SCAbm-His6, 
magenta; SCPae, green and SCEcl, purple) with SCEco (grey) on the left and with SCBsu 
(cyan) on the right. The overall domain and the "-helices from front and side view are 
shown.  
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appearance of the SCSpy interior channel is partly due to F81 of helix "2 pushing against 
helix "1$$ and distorting the helix.160 The corresponding residues in SCEfu-His6 and SCBsu 
are F80 and F83, both located in the same position (Figure 3.12a). The Phe residues 
come into close contact with "1$$ causing it to kink towards the helix "2$$. The "1$$ 
helix also comes into close contact with the C-terminal end of strand !4$$, causing a 
downward slope of the !-strand (Figure 3.12a). This kinked region contains 
predominately hydrophobic residues, more in the Gram-positive SCs than the Gram-
negative SCs (see section 3.3.8.2.1 for more detail). Conversely, the corresponding 
residue in SCEco is K74, which does not cause this distortion. Rather, there is a Glu 
residue within 3 Å of the Lys – in the loop between !3$$ and !4$$ – that may form a salt 
bridge (Figure 3.12a,b; explored more in section 3.3.8.2.2). These two residues are 
conserved in the other Gram-negative SCs examined here (Figure 3.12b). 
 
3.3.6.2 Domain II 
Domain II is the middle of the three domains comprising the SC monomer. The domain 
II of SCEfu-His6 appears to be positioned differently with respect to SCEco, particularly the 
C-terminal face. The C-terminal end of SCEfu-His6 helix "2$ is shifted 1.8 Å to the right 
and upwards compared to the SCEco helix "2$. This shift causes the helix "2$ to be 
closer to the kinked C-terminal end of helix "1$ than seen in SCEco (Figure 3.13a). 
There is a patch of hydrophobic residues here (I207, I145, V149 and G203) that perhaps 
cause this shift. SCEco also has a patch of hydrophobic residues here, however, there is a 
Gln at the corresponding position of V149 and an Arg at the position corresponding to 
G203 that could prevent this. The two helices retain the ~45° angle to each other that is 
seen in SCEco. The first !-sheet (strands !2$, !3$, !4$ and !5$) is shifted  
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Figure 3.12: The SC dimer interface. (a) Alignment of domains I and III of SCEco 
(grey), SCEfu-His6 (blue) and SCBsu (cyan). Insert highlights the two !-strands and two 
"-helices that make the interactions, with each secondary element numbered according 
to the SCEco numbering.77 The right shows that arrangement of the helices and the F80 
in stick representation and the residues that it contacts in "1$$. (b) Alignment of I and III 
of SCEco (grey), SCAbm-His6 (magenta), SCPae (green) and SCEcl (purple). Box zooms in 
on the specific interactions at the interface. Residues are displayed as stick 
representation, labelled according to the SCEco numbering. 
 
 
2.2 Å towards domain III. The second !-sheet remains similar to SCEco, except strands 
!1$ and !6$ are shorter. These changes are most likely due to the conformational strain 
caused by the specific residues found at the interface. Out of the three domains, this 
domain appears to show the least difference among the Gram-negative SCs (Figure 
3.13b). An exception is the loop region between strands !7$ and !8$ in SCAbm-His6, it is 
seven residues longer than the other SCs and therefore projects further from the 
N-terminal face than the other SCs.  
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Figure 3.13: Comparison of the structural arrangement of domain II. (a) 
Superimpositions of SCEfu-His6 (blue) with SCEco (grey, PDB entry 4K3S) on the left and 
with SCBsu (cyan, PDB entry 4TR6) on the right. Arrows indicate the direction of SCEfu-
His6 movement and the distance. (b) Superimpositions of Gram-negative SCs (SCAbm-His6, 
magenta; SCPae, green and SCEcl, purple) with SCEco (grey) on the left and with SCBsu 
(cyan) on the right. The overall domain and the "-helices from front and side view are 
shown.  
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Overall, domain II of the SCs are very similar. The changes in "-helices positions and 
amino acids sequence differences, lead to subtle changes in all twelve "-helices that in 
turn create the elliptical or circular shaped interior channel. These changes should have  
no significant impact on the interaction with and stability on DNA as the channel is 
large enough to house dsDNA. Furthermore, the positions of the Arg and Lys residues 
around the channel are nearly identical. 
 
3.3.7.1 Human PCNA 
Analogous to bacterial SCs, hPCNA tethers protein partners to DNA for them to carry 
out their functions, in DNA replication, repair and cell-cycle control.179,180 One of the 
prominent differences between PCNA and SCs is that hPCNA is a trimer (Figure 
3.14a). Each monomer is comprised of two structurally similar domains. There are two 
anti-parallel !-sheets comprised of four !-strands, linked by two "-helices. The angle 
between the !-sheets is ~45° resembling a wedge, very similar to that observed in the 
bacterial SCs. In domain I, each of the two !-sheets are comprised of four !-strands. 
Conversely, in domain II !-sheet 1 (comprising of !-strands !5$, !2$, !3$, !4$ and !4a$) 
has five !-strands while !-sheet 2 (comprising of !-strands !8$, !7$, !6$ and !1$) has 
four !-strands (Figure 3.14b). The lengths of the !-strands varies from 5–7 residues. 
The domains are linked by interconnecting domain loops and an extended !-sheet 
created by the eight H-bonds between two !-strands. The interior channel of PCNA is 
the same shape and diameter as Gram-negative SCs and is lined with Arg and Lys 
residues along the "-helices for interaction with the DNA backbone.  
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Figure 3.14: hPCNA structure with the peptides removed. (a) Cartoon structure of 
hPCNA, each monomer a different colour. (b) Structural arrangement of the secondary 
structure elements in the hPCNA monomer with "-helices shown as swirls and !-
strands as arrows. (c) Computed electrostatic surface, generated by COOT (PDB entry 
1U76).181 The N-terminal face on the left and the C-terminal face on the right. Blue – 
positive, red – negative and white – neutral residues. A cluster of negatively charged 
amino acids resides in the interdomain region (circle). The arrows indicate interface of 
monomers. 
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The electrostatic surface of the C-terminal face, where the interactions with protein 
partners occur, shows a cluster of negatively charged residues located in the inter-
domain region of the monomer (Figure 3.14c). This region is the main contact with 
protein partners, in particular the groove formed along the interconnecting domain 
loop.101,181  
The interface between the monomers is predominately hydrophobic, particularly on the 
C-terminal face. There are six H-bonds here, more than the five H-bonds in bacterial 
SCs. Additionally, hPCNA has possibly one ion pair, K117-E174, compared to the six 
ion pairs at the SCEco dimer interface.77 The Saccharomyces cerevisiae PCNA structure 
is similar to hPCNA, and also has one ion pair observed at the interface, D150-R110.182 
hPCNA is stable as a trimer in solution, with a predicted monomer-monomer KD of 21 
nM, three orders of magnitude higher than SCEco (KD of < 60 pM).183 Despite these 
many structural similarities with bacterial SCs, the sequence identity between SCEco and 
hPCNA is only 10%. 
 
3.3.7.2 T4 bacteriophage gp45 
The T4 bacteriophage gp45 protein is the DNA clamp within the T4 bacteriophage 
replisome, a protein-protein interaction hub that recruits replication and repair proteins 
to DNA to undertake their function. While the 6-fold arrangement of clamp domains is 
maintained, the protein is a trimer with an overall triangular appearance (Figure 3.15a). 
The diameter of the interior channel is ~35 Å, similar to the Gram-negative SCs. Each 
monomer consists of two domains comprising two !-sheets and two "-helices, which 
are connected by loops.  
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The two domains, however, are not structurally identical. Domain I contains one 
"-helix with four turns and another "-helix with three turns. The angle between the 
!-sheets is larger than the bacterial SCs: ~90°. Strands !2 and !5 are shorter than the 
other two strands in the first !-sheet, containing three residues compared to the seven 
residues of strand !3 and eleven residues of strand !4. The other !-sheet is comprised 
of three strands that are 4–6 residues in length. As such, there are fewer H-bonds 
between the strands, leading to divergence between the sheets. Domain II resembles the 
45° angled !-sheets seen in bacterial SCs and PCNA and each sheet contains four anti-
parallel !-strands. The main difference is the unequal helices: one helix has one turn 
and the other has four turns. The other proteins have 3–4 turns per helix. 
The computed electrostatic surface of both faces of gp45 shows the N-terminal face 
dominated by hydrophobic residues and the C-terminal face predominantly negatively 
charged (Figure 3.15b). Much like the SCs and PCNA, there are positively charged 
residues lining the interior channel for interaction with the phosphate backbone of 
DNA.  
The interface between the domains of the monomers is comprised of four H-bonds 
between strand !7 of domain I and strand !4$ of domain II. Interestingly, the interface 
of gp45 has been shown to be weaker than that of SCEco and PCNA in both biochemical 
and computational experiments, with an estimated monomer-monomer dissociation 
constant of 200–400 nM.103,183 The trimer is unstable in solution and only remains 
loaded onto DNA in the presence of the DNA polymerase.183 In molecular dynamics 
(MD) simulations in which the interfaces of gp45, SCEco and PCNA were steered apart 
by the steering forces and left to equilibrate, the gp45 remained in an open configuration 
whereas the other two proteins tended to re-close.103 
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Figure 3.15: Structure of gp45 from T4 bacteriophage (PDB ID 1CZD)102. (a) Cartoon 
representation of the gp45 structure, with the C-terminal face shown. Monomers are 
coloured differently. (b) Structural arrangement of the secondary structure elements in 
the gp45 monomer with "-helices are shown as swirls and !-strands as arrows.  (c) 
Computed electrostatic surface of the dimer, N-terminal face on the left, and C-terminal 
face on the right, generated using COOT. Blue – positive, red – negative and white – 
neutral residues.  
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3.3.8 Dimerization of SCs  
All the bacterial SCs exist as dimers in solution.184,185 It is known that SCEco and 
SCEco-His6 are able to exchange to form heterodimers in a range of buffers.52 To enhance 
dimer dissociation, there must be high salt present or charged residues at the interface 
must be mutated to small hydrophobic residues. There are some structural differences at 
the dimer interface of the bacterial SCs described here, yet there are similar trends with 
respect to composition of hydrophobic and charged residues.  
 
3.3.8.1 Subunit exchange between subset of ESKAPE SC dimers and SCEco 
NanoESI-MS was used to assess whether SC subunits from the different species could 
form heterodimers with SCEco, with the rationale being that the interfaces would have to 
be structurally and chemically similar enough for the dimerization. In general, peaks 
corresponding to heterodimeric ions were observed for all Gram-negative SC pairwise 
combinations. Equilibration is reached between the SCAbm and SCEco after 7 h, with the 
total abundance of each SC being 15 and 70%, respectively, and 15% corresponding to 
the heterodimer at 24 h (Figure 3.16a). The difference in the ion abundance from the 
SCs suggests that SCAbm does not ionise as efficiently as SCEco in these conditions 
considering that the same concentrations of SC protein were used. The same trend is 
seen with the SCAby and SCEco-His6 (Figure 3.16b) combination with the heterodimer 
being 15% of the total ion abundance after 24 h. For SCEco-His6 and SCPae, the 
heterodimer accounted for 40% of the total ion abundance, with an increase seen 
between 7 h and 24 h (Figure 3.16c). For SCEco-His6 and SCEcl the heterodimer formed 
from the subunit exchange is ~50% of the total ion abundance (Figure 3.16d). This was 
expected as the SCEcl is the most closely related to SCEco and has the highest sequence  
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Figure 3.16: Subunit exchange between (a) SCEco and SCAbm, (b) SCEco-His6 and SCAby, 
(c) SCEco-His6 and SCPae, and (d) SCEco-His6 and SCEcl. Equimolar concentrations of SC (5 
µM) were mixed in 200 mM ammonium acetate pH 7.6, and placed at 30°C, with 
aliquots withdrawn after the indicated times and analysed by positive ion nanoESI-MS. 
Coloured circles above each charge state show the identity of the dimer molecular ion 
based on mass. The three most abundant charge states are shown.  
 
 
identity. There were peaks corresponding to SC monomers at each time point, however, 
their abundance was < 5 % in all experiments.  
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For the SCEfu-His6 and SC Eco-His6 combination, there was no exchange seen after 24 h in 
these conditions (Figure 3.17). There is a higher abundance of SCEfu-His6 monomers, 
compared to the SC Eco-His6, which is consistent at every time point suggesting that the 
interface is not as strong relative to SC Eco-His6 in these conditions, and the monomers 
could still be exchanging in solution. To observe the exchanging between SCEfu-His6 
monomers, un-tagged SCEfu could be used in subunit exchange experiments with SCEfu-
His6 in the same conditions used here. This would be beneficial for the other ESKAPE 
SC, to see their propensity to undergo exchange between un-tagged and His6 tagged SC 
proteins in these conditions. The interfaces between SCEfu-His6 and SCEco may be 
structurally and chemically different enough that they are unable to interact (see section 
3.3.8.2).  
The monomers from each Gram-negative SC can exchange with SCEco, however, even 
at 30 °C the rate of exchange is relatively slow – taking place on a timescale of hours. 
This reflects the high stability of the SC dimers. It has been previously observed that 
high salt concentration increases the dissociation rate of SCEco dimers, suggesting the 
electrostatic interactions are important for interface stability.52  
To investigate the importance of the salt bridges on monomer-monomer dissociation, 
facilitating subunit exchange, these experiments were conducted in a buffer with 1 M 
NaCl, with time points taken at 3.5, 7 and 11 h. There was an increase in the rate of 
exchange, with the same total ion abundance of the heterodimer reached by 3.5 h in 1 M 
NaCl as seen previously in 200 mM ammonium acetate after 24 h (Figure D.1–D.5, 
Appendix). It appears from this data that the disruption of the salt bridges at the dimer 
interface could be the rate-limiting step for exchange of the SC dimers, affecting the 
dissociation rate of the SC monomers. Previous studies have estimated the SCEco dimer 
association rate at 6.5 × 106 M–1 s–1 and the equilibrium constant at < 60 pM.183,184  
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Figure 3.17: Subunit exchange between SCEco-His6 and SCEfu-His6. Equimolar 
concentration of SC (5 µM) were mixed in 200 mM ammonium acetate pH 7.6, and 
placed at 30°C, with aliquots withdrawn after the indicated times and analysed by 
positive ion nanoESI-MS. Coloured circles above each charge state show the identity of 
the dimer molecular ion based on mass.  
 
 
3.3.8.2 Interactions at the dimer interface 
The dimeric interfaces of SCs all have similar features: two "-helices and two !-strands 
(one of each from each monomer), and asymmetry in the electrostatic charge of the 
monomer. The N-terminal domain (I) is predominately hydrophobic with some 
positively charged residues and the C-terminal domain (III) is mostly hydrophobic with 
negatively charged residues. It is the combination of hydrophobic interactions and salt 
bridges that stabilise the interface. Additionally, the two !-strands form H-bonds (all 
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have five with the exception of SCEfu-His6, which has six) and create an extended !-sheet 
to reinforce this interaction.  
 
3.3.8.2.1 Hydrophobic residues in the dimer interface 
The hydrophobic residues of the dimer interface in SCEco are F106, L108 and I78 of one 
monomer and A302, L272, L273 of the adjacent monomer. These residues are 
conserved across the subset of ESKAPE SCs, with only SCEfu-His6 having L108, I272 
and A302 changed to Val, Leu and Val respectively (Table 3.9). This core is located 
closer to the C-terminal face with the residues still being 70–100% buried, according to 
the PDBePISA server (Figure 3.18).  
Several studies have identified mutations in the hydrophobic interface that led to loss of 
dimerization and consequently, the activity of the SC in DNA replication assays. The 
SCEco double-mutant of I272A/L273A and single mutant F106A are monomeric and 
lack activity in DNA replication assays.186 F106A, L108A and L273A single point 
mutations are still able to dimerise and retained a 70–100% activity compared to the 
wild-type SCEco in DNA replication assays.186,187 Dimerization of SCs is therefore vital 
for their function in E. coli, and we hypothesise the same is true for the other SCs 
considered here. 
SCEfu-His6 has two additional hydrophobic residues within close proximity (< 4 Å) to the 
hydrophobic interface. F80 and I306 have greater surface exposure than the other 
residues, but are in a position to interact and increase the area of the hydrophobic 
interfaces. F80 was hypothesised to be the key residue causing the distortion of helix 
"1$$ leading to the overall elliptical appearance of the dimer (see section 3.3.6.1.1). 
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Table 3.9: Residues forming the hydrophobic core at the dimer interface of the subset 
of ESKAPE SC. Predicted based on sequence alignment with SCEco (Figure E.1, 
Appendix). confirmed by crystal structures. Residues in bold are identical to SCEco. 
SCEco SCAbm SCAby SCPae SCEcl SCEfu 
I78 I86 I86 I78 I78 I84 
aK74 aK82 aK82 aK74 aK74 F80 
F106 F115 F115 F106 F106 F112 
L108 L117 L117 L108 V108 V114 
I272 I294 I294 I273 L273 L278 
L273 L295 L295 L274 L274 L279 
A302 A324 A324 A303 V303 V309 
aQ299 aQ321 aQ321 aQ300 aQ299 I306 
aResidues are not involved with hydrophobic core but are complementary to the SCEfu-
His6 residue that participates in the hydrophobic core at the dimer interface. 
 
3.3.8.2.2 Salt bridges 
Intermolecular ion pairs also contribute to the stability of the dimer interface. In SCEco 
there are six pairs: K74-E298 (2.9 Å), K74-E300 (2.5 Å), R96-E300 (4.7 Å), 
R103-E304 (3.0 Å), R105-E301 (3.3 Å), and R105-E303 (3.0 Å) (Figure 3.19a). Of 
those six, two pairs (R96-E300 and R103-E304) are comprised of buried residues and 
therefore the interactions may be relatively strong. The dimeric interface of SCEcl is 
practically identical to that of SCEco and the salt bridges are conserved (Figure 3.19d). 
This suggests that the KD of the monomer-monomer interaction would be similar to 
SCEco (< 60 pM), and explains the slow rate of exchange observed during the subunit 
exchange experiments. 
From structural and sequence alignments, the salt bridge pairs that may be retained in  
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Figure 3.18: Arrangement of hydrophobic core at the dimer interface of (a) SCEco (b) 
SCAbm-His6, (c) SCPae, (d) SCEcl and (e) SCEfu-His6. The residues are shown in stick 




both SCAbm and SCAby correspond to K82-E320 (K74-E298Eco), K82-D322 (K74-
E300Eco), R105-D322 (R96-E300Eco) and R114-E323 (R105-E301Eco) (Figure 3.19b). 
The R103-E304Eco salt bridge is lost as R103Eco is substituted for the neutral residue 
Asn in both SCAbm and SCAby (Table 3.10). The salt bridges involving E300Eco may not 
be present or are weaker as the corresponding residue is D322Abm/Aby, which has a 
shorter side chain, may not be able to come close in contact with the ionic partners 
residues. However, this residue along with R105 Abm/Aby and E326 Abm/Aby are the buried 
residues that could potentially form the strong intermolecular ionic pairs. Another 
interaction D322 Abm/Aby could be forming is with K82Abm/Aby (2.4 Å in the crystal 
structure)(Figure 3.19b). E303Eco is swapped with Ile in both SCAbm and SCAby; 
therefore the salt bridge with R105Eco is lost.  
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From sequence alignments, SCPae retains five of the six salt bridges observed in SCEco. 
The salt bridge R96-E300Pae may be weakened in SCPae as the Arg is replaced with Lys. 
According to the SCPae structure, K74-E299 (3.3 Å), K74-E301 (2.7 Å) and R103-E306 
(3.3 Å) are the salt bridges with the closest interactions (Figure 3.19c). The other 
residue pairs are too distant to form strong interactions: R103-E305 (9.9 Å), R105-E302 
(8.0 Å), K96-E301 (6.0 Å) and K96-E299 (8.5 Å). The same buried residues are 
conserved and buried according to PDBePISA analysis of the structure. 
 
Table 3.10: Residues of the subset of ESKAPE SC dimer interfaces that correspond to 
the residues forming six ion pairs in SCEco. Predicted based on sequence alignment with 
SCEco (Figure E.1, Appendix). Residues in bold are identical to SCEco. 
SCEco SCAbm SCAby SCPae SCEcl SCEfu 
K74 K82 K82 K74 K74 F80 
R96 R105 R105 K96 R96 Q102 
R103 N112 N112 R103 R103 K109 
R105 R114 R114 R105 R105 N111 
E298 E320 E320 E299 E298 E305 
E300 D322 D322 E301 E300 G307 
E301 E323 E323 E302 E301 K308 
E303 I325 I325 E304 E303 E310 
E304 E326 E326 E305 E304 E311 
 
 
From sequence alignments, there are two substitutions of charged residues in SCEfu-His6 
relative to SCEco to uncharged residues: K74 to F80 and E300 to G307. This means that 
three salt bridge interactions observed in SCEco are abolished in SCEfu-His6 (K74-E298Eco, 
K74-E300Eco and R96-E300Eco). The location of the two substitutions is close to the 
hydrophobic core. F80 is most likely contributing to the interactions in the core (Figure 
Amy E. McGrath  103 
 
 
Figure 3.19: Arrangement of the salt bridges at the dimer interface (a) SCEco (b) 
SCAbm-His6, (c) SCPae (d) SCEcl and (e) SCEfu-His6. Residues of the proposed salt bridges 
are in stick representation and labelled.  
 
 
3.18e). Salt bridges equivalent to the R103-E304Eco salt bridge is present, but the Arg is 
substituted for Lys (K109–E311; Figure 3.19e; Table 3.10). The two salt bridges 
formed with R105Eco are abolished, as the corresponding residue is the neutral Asn. 
Additionally, a residue equivalent to E304Eco is maintained (E311Efu-His6) but residue 
E30Eco is substituted with K308 in SCEfu-His6. According to the PDBePISA server, a 
potential salt bridge is formed between residues R87 and E274 of SCEfu-His6, with a bond 
distance of 3.2 Å (Figure 3.19e). These are buried residues and so the interaction may 
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be relatively strong. In total, there are four salt bridge interactions compared to the six 
of SCEco.  
SC subunits are able to exchange with each other in solution. However, the formation of 
heterodimers relies on the interface being structurally and chemically similar. In terms 
of the ability to form heterodimers with SCEco or SCEco-His6, SCEcl was the best followed 
by SCPae, SCAbm-His6 and SCAby and then SCEfu-His6. This may be explained by the degree 
of similarity of the dimer interfaces. The observation that the SCEcl is identical to SCEco 
excluding the one mutation (L262 to S262), explains the large proportion of 
heterodimers observed. Only the peptide backbone of L262Eco is involved in H-bonding 
to form the extended !-sheet at the interface, therefore the substitution to any amino 
acid that is not a Pro will likely have minimal affect on the interaction. The abundance 
of heterodimers formed is similar to SCEco/SCEco-His6 heterodimers observed 
previously.52,188 SCPae also has one substitution at the interface, R96K. While there were 
heterodimers formed, this substitution affects the salt bridge with E301Eco. The weaker 
interaction of Lys compared with Arg with E301Eco may explain the heterodimer 
population. These results could suggest a slight difference in SCPae monomer-monomer 
affinity with the equilibrium shifted more towards the SC dimers rather than the 
heterodimers. 
For the SCAbm and SCAby, the abundance of the heterodimers with SCEco was not as high 
as the previous two SCs considered here. However, that the abundance of their 
homodimers were low compared to SCEco, suggests that the Acinetobacter SCs do not 
ionise as efficiently as SCEco in these conditions. The heterodimer abundance exceeded 
the abundance of the original dimers, but not that of SCEco. It is difficult to assess 
whether e.g. the loss of salt bridge (equivalent to R105-E303Eco) affects the ability to 
form heterodimers when the starting abundances are different. Future work would 
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involve scanning concentrations that will improve the ion abundance of SCAbm and 
SCAby to perhaps draw a confident conclusion to the effect of the Ile substitution on the 
ability to dimerise with SCEco monomer. The structure of the "-helices and !-strands at 
the dimer interface are conserved with respect to SCEco, so this aspect of the structures 
should not have a negative impact on the ability of SCAbm and SCAby to form 
heterodimers with SCEco. 
SCEfu-His6 was not observed to form heterodimers with SCEco. In addition to some 
differences in the residues comprising the salt bridges at the dimer interface, there are 
other structural differences. The "-helix of domain III is shifted by 1.8 Å and the strand 
!4$$ is sloping towards the helix to a greater extent in SCEfu-His6 when compared with 
SCEco (see section 3.3.6.1). These structural differences may prevent the formation of 
heterodimers. The two substitutions (K74F and E300G) result in a loss of three salt 
bridges (K74-E298Eco, K74-E300Eco and R96-E300Eco), one of which was predicted to 
be particularly strong (K74-E300Eco). This weakened interface was observed through 
the higher abundance of SCEfu-His6 monomers at each time point relative to SCEco 
monomers. To elaborate further on the potential of exchange, un-tagged and His6 
tagged SCEfu protein would need to be purified and assessed in the same experiments.  
 
3.3.8.3 SCs are dynamic in solution 
Using hydrogen-deuterium exchange mass spectrometry, Fang and co-workers (2014) 
showed that the SCEco is dynamic in solution.185 They found that the three domains 
exhibited different dynamics, even though the structures of those domains are highly 
conserved. Domain I, which controls the opening of the clamp by dissociating from 
domain III, contained several highly flexible regions that underwent partial cooperative 
unfolding with a half-life of ~3.5 h. As such, they showed evidence that the dimer 
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interface opens spontaneously and is therefore not always a closed ring in solution. The 
dimer half-life is similar to that of SCEco on DNA (~2 h).60,183 When PCNA and gp45 
were studied using the same technique, domain II was observed to be more dynamic 
then domain I.185  
Clamp opening has been studied using MD simulations. SCEco, when opened by steering 
forces, tended to re-associate, forming the energetically favourable H-bonds and salt 
bridges together with the hydrophobic interactions on the C-terminal face of the 
interface.103 A size exclusion chromatography-small angle x-ray scattering 
(SEC-SAXS) experiment of the Pol III %, %$, and γ subunits of CLC with the SCEco 
revealed that SC adopted an open conformation, with the dimer interface opening by 
25–30 Å.189 Conversely, without the CLC, the SC in isolation was a closed dimer in 
solution. The nanoESI-MS experiments conducted here show that the majority of the 
species were dimers, however, these experiments are unable to discern between closed 
and open conformations of the dimers. For the experimentally determined mass of a 
peak envelope to be that of a SC dimer, at least one of the interfaces must be in the 
closed conformation.  
The differences observed between our results and past studies185,189 are due to the 
concentration of SC used in the experiments. The hydrogen exchange mass 
spectrometry study used a SC concentration of ~200 pM whereas this study and the 
SECS-SAXS experiments used 5 and ~100 µM, respectively. At higher concentrations, 
the SC protein tends to adopt a close, rigid conformation in solutions, but is generally 
more dynamic and exchanges subunits at low concentrations.189 The data presented here 
suggests that these SCs are stable in solution as dimers, but are still dynamic. The 
heterodimer formation occurring on an hour timescale reflects the persistence and 
strength of the dimerization interaction. 
Amy E. McGrath  107 
3.3.8.4 The dimer interface as an antibacterial target 
Given the conserved nature of the interface amongst the ESKAPE subset members with 
SCEco, the dimer interface is a potential target for SC inhibitors. Developing an inhibitor 
of the SC dimerisation could lead to a loss of SC function as a processivity factor and 
protein anchor to DNA during DNA replication and repair, as monomeric SC cannot 
physically encircle and interact with dsDNA.60,77,79,156 The two main requirements for 
inhibition at this site is a small-molecule with (i) an affinity > 60 pM, and can remain 




The majority of ESKAPE SCs subset members were successfully purified and 
crystallised, and their structures solved. The structures were similar to known bacterial 
SC structures, despite the varying sequence identities. The main difference between the 
Gram-negative and Gram-positive SCs was the position of the "-helices at the dimer 
interface that influences the elliptical vs. circular-shaped central channel. The overall 
structures are similar to human PCNA and T4 bacteriophage gp45. Instead of being 
dimers, these other proteins are trimmers; however, the central channel is large enough 
to accommodate dsDNA. 
The interactions that form the dimer interface of the SCs can be classed as follows: an 
extended !-sheet, a hydrophobic core and salt bridge pairs. The extended !-sheet and 
hydrophobic core were conserved in all SCs; however, there were varying numbers of 
salt bridges. All the Gram-negative SCs formed heterodimers with SCEco, whereas the 
Gram-positive SCEfu-His6 could not. The combination of the different residues at the 
interface and the shifted "-helices create an interface foreign enough to SCEco that it 
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could not efficiently interact with SCEfu-His6. That being said, SCEfu-His6 was the only SC 
who had a monomer concentration at around 10% abundance consistently up to 24 h, 
leading to a proposed difference in KD of the monomer-monomer interaction. 
Nevertheless, our data suggests that these SCs are more stable in solution as dimers, but 
are still dynamic. Furthermore, the formation of heterodimers occurs on the hour 
timescale reflecting the strength of these interactions. Overall, these SCs are structurally 
similar enough that their function is most likely the same in all the bacterial species, 








INTERACTION BETWEEN SCs AND LMs
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4.1 INTRODUCTION 
 
Transient protein-protein interaction (PPI) hubs, like the SC, govern a plethora of 
biological processes.190,191 The molecular information of these interactions, which are 
temporary and readily associate/dissociate,190,192 is essential for understanding vital 
processes within the cell. Typically, there are two types of PPIs: domain-domain 
interactions and domain-motif interactions (DMIs), both of which are used in the 
process of DNA replication. For the latter interaction, the motif is generally a short 3–
10 amino acid sequence found in terminal or loop regions of the partner protein that 
binds into a small groove on the surface of the target protein.193,194 An example of DMIs 
in DNA replication is the interaction between the SC and its protein-binding partners. 
The SC functions as a PPI hub and recruits these partner proteins to the DNA for them 
to carry out their specific function. Thus far, there have been at least ten proteins 
identified that interact with the SC in this manner (Table 4.1). All these proteins have a 
short LM that is vital for the interaction with the SC.89 The LM is either hexameric or 
pentameric; QLx1Lx2F/L (where S/D is preferred at x1; x2 may be absent).90,91  
The LM’s interact at a common binding site on the SC monomer.47 The binding pocket 
is comprised of two distinct sub-sites: sub-site I is the wider and shallower of the two 
and sub-site II is comparatively narrower and deeper (Figure 4.1).76 From the co-crystal 
structure with the consensus LM sequence, we know exactly where the LM residues 
reside in the pocket (Figure 4.1).89 The Q1L2 dipeptide binds into sub-site II, the L4F5 
dipeptide interacts in sub-site I and x3 links the two by spanning the border between the 
two sub-sites. This mode of binding is consistent with the co-crystal structures of LMs 
from protein partners. The main variation in binding is with the orientations of the F5 in  
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Figure 4.1: Co-crystal structure of SCEco in complex with the LM AcQLDLF (PDB 
entry 3Q4J).76 SC is shown in surface representation, with the residues lining the pocket 
coloured according to location: sub-site 1 (yellow), bordering residues (orange) and 
sub-site II (red). The peptide is coloured using the CPK convention except carbon 
(green). 
 
sub-site I (Figure 4.2). As sub-site I is wide, it can accommodate F5 bound in different 
orientations. All these structures show the side chains of x1 and x2 pointing out of the 
pocket into solution, suggesting that these residues are less important for the interaction. 
Indeed, the most variation in LM sequence is seen at these positions. 
The LM interaction with SCEco has been extensively characterised, and the interactions 
of LM peptides with other bacterial SCs have been demonstrated.75,159 These LMs are 
conserved in bacterial species.90,91 The specific interactions of the LM residues with 
those in the binding pocket has been characterised using a glycine and alanine scan.80 It 
was found that Q1, L4 and F5 are vital for the interaction and that L4F5 must be bound 
into sub-site I first to lock the M362 ‘gate’ in the open conformation for Q1 to bind into 
sub-site II. Through MD simulations, a buried water molecule was observed to be 
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Figure 4.2: Superimposition of the LM-binding region in protein partner co-crystal 
structures. The LM’s are from % (green, 1JQL)65, Pol IV-LF (cyan, PDB entry 1UNN)95, 
Pol IV-CTD (yellow, PDB entry 1OK7)195, Pol II (light pink, PDB entry 3D1E)89, 
"-CTD (magenta, PDB entry 3D1F)89, Pol V (purple, PDB entry 4K74)97. The residues 
in the binding pocket that interacts with the LM are shown, coloured according to 
location in the pocket: yellow residues line sub-site I, red line sub-site II and orange 
border to two sub-sites. 
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II.80 Though this binding mechanism was characterised in SCEco, there is no data for 
other bacterial species. There have been reports of the interaction of LM peptides with 
other bacterial SCs (such as SCMtu, SCPae, SCBsu and SCSau),75,159 however, the 
mechanism of interaction in these other species has not been investigated. 
 
4.1.1 Aims of this Chapter 
This chapter describes experiments intended to explore the interaction of the ESKAPE 
SCs subset with the consensus LM, QLDLF. FP was employed to assay LM binding to 
the subset ESKAPE SCs. An Ala scan of the LM revealed the contributions of different 
residues to SC binding. Molecular dynamics (MD) simulations were run to produce 
models and ascertain the stability of LM peptides bound to the solved ESKAPE SC 
structures. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Proteins 
SCs were overproduced and purified as described in section 3.2.2 and stored at –80 °C. 
Proteins were then dialysed against the appropriate buffer before use.  
 
4.2.2 FP assay 
4.2.2.1 Binding assay 
All experiments were conducted with a POLARstar Omega plate reader (BMG 
LABTECH) using non-treated black sterile 96-well plates (Greiner, USA). The 
fluorescent peptides (Table 4.1), at 10 nM concentration, and proteins were in the 
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buffer 10 mM HEPES pH 7.4, 1 mM EDTA, 1 mM DTT, 0.07% (v/v) Nonidet P-40 and 
5% (v/v) DMSO. Blank control (buffer alone) and negative control (buffer and 
fluorescent peptide) were used for data standardisation. As SCEco has been tested with 
the same fluorescent peptides,80 the positive control consisted of buffer, fluorescent 
peptide and SCEco. To generate data points for saturation curve, the SC proteins were 
serially diluted from 10 µM to 0.0098 µM, and 0 µM concentration. Experiments were 
carried out in quadruplicates.  
Curves were fitted using the binding-saturation curve fitting from GraphPad Prism 





     ………………………………………………………………….... (eq. 4) 
 
where Y is the polarization in mP units, Bmax is the maximum number of binding sites 
available in mP, KD Is the equilibrium dissociation constant in µM and X is the 
concentration of the SCs in µM. From this we can extrapolate and interpret the Bmax and 
KD parameters of the interactions. The Bmax can assist with understanding the similarity 
of fluorescent peptide binding to the SCs, particularly if the fluorophore is affecting the 
interactions, and the KD gives us the equilibrium dissociation constant. 
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4.2.2.2 Competition assay 
All FP experiments were conducted with a POLARstar Omega plate reader using 
non-treated black sterile 96-well plates (Greiner, USA). The buffer contains 10 mM 
HEPES pH 7.4, 1 mM EDTA, 1 mM DTT, 0.07% (v/v) Nonidet P-40 and 5% (v/v) 
DMSO. P2 was used for the competition assay with 10 nM of tracer and specified 
concentrations of SC monomer. Blank control (buffer), negative control (buffer and 
fluorescent peptide) and positive control (buffer, fluorescent peptide and SC monomer) 
were used for data standardisation to yield the extent of inhibition. Experiments were 
carried out in duplicate. Peptides used as competitors in this assay are listed in Table 
4.2. Majority of the peptides were acetylated to remove the positive charge from the N-
terminus and to mimic the main chain conformation of a protein, as these peptides are 
the binding regions of protein partners. Peptide 1 was not acetylated to assess the 
contribution the acetyl group has to the peptide binding. 
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4.2.2.2.1 Data analysis 
To generate the data points, the mP values were converted to per cent inhibition with 
the following equation: 






     …………………………………………. (5) 
where SC/P2 is the mP from the protein and fluorescent peptide alone, data point is the 
mP from the addition of the competing peptide, and the blank is the mP from the 
fluorescent peptide in isolation.  
Curves were fitted using the response vs. log[inhibitor] – variable slope algorithm in 
GraphPad Prism v5.01, with percent inhibition (%) on the Y-axis and log peptide 
concentration on the x-axis (µM). The Top was constrained to 100 and the Bottom to 0. 
The equation used was: 
 




     ……………………………………... (eq. 6) 
 
where Y is the percent inhibition (%), Top is the maximum percent inhibition (fixed at 
100%), Bottom is the minimum percent inhibition (fixed at 0%), log IC50 is the log of 
the concentration of competing peptide (µM) that gives a response half way between 
Top and Bottom , [X] is concentration of the SC and the HillSlope is the steepness of 
the curves (can be constrained to –1, indicating negative cooperative binding where one 
peptide is bound per binding site). From these results, the IC50 is extrapolated and 








     …………………………………………………………………... (eq. 7) 
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whereby, Ki is the equilibrium dissociation constant of the SC and competing peptide 
(µM), [R] is the concentration of SC (µM), KD is the equilibrium constant of the SC and 
tracer interaction (µM) and IC50 is the concentration of inhibitor required to cause 50% 
inhibition (µM).  The binding energy of the interaction is calculated using the Gibb’s 
free energy of binding (ΔG°) determined from the resulting KD: 
 
Δë° = -−Rîlnåñ     ……………………………………………………………... (eq. 8) 
 
whereby, R is the gas constant (1.98 × 10-3 kcal K–1 mol–1) and T is the temperature in 
K.   
 
4.2.3 MD simulation, molecular mechanics calculation 
The peptide AcQLDLF was modelled into the binding sites of SCs based on the crystal 
structure of the SCEco complex with this peptide (PDB ID 3Q4J).76 All dynamic 
trajectories were calculated by NAMD196 using the CHARMM27 all-atom force field. 
197,198 Structures were embedded in cubic water boxes (SCEco, 66 Å × 105 Å × 110 Å; 
SCEcl, 66 Å × 110 Å × 105 Å; SCPae, 110 Å × 110 Å × 64 Å; SCAbm-His6, 114 Å × 110 Å 
× 71 Å; and SCEfu-His6, 65 Å × 113 Å × 106 Å). Sodium and chloride ions were added 
(target concentration 100 mM) such that the systems had zero net charge. All 
simulations were run as NpT ensembles (temperature 310 K; pressure 101.325 kPa) 
with periodic boundary conditions. Temperature was controlled using Langevin 
dynamics (damping constant 5 ps–1). Pressure control used the Nosé-Hoover Langevin 
piston (period 100 fs; decay rate 50 fs). A multiple time-step approach was used with 1, 
2, and 4 fs for bonded, non-bonded and long-range electrostatic calculations, 
respectively. The Particle-mesh Ewald with a grid resolution of ≤1 Å was used to 
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calculate long-range electrostatic forces. All other non-bonded interactions were 
smoothly scaled to zero between 10 and 12 Å. All systems were subjected to energy 
minimisation (10,000 steps) prior to equilibration by MD. 
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 Binding pockets of solved ESKAPE SC structures 
All SC monomers have a binding pocket that is the site of interaction with 
protein-binding partners. The pocket is located between domains II and III on the 
C-terminal face of the monomer and consists of two sub-sites.195 Sub-site I is a wide 
pocket with the dimensions 8 Å × 10 Å × 8.5 Å deep.89 The residues lining the sub-site 
of SCEco are R152, L155, T172, G174, H175, R176, L177, P242, V247, S346, V360, 
and V361. Sub-site II is narrow and deeper than sub-site I, with the dimensions 14 Å × 
7.5 Å × 4.5 Å deep.89 The SCEco sub-site is shaped by the residues N320, Y323, V344, 
M362, P363, M364, R365 and L366. The main residues involved in the interaction with 
protein partners are located at the C-terminal ends of the !-sheets and "-helices of these 
domains, with some residues located on the interconnecting domain loop (Figure 4.3a). 
The electrostatics of this area was predominately neutral, with some charges around 
sub-site II (see section 3.3). 
From the crystal structures (see sections 3.3.2, 3.3.3, 3.3.4, and 3.3.5), the residues that 
line the pocket appear to be highly conserved, particularly in the Gram-negative SCs 
(Table 4.3), despite different degrees of sequence identity with SCEco (SCEcl, 95%; 
SCPae, 58%; SCAbm, 44%; SCAby 45%; and SCEfu-His6, 27%). SCEcl has an identical pocket 
to SCEco, while both SCPae and SCAbm-His6 have one substitution, V344N, in sub-site II. 
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This residue sits at the top of sub-site II and interacts predominately with the side chain 
of L2 of the QLDLF LM, which has previously been shown not to be significant to the 
binding of the LM in the SCEco binding pocket.76,80 The conservation of the peptide-
binding pocket in these species suggests that the mechanism of interaction is conserved 
with respective protein partners. 
In contrast, the SCEfu-His6 has the most differences when compared to the SCEco pocket 
(Figure 4.3b). The residue substitutions in sub-site I are: G174S, V247L, S346P, 
V360L and V361L. These are mostly aliphatic amino acid changes, with similar size 
side chains. Sub-site II changes include: V344I, M362T and M364V. Possibly the most 
important change is the M362T (in SCEfu-His6), as the Met residue at this position has 
been previously implicated in regulating interactions in the pocket. 78,80 M362 was 
shown in SCEco to be flexible in MD simulations when the pocket was unoccupied,78 
and acts as a “gate” that opens up between sub-site I and sub-site II.80 The L4F5 acts as 
an anchor to lock the M362 in an open conformation, allowing the Q1L2 motif to bind in 
sub-site II. 
Residue M362 will change to an open conformation once the L4F5 dipeptide is bound 
into sub-site I that then allows for the Q1 to interact in sub-site II.80 A previous study 
has suggested that Gram-positive SCs, particularly SCBsu and SCSau, may have a 
different mechanism of LM binding.75 These SCs have the same pocket as SCEfu-His6, 
except for the substitution T370L (the corresponding residue to SCEco M362; Table 
4.3). The Gram-positive SCs interaction with another consensus LM, QLVLGL, was 
approximately 1000-fold weaker than with the Gram-negative SCs.75 This suggests that 
either the T370L or other substitutions are important for the interaction. 
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Figure 4.3: Selected residues lining the binding pocket of SCs. (a) The structural 
alignment of the Gram-negative SCs: SCEcl (purple), SCPae (green) and SCAbm-His6 
(magenta). Residues with coloured labels, coloured according to the structure colours, 
are different to the equivalent residues in SCEco. (b) The Gram-positive SCEfu-His6 
binding pocket residues. Residues with red coloured labels are those that are different to 




4.3.1.1 Mutagenesis studies of pocket residues 
Mutagenesis studies of residues within the SCEco pocket have shown the significance of 
certain residues to interactions with binding partners. One study used chemical 
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cross-linking to show that the individual mutations in the SCEco pocket, G157S, V170M 
and P363S, impaired the interaction between SCEco and UmuD, UmuD$ and the catalytic  
core Pol III " subunit.199 Another mutation, G157C, has been shown to arrest 
reconstituted DNA replication assays by causing an accumulation of initiation  
 
Table 4.3: Residues lining the peptide binding pockets of different bacterial SCs. 
Residues that are identical to the equivalent residues in SCEco are in bold. Determined 
based on sequence alignments (Figure E1, Appendix). 
Sub-
site 
SCEco SCAbm SCAby SCPae SCEcl SCEfu SCSau SCBsu 
I R152 R156 R156 R152 R152 R158 R160 R159 
I L155 L159 L159 L155 L155 L161 L163 L162 
I T172 T176 T176 T172 T172 T176 T180 T179 
I G174 G178 G178 G174 G174 S180 S182 S181 
I H175 H179 H179 H175 H175 H181 H183 H182 
I R176 R180 R180 R176 R176 R182 R184 R183 
I L177 L181 L181 L177 L177 L183 L185 L184 
I P242 P258 P258 P242 P242 P248 P249 P250 
I V247 V263 V263 V247 V247 L253 L254 L255 
II N320 N336 N336 N321 N320 N328 N330 S337 
II Y323 Y339 Y339 Y324 Y323 Y331 Y333 Y340 
II V344 N360 N360 N345 V344 I352 M354 M355 
I S346 S362 S362 S347 S346 P354 P356 P357 
I V360 V376 V376 V361 V360 L368 L370 L371 
I V361 V377 V377 V362 V361 I369 I371 I372 
II M362 M378 M378 M363 M362 T370 L372 L373 
II P363 P379 P379 P364 P363 P371 P373 P374 
II M364 M380 M380 M365 M364 V372 I374 V375 
II R365 R381 R381 R366 R365 R373 R375 R376 
II L366 V382 V382 L367 L366 T374 T376 T377 
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intermediates on DNA.200 Additionally, deletion of the five C-terminal residues, 362-
MPMRL-366, disrupts the interaction with CLC Pol III % and γ/τ subunits, and to a 
lesser degree, the catalytic core Pol III " subunit.201 Furthermore, mutating P363, 
M364, R365 and L366 in SCEco to Ala compromised the interaction with the Pol III % 
and " subunits.69 These studies indicate the importance of these residues for the 
function of the pocket and the high conservation suggests that the interaction between 
the ESKAPE SCs subset and respective protein partners is conserved.  
 
4.3.2 Binding of QLDLF peptide 
The protein-binding partners of SCEco all interact in the peptide-binding pocket with a 
conserved LM, QLx1Lx2F/L (where S/D preferred at x1; x2 may be absent), found in its 
binding partners.90,91 The LM interaction with SCEco is the most extensively 
characterised,80,89,202 and interactions between the LM peptides and other bacterial SCs 
have been demonstrated.75,159 The contributions of individual residues in the LM to SC 
binding, however, have not been investigated outside of SCEco. In the present study, the 
binding of a fluorescently-labelled peptide (5FAM-Q1L2D3L4F5; “P1”) to the bacterial 
SCs was assayed by FP. From the co-crystal structure, the exact location and interaction 
of the pentapeptide in the peptide binding pocket of SCEco is known (Figure 4.1; PDB 
entry 3Q4J).76  
The affinity of P1 determined for SCEco (KD = 29 nM) was similar to that reported 
previously (KD = 70 nM),80 while the affinity to the other SC varied from low to mid nM 
(Table 4.4). The maximum number of binding sites available for each SC (Bmax) varied 
among the SCs, by 100–200 mP (SCEco has Bmax ~250 mP, Figure 4.4a). The Bmax 
should be similar amongst the bacterial SCs as the concentration was the same and the 
pocket is conserved — with one peptide binding site per monomer. The fluorophore in 
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the tracer could bind non-specifically to the SC, giving differences in Bmax. To 
determine if this was the case another tracer peptide was used, whereby residue D3 was 
substituted with Lys that was then labelled with 5FAM to produce 
Ac-Q1L2K(5FAM)3L4F5; “P2”. The co-crystal structure with the LM peptide (Figure 
4.1) showed the side chain of residue D3 is directed out of the pocket. Therefore, the 
5FAM-labelled K3 residue was hypothesised to be less prone to interact with the SC. 
The KD of P2 for SCEco was 80 nM, as determined previously.80 The affinity of P2 for 
SCEcl was 166 nM, while SCAbm, SCAby and SCPae had lower affinity with KD values in 
the range of 230–460 nM. SCEfu-His6 had an affinity similar to SCEco, at 87 nM. The Bmax 
is similar amongst the bacterial SCs with the P2 tracer (Figure 4.4b).  
 
 
Figure 4.4: Interaction of fluorescently-labelled peptides with SCs. (a) P1 and (b) P2, 
determined by FP experiments. SCEco, black; SCEcl, purple; SCPae, green; SCAbm, 
magenta; SCAby, orange; and SCEfu-His6, blue. Quadruplicates with error bars indicating 




Table 4.4: KD values in µM for binding of 5FAM-labelled peptides to SC, determined 
by FP experiments. 
 SCEco SCEcl SCPae SCAbm SCAby SCEfu-His6 
P1  0.029 0.063 0.070 0.350 0.430 0.697 
P2  0.080 0.166 0.460 0.280 0.230 0.087 
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Interestingly, the SCEfu-His6 had a similar affinity for P2 as SCEco. This suggests that the 
M362T substitution may not be negatively affecting the binding of the LM and that the 
substitutions throughout the pocket are not detrimental to the binding. The QLVLGL 
consensus LM interacts in the same manner as the QLDLF consensus LM.76,95,203 
 
4.3.3 Contributions of LM residues in the pocket 
The contributions of LM residues to the SCEco binding were characterised previously 
with Ala and Gly scanning. The same systematic approach was undertaken with the Ala 
mutants of the Ac0Q1L2D3L4F5, to assess the relative side chain contributions in the 
pockets of the subset of ESKAPE SCs. The binding affinities of the alanine mutants 
were measured using a FP competition-based assay, employing the 
fluorescently-labelled tracer P2 (see Table 4.4 for equilibrium dissociation constants). 
The inhibition of tracer binding to the SC was plotted against peptide concentrations to 
calculate the IC50 values. From this, the KD and Gibbs free energy (ΔG°) of the 
competing peptide interaction with the SC were calculated (Table 4.5). 
Generally, the patterns of peptide binding are similar for all SCs: the AcQLDLF peptide 
affinity ranges between 0.7–3.2 µM, whereas the un-acetylated peptide binds 40–50-
fold weaker with SCEco, SCEcl and SCAbm and 115–220-fold weaker with SCPae, SCAby 
and SCEfu-His6 (Table 4.5). The acetyl group mimcs the main chain of a protein, and 
provides a carbonyl oxygen that can accept a H-bond. From these results, an additional 
H-bond has formed providing a tighter interaction between the AcQLDLF peptide and 
the ESKAPE subset SCs. Affinity for the Gram-negative SCs decreased 65–90-fold 
with the Q1A mutation, whereas the affinity for the SCEfu-His6 pocket decreased only 16-
fold. Replacing L2 or D3 with Ala had little affect on the affinity of the peptide for the 
various SCs, particularly the D3 substitution, when compared to the AcQLDLF peptide.  
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Table 4.5: Comparison of Ala scan on LM consensus peptide binding to the SCs. 
 SCEco SCAbm SCAby SCPae SCEcl SCEfu-His6 
QLDLF 
IC50 (µM) 79.4 70.2 392.2 674.1 87.6 1250.0 
KD (µM) 39.7 29.3 178.3 321.0 54.8 367.6 
∆G  
(kcal mol–1) 
–6.0 –6.2 –5.1 –4.7 –5.8 –4.7 
AcQLDLF 
IC50 (µM) 1.7 1.7 1.8 2.7 1.7 10.9 
KD (µM) 0.9 0.7 0.8 1.7 1.1 3.2 
∆G  
(kcal mol–1) 
–8.2 –8.4 –8.3 –7.8 –8.1 –7.5 
AcALDLF 
IC50 (µM) 122.9 108.0 138.8 292.3 155.1 178.3 
KD (µM) 61.5 45.0 63.1 139.2 96.9 52.4 
∆G  
(kcal mol–1) 
–5.7 –5.9 –5.7 –5.2 –5.5 –5.8 
AcQADLF 
IC50 (µM) 15.4 17.4 36.5 22.0 15.8 112.2 
KD (µM) 7.7 7.3 16.6 10.5 9.9 33.0 
∆G  
(kcal mol–1) 
–6.9 –7.0 –6.5 –6.8 –6.8 –6.1 
AcQLALF 
IC50 (µM) 1.7 1.7 1.8 2.4 1.5 4.7 
KD (µM) 0.9 0.7 0.8 1.1 0.9 1.4 
∆G  
(kcal mol–1) 
–8.2 –8.4 –8.3 –8.1 –8.2 –8.0 
AcQLDAF 
IC50 (µM) 37.7 157.6 318.0 175.3 74.2 649.7 
KD (µM) 18.9 65.7 144.5 83.5 46.4 191.1 
∆G  
(kcal mol–1) 
–6.4 –5.7 –5.2 –5.5 –5.9 –5.1 
AcQLDLA 
IC50 (µM) 212.4 278.7 492.5 > 1000 146.5 > 1000 
KD (µM) 106.2 116.1 223.9 an.d. 91.6 n.d. 
∆G  
(kcal mol–1) 
–5.4 –5.3 –5.0 n.d. –5.5 n.d. 
AcQL 
IC50 (µM) > 1000 > 1000 > 1000 > 1000 > 1000 > 1000 
KD (µM) n.d. n.d. n.d. n.d. n.d. n.d. 
∆G  
(kcal mol–1) 
n.d. n.d. n.d. n.d. n.d. n.d. 
AcLF 
IC50 (µM) 226.0 209.4 156.0 228.0 337.0 186.2 
KD (µM) 113.0 87.3 70.9 108.6 210.6 54.8 
∆G  
(kcal mol–1) 
–5.4 –5.5 –5.6 –5.4 –5.0 –5.8 
an.d., not determined as the IC50 was > 1000 µM. 
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This suggests that sub-site II of the SCEfu-His6 pocket may be amenable to binding 
peptides with residues other than Gln at position 1. 
The greatest effect on binding affinity to all SCs was observed for peptides where L4 
and F5 were substituted for Ala. The L4A mutant had a 20-fold decrease in affinity of 
interaction with SCEco, and a ~40-fold decrease with SCEcl. With the other SCs, the 
affinity decreased 50–180-fold. The F5A mutant resulted in the greatest decrease in 
affinity for the SCs pockets, with > 84-fold decrease and no binding observed for SCPae 
and SCEfu-His6. It is clear from these results that Q1, L4 and F5 are vital for interactions 
within all the ESKAPE SCs assessed. Furthermore, F5 appears to have the greatest 
impact on binding affinity of the LM in the pocket. To assess the contributions in the 
two sub-sites, the Q1L2 and L4F5 dipeptides were examined individually. There was no 
interaction observed between the subset of ESKAPE SCs and the AcQL dipeptide, 
while a weak interaction was observed with the AcLF dipeptide (5-fold weaker 
compared to AcQLDLF with SCEfu-His6 and 40–190-fold weaker in the rest). 
Additionally, it appears from these results that the Gln at position 1 is not as essential 
for binding into the SCEfu-His6 binding pocket, as in the other SCs, due to the similar 
affinities observed with the AcLF and AcALDLF peptides. 
The co-crystal structure shows that the Q1, L4 and F5 residues are buried directly into 
the two sub-sites and our observations show that these residues are essential for the 
interaction. Analysis of two dipeptides binding shows that sub-site I can bind the L4F5 
without the rest of the LM, while sub-site II cannot bind the Q1L2. This is consistent 
with our knowledge of the LM interaction in the SCEco pocket: sub-site I must be 
occupied first for LM interactions with sub-site II to occur.80 As the pockets are well 
conserved, this data suggests that the mechanism of interaction is conserved within 
these other bacterial species. 
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4.3.3.1 Putative LMs from ESKAPE partner proteins 
For PPI hubs such as the SC, there needs to be a hierarchy of interaction that allows for 
the exchanging of protein when needed. By doing so, the SC governs the interplay of 
DNA replication and repair proteins to the DNA. The competition of binding involves 
conservative substitutions in the LMs of binding partners that affect the affinity for the 
pocket, typically being 0.5–10 µM,190,192 and the dynamics of the system to allow the 
different proteins to come in close vicinity of the SC. 
The partner proteins of SCs from bacteria other than E. coli are less studied, but due to 
the importance of this protein for cell survival and metabolism, it is expected that the 
interactions are largely conserved. Through sequence alignments, the Q1, L4 and F5 
residues appear to be conserved across the bacterial species-binding partners (Figure 
4.5).90,91 The Gram-negative Pol III " subunit (DnaE), Pol III % subunit (HolA), and 
DNA Pol V (UmuC) have a LM sequence in the same location in the protein as in the 
E. coli homologs. Interestingly, not all the LMs have the Q1 residue, but may contain 
either His, Ile, Ser, Asn or Thr (Figure 4.5).  
Not all protein partners have LMs at the same location in the protein sequence as 
E. coli, e.g. Pol III # subunit where the LM is located either ~60 amino acids from the 
C-terminus or at the extreme C-terminus. The Pol III # subunit (dnaQ) in the 
Acinetobacter spp. is combined with the RNAse-H1 protein (in a single gene), with a 
LM sequence occurring at the C-terminus of the gene. Another example is the homolog 
of the Pol III # subunit in Gram-positive bacteria, which occurs at the C-terminus of the 
PolC gene that contains a replicative DNA polymerase domain. In these proteins, there 
are potential LMs at the C-terminus, suggesting that the PolC interactions with SCs are 
conserved in Gram-positive bacteria. For all the LMs, the L4F5 or L4x2F5 dipeptides are 
well conserved. However, it is important to note that the Pol III " subunit in some 
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bacterial species, for example in M. tuberculosis, has a proofreading polymerase and 
histidinol phosphatase-domain and therefore do not contain an Pol III # subunit.204 





Figure 4.5: Alignment of the regions containing the putative SC LMs from members of 
the DnaE, DnaQ, PolC, PolB, HolA, DinB and UmuC families. Representative 
sequences from fully sequences genomes are shown. Amino acids that aligned with the 
reported E. coli LM from other bacteria are highlighted in bold. *Indicates the terminal 
amino acid in the protein sequence.  
 
 
interaction with the LM. It would be interesting to test the peptides with the Gram- 
positive SCs that have the M362L substitution, i.e. SCBsu and SCSau, to ascertain 
whether the contributions and affinities are similar. As the other residues lining the 
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pocket are well conserved with SCEfu-His6, this could narrow down the importance of this 
one amino acid substitution for its affect on the mechanism of interaction. 
 
 
4.3.4 Sub-site II buried water network 
As the reproducibility of native SC crystals was low, soaking-in experiments with the 
AcQLDLF peptide were not performed. Instead, several attempts were undertaken to co-
crystallise the AcQLDLF peptide with the subset of ESKAPE SCs, however, no crystals 
diffracting to resolutions < 3 Å were obtained. To overcome this, we turned to 
modelling and MD simulations. Starting with the hypothesis that LM-binding is similar 
in SCs, the structure of SCEco in complex with AcQLDLF (PDB entry 3Q4J) was used 
as a template to model the peptide in the binding sites of SCPae, SCEcl, SCAbm-His6 and 
SCEfu-His6. These models were then subjected to MD simulations to probe the dynamics 
and stability of the peptide interactions in the binding pockets. The SCEco/AcQLDLF 
complex was also simulated for comparison. 
In all cases, the peptides and SCs had a consistent radius of gyration and the global root-
mean-square-fluctuation (RMSF) over the course of the 20 ns (Figure 4.6), and showed 
no structural deviations. The L4F5 dipeptide remained bound in the sub-site I pocket, 
making several contacts with the hydrophobic residues lining the sub-site. Residue F5 
sampled multiple conformations within the pocket. A buried water molecule (W1) was 
observed within sub-site II from the beginning of all the simulations. This structural 
water molecule was observed in the crystal structures and is crucial for stabilizing the 
buried Q1 side-chain in sub-site II in SCEco. In the cases of SCEco, SCPae and SCAbm-His6, 
water molecules equivalent to W1 in SCEco were observed in the simulations, restrained 
by H-bonds to M362 O, P363 O and N320 N (SCEco numbering) (Figure 4.7a–c).  
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Interestingly, two water molecules were observed in sub-site II of SCEcl and SCEfu-His6 
after 20 ns MD simulation (Figure 4.8). W1 was buried in the cavity from the start of 
the simulation, and W2 binds after 5 ns for SCEcl or 13 ns for SCEfu-His6 (Figure 4.8c,d). 
Both water molecules interact with the Q1 side-chain. Water molecules W1 and W2 form 
H-bonds with each other, and W2 forms an additional H-bond with H175Ecl and H181Efu-
His6. The Q1 side chain can also form a H-bond with the peptide backbone of N320. The  
 
 
Figure 4.6: MD simulations of AcQLDLF LM complexed with (a) SCEco, (b) 
SCAbm-His6, (c) SCPae, (d) SCEcl, and (e) SCEfu-His6. The top row indicates the radius of 
gyration of the protein (coloured according to structure), and peptide (cyan). Bottom 
row shows the RMSF of both protein and peptide over 20 ns, coloured according to the 
top row.  
 
 
L2-NH group H-bonds with the backbone of P363 (and corresponding residues) to help 
maintain the conformation of Q1 (Figures 4.7 and 4.8). 
Typically, proteins utilise buried water molecules to provide better van der Waals 
interactions.205 The buried water molecule(s) facilitate a H-bonding network within 
sub-site II and allow for the interaction between SC and Q1 in the partially hydrophobic 
cavity. The buried water molecules and their interactions represents the kinetic barrier 
for ligand association/dissociation in sub-site II, and may have an impact on ligand  
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Figure 4.7: Arrangement of residues and AcQ1L2 dipeptide in sub-site II after 20 ns MD 
simulation.  The left panels show the buried water molecule, the hydrogen bond 
network formed and the right panels show the Q1 buried in the cavity and the 
interactions it makes with both the water molecule and the neighbouring residues. (a) 
SCEco, (b) SCAbm-His6, and (c) SCPae. Graphs show the bond distance (Å) between the Q1 
Oε1 and W1 over the course of the simulation (ns) for  (d) SCEco, (e) SCPae and (f) 
SCAbm-His6. The LM peptide subset in (d) shows the average B-factor distribution over 
the simulation.  
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Figure 4.8: Arrangement of residues, AcQ1L2 dipeptide and W1 and W2 in sub-site II of 
SCEcl and SCEfu-His6.  The left panels show the buried water molecule, the H-bond 
network formed and the right panels show the Q1 buried in the cavity and the 
interactions it makes with both the water molecule and the neighbouring residues. (a) 
SCEcl and (b) SCEfu-His6. Graphs show the bond distance (Å) between the Q1 Oε1 and W1 
(left) and W2 (right) over the course of the simulation (ns) for (c) SCEcl and (d) 
SCEfu-His6.  
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affinity.80 Steered MD simulations were used to observe that W1 was retained in 
sub-site II of SCEco after the Q1L2 residues had dissociated.80  
The results here can be interpreted in terms of the differing affinities observed in the 
LM consensus mutation studies (see section 4.3.3). The L4F5 dipeptide fully occupies 
sub-site I, however, this would not be possible if the sidechains were reduced to Ala. 
The methyl group of Ala is unable to form the stabilizing multiple hydrophobic contacts 
formed by Leu and Phe, significantly reducing the affinity of the peptide in the pocket. 
Similarly, Q1A mutation would result in the loss of the vital interaction with the buried 
water molecule in sub-site II, leading to the decreased affinity of the LM peptide for the 
pocket. The carbonyl group of the AcQLDLF peptide acetyl group contributes in an 
additional H-bond interaction with the group corresponding to R365NHEco conserved in 
all SCs. The peptide H-QLDLF, where the N-terminus is unacertylated, unsurprisingly 
resulted in the > 40-fold weaker affinity observed amongst the ESKAPE subset SCs.  
The side chains of L2 and D3, in all simulations, did not form significant interactions 
with SCs. The L2A and D3A LM peptides would not show a significant loss of 
interaction. Furthermore, the D3 side chain was facing into solution and sampling 
various orientations over the 20 ns simulation. By substituting the Asp for Lys in the P2 
tracer, it can be speculated that the Lys side chain and 5FAM fluosrecent probe would 
not form an interaction with the SCs. Conversely, N-terminally labeling the LM peptide 
with the fluorescent probe could cause steric hindrance in some SCs or binding in others 
due to the probes position. The resdiues outside of the binding pocket, those that would 
interact with the probe, less conserved and would give varying results of binding. This 
agrees with the results observed from the FP binding experiments (see section 4.3.2).  
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4.4 CONCLUSIONS 
 
PPIs govern a plethora of biological processes that are essential for cell survival. The 
SC is a PPI hub that acts as a tether to DNA for other protein partners involved in DNA 
replication and repair. The partner proteins interact in a binding pocket on the surface of  
the SC through a short LM sequence. Our knowledge of these interactions has been 
predominately through studies with SCEco. Here, the details of the interaction between 
the LM and the ESKAPE SCs subset were investigated.  
The LM binding site of the ESKAPE SCs is largely conserved, in terms of structure and 
the composition of amino acids that line the pocket, with only one non-conservative 
substitution each in the pockets of SCPae and SCAbm-His6 relative to the SCEco structure. 
The SCEfu-His6 has four substitutions in sub-site II, with the most noteworthy being the 
M362T substitution. All pockets were able to recognise the QLDLF LM and from the 
Ala scan, the three residues that are crucial for the interaction are Q1, L4 and F5. 
Additionally, the same anchor-based model of peptide binding appears to apply to these 
SCs as previously seen in SCEco,73 whereby sub-site I must be occupied with the L4F5 
dipeptide for the ‘M362’-gate to open up and allow interaction of the Q1 into sub-site II. 
While the SCEfu-His6 did interact approximately 10-fold weaker with the QLDLF 
compared to SCEco, the same trend in binding was observed, despite the M362T 
substitution. The MD simulations of the ESKAPE SCs subset and LMs suggested that a 
conserved, buried water molecule lies in sub-site II that stabilised the Q1 side-chain, and 
mediated interactions in the pocket through a H-bonding network.  
Other Gram-positive SCs, such as SCBsu and SCSau, have a similar pocket to SCEfu-His6 
including the M362T substitution relative to SCEco, and these SCs have previously been 
shown to interact much more weakly with the LM than SCEfu-His6.75 It would be 
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interesting to conduct the same Ala scan on peptides binding to these SCs to ascertain 
whether the anchor-based mechanism is still conserved, particularly given that the 
putative LMs from the respective protein partners is similar. 
In conclusion, the LM recognition and mechanism of interaction within the binding 
pocket appears to be conserved between SCEco and ESKAPE SCs subset. This strongly 
suggests that new antibacterials developed using SCEco as a template will have 
broad-spectrum activity. While transient interactions, such as those that occur in the SC 
binding pocket, are challenging for inhibitor discovery, the conserved nature of these 
interactions across these different bacteria, and the importance of this protein for 









DEVELOPMENT OF INHBITIORS FOR 
THE ESKAPE SC PROTEIN-BINDING 
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5.1 INTRODUCTION 
 
The increase of antibiotic resistance has prompted research into new bacterial targets for 
innovative antibiotics. Many factors have contributed to the rise of multi-drug resistant 
human-pathogenic bacteria, including antibiotic misuse, acquisition of antibiotic 
resistance genes, and genetic mutations.15,206,207 There are now reported cases of E. coli 
strains harbouring the mcr-1 gene with resistance to colistin, a “last resort” antibiotic, in 
China,208 Malaysia, USA209 and a multitude of European and South American 
countries.210-217 The situation, globally, is that minor injuries can become life 
threatening if no new antibiotics or treatments are established. 
For an inhibitor to target intracellular interactions, like the bacterial SC, it must be able 
to cross the cell membrane, survive inside the cell long enough to act on its target, not 
be exported by efflux pumps, etc.193 Peptide-based inhibitors generally are inappropriate 
as they can be rapidly degraded by the proteases produced by the human body, do not 
diffuse well through cells and are regarded as poor oral drugs.218-222 Natural products 
have been the main source of antibiotics clinically used. Yet, identifying new classes of 
antibiotics is becoming increasingly difficult.223 There are two main methods for 
discovering starting compounds for the design of inhibitors of protein pockets: HTS and 
FBS. The relatively new FBS has been successful in the development of a PPI inhibitor 
in the treatment of B-cell lymphoma 2.193 
SC inhibitors have been identified from HTS, FBS and natural toxins (Table 5.1). The 
small molecule inhibitors that have been structurally characterised with the SC bind into 
sub-site I of the binding pocket only.72,73,89,202,224 The Streptomyces-derived compound 
griselimycin exhibits activity against Mycobacterium tuberculosis by blocking the 
peptide binding site of the SCMtu. It covers the whole binding pocket, rather than 
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protruding into the sub-sites, and is > 1000-fold more active against SCMtu and SCMsm 
than against SCEco.74 SocB is a toxin in the toxin-antitoxin system of Caulobacter 
crescentus, that blocks the binding pocket of the SC, disrupting DNA replication.225 
FBS has been used to identify a lead scaffold THC for inhibiting SCEco.72,73 
 
Table 5.1: Known inhibitors of the SC binding pocket.  






Biphenyloxime ether Peptidomimetic SCEco 202 
SocB Toxin bSCCcr 225 
Griselimycin Natural product SCMtu, SCMsm, SCEco 74 
P7, P14 Peptidomimetic, 
unnatural amino 
acid incorporation 
SCEco, SCPae, SCMtu 76 
Vedaprofen aNSAID SCEco 224 
Bromfenac NSAID SCEco 224 
Carprofen NSAID SCEco 224 
THC-derivatives Small molecule 
(FBS) 
SCEco 72,73 
aNSAIDS, nonsteroidal anti-inflammatory drugs; bSCCcr, SC from C. Crescentus 
 
 
THC-based compounds have antibacterial activity against E. coli, A. baylyi, B. subtilis 
and S. aureus.72 The THC scaffold has been optimised, forming a series of five 
derivatives that have been shown to inhibit E. coli in DNA replication assays in vitro 
and mimic the anchor-based binding of the L4F5 dipeptide.72,73 
As described in Chapter 3, hPCNA and gp45 proteins are structurally similar to the 
bacterial SCs, and have the same function as PPI-hubs involved in DNA replication and 
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repair (sections 3.3.7.1 and 3.3.7.2). The hPCNA, like bacterial SCs, recognises a 
consensus sequence (PCNA-interacting protein box (PIP-box; Table 5.2) from protein 
partners that interacts in a hydrophobic groove in each monomer. While the recognition 
sequence is different, there is potential that inhibitors developed specifically for the 
bacterial SC could have the same interaction with the hPCNA. 
 
5.1.1 Aims of this Chapter 
This chapter aims to ascertain whether the five THC-derivatives are potential 
broad-spectrum bacterial SC inhibitors. FP competition assays will be utilised to 
determine if the compounds can out-compete the LM for binding into SC pockets. 
Additionally, the compounds will be assessed to determine any interaction between the 
compounds and hPCNA. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Proteins  
SCs were overproduced and purified as described in section 3.2.2 and stored at –80°C, 
then dialysed against the appropriate buffer before use. The hPCNA and Acp21 peptides 
were a generous gift from Dr John Bruning at the University of Adelaide.  
 
5.2.2 Compounds 
THC-derived compounds (Table 5.3) were synthesised by Dr. Louise Whittell and Mr. 
Alexander Martyn under the supervision of Dr. Michael Kelso from the School of 
Chemistry, University of Wollongong.72,73 The compounds were of > 95% purity as 
confirmed by mass spectrometry. MarvinSketch was used for drawing, displaying and  
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Table 5.2: The majority of the hPCNA protein partners and their PIP-box. Conserved 
residues are in bold. 
Protein partner Function PIP-box Reference 
p21 Cell cycle regulation QTSMTDFY 101,226 
DNA Pol % DNA replication and repair  QVSITGFF 181 
DNA Pol ! Base excision repair QLQKV-HF 227 
DNA Pol η Translesion synthesis  MQTLESFF 228,229 
DNA Pol κ Translesion synthesis KHTLDIFF 228,229 
DNA Pol ι Translesion synthesis KKGLIDYY 229 
DNA Pol # DNA replication and repair QKKISELF 230,231 
RNase H2B RNA nuclease MKSIDTFF 232 
MCMT  QTTITSHF 233 
MSH3 Mismatch repair QAVLSRFF 234 
MSH6 Mismatch repair QSTLYSFF 234 
UNG2 Base excision repair QKTLYSFF 235 
ING1 Tumor suppressor QLHLVNYV 236 
WRN ATP-dependent DNA 
helicase and exonuclease 
QWKLLRDF 237 
XPG Nucleotide excision repair QLRIDSFF 238 
FEN1 DNA replication nuclease 
and maturation of Okazaki 
fragments 
QGRLDDFF 181,238 
Topo-II" Separates daughter DNA 
strands 
QTTLAFKP 239 
LigI Maturation of Okazaki 
fragments 
QRSIMSFF 240,241 
Rfc1 Loads/unloads PCNA -MDIRKFF 179,240 
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Table 5.3: THC-derived compounds used in this study. Blue regions indicate the 
changes compared to the previous compound.  
Cpd Structure aMW bHAC ccLogP dcLogD 
1e 
 
249.7 17 2.84 0.0 
5a 
 
364.8 25 1.55 –4.5 
5b 
 
409.2 25 1.82 –4.6 
5l 
 
454.9 32 4.05 –2.4 
5m 
 
454.9 32 4.05 –2.4 
6c 
 
643.9 43 4.83 –1.8 
aMW, molecular weight in Da 
bHAC, heavy atom count 
ccLogP is the calculated partition coefficient of the compound in its neutral form. 
Calculated using MarvinSketch, based on molecular structure. 
dcLogD is the calculated distribution coefficient of a compound, taking into account 
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characterising the chemical structures, version 16.6.13, 2016, ChemAxon 
(http://www.chemaxon.com). 
 
5.2.3 FP assay 
FP inhibition assays with the subset of ESKAPE SCs was performed as described in 
section 4.2.2. 
 
5.2.3.1 hPCNA-p21 binding assay 
All FP experiments were conducted with a POLARstar Omega plate reader using non-
treated black sterile 384-well plates (Corning, USA). A fluorescent peptide containing 
the PIP-box motif (5FAM-p21s: 5FAM-GRKRRQTSMTDFYH; 300 nM) and hPCNA 
in the buffer 35 mM HEPES, pH 7.4, 10% (v/v) glycerol, 1 mM DTT, 0.07% (v/v) 
Nonidet P-40 were used. DMSO was added to the experiments to a final concentration 
of 10% (v/v). Blank control (buffer alone) and negative control (buffer and fluorescent 
peptide) were used for data standardisation. To generate data points for saturation curve, 
the hPCNA protein was serially diluted from 10 µM to 0.0098 µM, and 0 µM 
concentration. Experiments were carried out in quadruplicates. Curves were fitted using 
the binding-saturation curve fitting from GraphPad Prism v5.01 (GraphPad Software, 
USA). 
 
5.2.3.2 hPCNA-p21 competition assay 
All fluorescence experiments were conducted with a POLARstar Omega plate reader 
(BMG Labtec) using non-treated black sterile 384-well plates (Corning, USA). The 
buffer contains 35 mM HEPES pH 7.4, 1 mM DTT, 10% (v/v) glycerol, 0.007% (v/v) 
Nonidet-P40. 5FAM-p21s (see section 5.2.3.1) was used as the fluorescently-labelled 
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tracer to a total of 300 nM, with 800 nM hPCNA calculated as the monomer. A blank 
control (buffer), negative control (buffer and tracer) and positive control (buffer, tracer 
and hPCNA) were used for data standardisation to yield the extent of inhibition. To 
generate data points for the dose-response curve the compound was serially diluted 
from 10 to 0.020 µM, and 0 µM concentration, in DMSO prior to addition to the 
reaction mixture, with a total DMSO concentration of 10% (v/v). The peptides p21-WT 
(GRKRRQTSMTDFYHSKRRLIFS) and p21s (GRKRRQTSMTDFYH) were used as 
the positive controls for inhibition. Experiments were carried out in duplicates.  
 
5.2.3.3 Data analysis 
The Ki of the inhibitors were determined as per the protocol outlined in section 
4.2.2.2.1.  
 
5.2.3.3.1 Ligand Efficiency metrics 
Ligand Efficiency (LE) metrics are a guideline used during the optimisation of 
fragments hits to leads, to determine the drug-likeness of compounds.243,244 These 
metrics were initially proposed to compare binding energy and affinity per atom,245,246 
and now have evolved to incorporate lipophilicity,247 molecular mass, polar surface 
area, physicochemical properties248,249 and functional group contributions.243 By 
analysing the free binding energy per non-hydrogen atom, we are able to attribute the 
entire intermolecular interaction to the ligand alone by quantifying each heavy atom 
(HA) contribution to binding (eq. 9).246 
 
LE = ∆G°/HA 
      = –RTln(KD)/HA      ………………………………..………………………… (eq. 9)  
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LE defined in this way does not account for differences in atom types or functionality, 
leading to a number of other metrics. Lipophilic ligand efficiency (LLEAT) describes the 
difference between the activity and lipophilicity, utilizing the distribution partitioning 
coefficient cLogD.247 The ∆G* is the modified free energy change that subtracts the 
non-specific lipophilic component — the energy accompanying the conversion of a 
ligand from an aqueous environment to a hydrophobic environment (eq. 10).248 The 
cLogD is the estimated specificity of a molecule binding to the target relative to 
partitioning into 1-octanol, and considers both the ionized and un-ionised forms of the 
compound.247 The LLEAT (eq. 11) is the scaled to be comparable to LE. 
 
∆G* = ∆G° – ∆Glipo 
        = RTln(KD) + RTcLogD      ..……………………………………………… (eq. 10) 
LLEAT = 0.11 – ∆G*/HA      .………………………………………………….... (eq. 11)  
 
The lipophilicity-corrected ligand efficiency (LELP, eq. 12) value is a lipophilic metric 
that indicates the price of LE paid in lipophilicity.249  
 
LELP = cLogP/LE      .……………………………………………………...…... (eq. 12)     
 
This takes into account a molecules’ affinity for the target, size, and its target 
specificity. The cLogP is the calculated partition coefficient for the neutral compound 
between octanol and water.248 LELP has been used to identify successful leads from 
FBS. The ideal value is close to 0 in the positive range as the affinity for the target 
improves.249 
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5.3 RESULTS AND DISCUSSION 
 
5.3.1 Inhibition of SC binding pocket with THC-derivatives 
It has previously been demonstrated that the THC-derivatives (Table 5.3) bind to 
sub-site I of SCEco.73 Here, four of these derivatives with the highest affinity for the 
SCEco binding pocket were assayed for inhibition of the ESKAPE SC subset interactions 
with a LM peptide. The FP assay described previously (section 4.2.2.2) was employed, 
with the P2 tracer, to quantify binding of the compounds to ESKAPE SCs subset.  
The THC compound, 1e, had similar affinity among the binding pockets of the 
Gram-negative SCs. The Ki range was 46–65 µM (Table 5.4). The affinity of 1e was 
highest with SCEfu-His6 at 11 µM. From the SCEco/1e crystal structure (Figure 5.1a), 1e 
binds directly into sub-site I, fully occupying it. The Cl atom is anchored in a pocket 
formed by M362, S346, V360, L177 and V274 — the same site that L4 of the LM 
occupies (see Chapter 4; PDB entry 4OVF).73 The carboxylic acid moiety forms 
H-bonds with P242 and R152 and occupies the F5-binding region of sub-site I. As sub-
site I of the SCEcl, SCAbm-His6 and SCPae binding pockets are identical to SCEco, 1e may 
bind in a similar fashion, giving the similar Ki. A possible reason for the tighter 
interaction of 1e with SCEfu-His6 is the M362T substitution. The carbonyl group of the 
M362 backbone is essential for the Cl interaction, and the additional hydroxide group of 
the Thr side chain could provide another point of interaction with the Cl atom. The 
G174S substitution in SCEfu-His6 may have the similar affect. 
The glycine carboxylate groups of 5b and 5a were predicted to occupy the region of the 
LM D3 side chain.16 An increased affinity for the SC pockets was observed with both 
compounds compared to 1e. The bromo- analogue 5b was slightly more potent than the 
chloro- analogue 5a, as observed previously with SCEco.73 The SCEco/5b crystal structure 
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shows the glycine carboxylate sitting atop G174 and H-bonding to the nitrogen of the 
H175 imidazole ring and to the R152 guanidinium group (Figure 5.1b; PDB entry 
4OVH).73 The positioning of the glycine carboxylate suggested that the compound 
could be improved by extending it into sub-site II to fully occupy the binding pocket of 
the SCs. A phenyl group was attached, and produced two enantiomers: the 
R-enantiomer (5l) and the S-enantiomer (5m). With the Gram-negative SCs, there was 
an increase in affinity for the pocket for 5l compared to 5b with SCEco and SCEcl; 
however, the affinity slightly decreased with SCPae, SCAbm and SCAby. 5l also bound 
~3-fold weaker in the latter SCs compared to SCEco and SCEcl. 5m affinities for the SC 
pockets ranged from 4.2–13 µM, slightly higher than 5l in all SC, except SCEco and 
SCEcl (Table 5.4). The co-crystal structure of SCEco/5l (Figure 5.1c; PDB entry 4PNU)73 
showed the phenyl group pointing towards sub-site II, suggesting opportunities to 
extend the molecule into the second sub-site and enhancing affinity. Conversely, the co-
crystal structure of SCEco/5m (Figure 5.1d; PDB entry 4PNW)73 revealed a 
conformational change in the loop region H148-Y154, termed the DNA-binding loop 
(DB-loop; see section 5.3.1.2), initiating the opening of what was termed sub-site III.73 
This region is conserved in the Gram-negative SCs (Table 5.5), and the affinities are 
similar to SCEco suggesting that sub-site III is formed upon binding of 5m to these SC 
pockets. SCEfu-His6 appears to have higher affinity with the 5l and 5m compounds than 
the Gram-negative SCs (Ki values of 1.6 and 1.9 µM, respectively). 
It is possible that the DB-loop rearrangement may not occur with the SCEfu-His6 as the 
relevant residues are not conserved. In the Gram-negative SCs, the loop has the 
sequence QDVR[F/Y]Y (F in the Acinetobacter spp.) and in SCEfu-His6 it is HESRPI 
(Table 5.5). The rearrangement is attributed to the swapping of the positions of SCEco  
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Table 5.4: Inhibition of the SCs by the THC-derivatives, determined by FP 
experiments.  
Compounds 
 1e 5b 5a 5l 5m 6c 
SCEco 
IC50 (µM) 123 12 19 2.3 6.3 15 
Ki (µM) 61.5 6.0 9.5 1.2 3.2 7.5 
LE (kcal mol–1) 0.34 0.28 0.27 0.25 0.23 0.16 
LLEAT 0.45 0.50 0.49 0.40 0.38 0.29 
LELP 8.35 3.10 6.74 16.2 17.6 30.2 
SCAbm 
IC50 (µM) 111.0 7.1 17.0 15.0 6.3 40.0 
Ki (µM) 46.3 3.0 7.1 6.3 2.6 16.7 
LE (kcal mol–1) 0.35 0.30 0.28 0.22 0.24 0.15 
LLEAT 0.46 0.52 0.50 0.37 0.39 0.28 
LELP 8.11 2.98 6.50 18.4 16.9 32.2 
SCAby 
IC50 (µM) 143.0 12.0 23.0 18.0 13.0 92.0 
Ki (µM) 65.0 5.5 10.5 8.2 5.9 41.8 
LE (kcal mol–1) 0.33 0.29 0.27 0.22 0.22 0.14 
LLEAT 0.44 0.51 0.49 0.37 0.37 0.27 
LELP 8.61 3.04 6.74 18.4 18.4 34.5 
SCPae 
IC50 (µM) 105.0 8.5 20.0 13.0 9.8 40.0 
Ki (µM) 50.0 4.1 9.5 6.2 4.7 19.0 
LE (kcal mol–1) 0.34 0.29 0.27 0.22 0.23 0.15 
LLEAT 0.45 0.51 0.49 0.37 0.38 0.28 
LELP 8.35 3.04 6.74 18.4 17.6 32.2 
SCEcl 
IC50 (µM) 100 5.4 16 4.3 4.2 17 
Ki (µM) 62.5 3.4 10.0 2.7 2.6 10.6 
LE (kcal mol–1) 0.34 0.30 0.27 0.24 0.24 0.16 
LLEAT 0.45 0.52 0.49 0.39 0.39 0.29 
LELP 8.35 2.98 6.74 16.9 16.9 30.2 
SCEfu-His6 
IC50 (µM) 38.9 an.d. an.d. 5.6 6.5 an.d. 
Ki (µM) 11.4 n.d. n.d. 1.6 1.9 n.d. 
LE (kcal mol–1) 0.40 n.d. n.d. 0.25 0.24 n.d. 
LLEAT 0.51 n.d. n.d. 0.40 0.39 n.d. 
LELP 7.1 n.d. n.d. 16.2 16.9 n.d. 
an.d., not determined as there was no more compound available. 
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residues Q149-D150 and R152-Y153. Assuming the rearrangement is conserved; 
H155-E156 and R158-P159 would need to swap in SCEfu-His6. Co-crystallisation of 5m 
with SCEfu-His6 has proven unsuccessful thus far. 
 
Table 5.5: Alignment of the residues of the DB-loop 
region in bacterial SCs. Residues in bold are identical 













The co-crystal structure of SCEco/5m additionally revealed that the phenyl group 
occupied half of sub-site III.73 To see if sub-site III could be fully occupied, 5m was 
modified with an addition of a 3,5-dichloroisonicotinamide on the para-position of the 
phenyl group, producing 6c. However, the affinity decreased at least 3-fold in all SCs. 
Upon further inspection of the crystal structure of SCEco/5m (Figure 5.1d), the 
meta-position of the phenyl ring may be the optimal place for the functional group to sit 
in the sub-site without disrupting the phenyl groups position. There have been several 
attempts to solve the co-crystal structure of 6c and SCEco, however, soaking in the 
compound led to destruction of crystals and co-crystallisation has only resulted in 
density in sub-site I that appears to be the THC scaffold. The  
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Figure 5.1: Co-crystals of THC-derived compounds in SCEco binding pocket: (a) 1e 
(PDB entry 4OVF), (b) 5b (PDB entry 4OVH), (c) 5l (PDB entry 4PNU) and (d) 5m 
(PDB entry 4PNW). H-bonds are indicated by dotted line, with bond lengths shown in 
Å. Residues lining the pocket are coloured according to location: sub-site I (yellow), 
bordering residues (orange) and sub-site II (red). 
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3,5-dichloroisonicotinamide moiety may be causing disorder on the rest of the 
compound making it non-observable in an electron density map. Additionally, several 
attempts at co-crystallisation of compound 5m with the ESKAPE SCs subset have 
resulted in crystals that diffract only to low resolution (> 4 Å). 
 
5.3.1.1. The Halogen-binding pocket 
Halogen atoms can form stabilizing bonds with proteins, particularly with the peptide 
backbone, through halogen bonding.250-253 This form of non-covalent interaction 
contributes favourably to protein-ligand, or protein-inhibitor in this case, interactions 
and the strength of the interaction increases with the electron-withdrawing ability of the 
groups bound to the halogen.250,251 Halogen bonding is the non-covalent interaction 
between a halogen atom (a Lewis acid), and a Lewis base (oxygen, nitrogen, sulfur and 
aromatic rings).250,251 The anisotropic distribution of electrostatic potential around 
halogen substituents gives them the ability to act as both electrophiles and nucleophiles: 
electrophile in the ‘head on’ orientation (halogen bonding) and nucleophile in the ‘side 
on’ orientation (H-bonding).251 The H-bond interactions between halogen atoms and 
NH3 and OH groups can occur even when the intermolecular separation is > 3.4 Å.251 
Increasing the size and polarizability of the halogen atom has been correlated with an 
increased strength of interaction.250-252,254  
The SC halogen-binding pocket is part of sub-site I, the site where L4 of the L4F5 
sub-motif binds. The SCEco residues M362, S346, V360, L177 and V247 line this 
pocket (Figure 5.2a). In all the THC-derived co-crystal structures, the carbonyl group 
of V360 backbone points ‘head on’ to the halogens (Cl/Br) and the amide groups of 
L177 and M362 engage ‘side on’ to the halogens (Figure 5.2b). Both halogen- and 
H-bonding are required for the halogen to be anchored in the pocket. From a structural 
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alignment of SCEco with the SCEfu-His6 structure, the residues lining this pocket are not 
all conserved but there is potential for the halogen and H-bonding to be maintained 




Figure 5.2: Halogen-binding pocket of SCEco. (a) Superimposition of THC-derived 
compounds 1e (gray), 5b (cyan), 5l (magenta) and 5m (green) bound into the halogen 
pocket (b) The interactions made by the halogen atom with the pocket residues. (c) 
Structural alignment of SCEco/1e (gray) and SCEfu-His6 (blue) pocket residues interacting 
with the halogen for all structures. Dotted lines indicate the potential halogen and H-





between the halogen and the OH-group of the Thr side chain. The similar affinities 
among the different SCs suggest that the same halogen-binding pocket is utilised, and 
that the overall binding modes are the same. 
 
5.3.1.2 Conformational change and inhibiting the SC-DNA interaction 
The SC encircles dsDNA to maintain its function as a protein recruiter to the DNA. 
Consequently, there are several points of interaction with DNA: (i) the Arg and Lys 
lining the interior channel of SC interacting with the phosphate backbone of the DNA, 
and (ii) the key interaction of the DNA with the DB-loop.  
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The co-crystal structure of the SCEco with a DNA template (Figure 5.3a) showed 
specifically the interaction of the SC residues Q149 and R24 with the phosphate 
backbone of the DNA. These are two solvent exposed residues that act as anchor points 
for the DNA, most likely contributing to the ~22° angle of the DNA passing through the 
channel. Mutating both theses residues to Ala resulted in greatly reduced in vitro DNA 
replication activity and clamp loading, with the double mutant highly deficient in both 
assays.156 As the KD for the interaction of both Q149A and R24A mutants with the 
clamp loader (35 and 40 nM, respectively) was similar to apo-SCEco (25 nM), the defect 
was postulated to be due to the weakened interaction with DNA. 156 
The Q149 residue is located in the DB-loop, that is situated next to sub-site I of the 
binding pocket (Figure 5.3b). The DB-loop in SCEco, 148–HQDVRYY–154, has been 
implicated in the interaction with dsDNA – mutating the residues in the loop to Ala 
weakens SC/DNA interactions and impairs clamp loading assays.255 Much like the 
Q149A SC mutant, the DB-loop to Ala SC mutant had a similar affinity for the clamp 
loader complex (43 nM) as the wild-type SC (27 nM).255 Q149 is implicated in sensing 
DNA presence and interacting with D150, which then contacts R152.64,256 Importantly, 
the Q149 residue is mostly conserved in the Gram-negative ESKAPE SCs (Figure 
5.3c). In SCEfu-His6, the corresponding residue in the sequence alignment is H155; 
however, residue Q154 is located in the corresponding position in the structural 
alignments (Figure 5.3c and Figure E.1, Appendix). Other Gram-positive SCs, such 
as SCSau and SCBsu, have either a Thr of Ser residue at these positions (Table 5.5) that 
have the potential to form a single H-bond with the phosphate backbone.257,258  
As described previously (see section 5.3.1), binding of 5m triggers movement of the 
DB-loop in such as way that the Q149 would no longer interact with the phosphate 
backbone. The hydroxyl groups of Y153 and Y154 face towards the compound further 
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from the DNA, and the R152 residue has shifted towards the DNA (away from sub-site 
I) (Figure 5.3d). Given the high level of sequence conservation, similar movements in 
this loop have a high chance of occurring in other Gram-negative SCs. In the Gram-
positive SCs, the Y153 and Y154 are not conserved, and compound-induced movement 
of the DB-loop should be regarded as less certain. A crystal structure of this complex 
would allow confirmation. Unfortunately, all crystals obtained diffracted to low 
resolution and therefore the structure remains unsolved. 
 
5.3.1.3. LE of compounds and Lipinski’s ‘rule of 5’  
A high affinity for a target is not the only parameter to consider when optimizing a lead 
compound to a drug. There are numerous physicochemical properties of drugs that 
contribute in determining solubility, membrane permeability, target promiscuity, 
toxicity, metabolic stability.243 The Lipinski ‘rule of five’ is a set of four parameters that 
describe the absorption and permeability of an inhibitor and were used as guidelines 
when optimizing compounds to oral drug candidates.259 The rule states that a compound 
should have no more than 5 H-bond donors (expressed in the sum of OHs and NHs), a 
MW below 500 Da, no more than 10 H-bond acceptors (Ns and Os) and a cLogP less 
than 5. 
The cLogP property reflects the lipophilicity of a compound. This is the calculated 
partition coefficient for the neutral compound between octanol and water, and takes into 
account the size, polarity and H-boning of a compound.248 Those compounds that have a 
high lipophilicity (greater than 5) are more likely to have off target binding, poor 
solubility and metabolic clearance.247,248 For an oral drug, the ideal cLogP is between 0 
and 3. A cLogP over 4 could result in a toxic accumulation in fatty tissues. 260 cLogD is 




Figure 5.3: Interaction between DNA and Q149 residue of SC. (a) alignment of 
ESKAPE SCs to the SCEco/DNA co-crystal structure. (b) Interaction between the DNA 
and DB-loop of SCEco, shown in sticks representation. (c) Corresponding Q149 residue 
in ESKAPE SCs highlighted: SCEcl (Q149; purple), SCPae (Q149; green), SCAbm-His6 
(Q159; magenta), and SCEfu-His6 (Q154; blue). (d) Alignment of SCEco/DNA (white) and 




similar to cLogP, except all neutral and ionised forms of the molecule are accounted 
for. An increase of the cLogD above 0 will in theory decrease renal clearance of the 
compound and increase the metabolic clearance.261 These numbers should be regarded 
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as guides only: there have been several compounds whose parameters lie outside those 
recommended in these rules and are available in the clinical setting. The characteristics 
of these inhibitors are: MW > 500 Da, cLogP 0–7.5, > 5 H-bond donors and > 10 H-
bond acceptors.262 Examples of orally active approved drugs are rifampicin (targeting 
RNAP), etoposide (targeting DNA topoisomerase-IIb) and simeprevir (targeting 
Hepatitis C virus NS3/4A protease).262 
The LE metrics are a relatively new concept used as a guideline for lead 
optimisation.243,245 LE has been used to quantify the average contribution of a HA in a 
compound binding, in terms of Gibb’s free energy, to the protein target.243  
The LLEAT describes the difference between activity and lipophilicity to give the 
estimate of the compound binding to the target relative to partitioning in 1-
octanol.243,245,248 It is used in conjunction with LE for lead optimisation, as it is scaled to 
be comparable to LE. Compounds with both LE and LLEAT ≥ 0.3 are likely to be 
optimised to potent molecules with the appropriate oral drug physicochemical 
properties.  
LELP is a metric that accounts for lipophilicity as well as MW influence.249 It indicates 
the LE price paid in lipophilicity. The optimal value for LELP during lead discovery is 
–10 < LELP > 10, the range defined by the LE value of 0.3 and –3 < cLogP > 3. LELP 
is only negative when cLogP is negative and the greater the absolute value of LELP, the 
less drug-like the compound. To keep within the Lipinski zone, the LELP would need to 
be less than 16.5. 
With the THC-derived compounds, all compounds except for 6c are within the  
Lipinski ‘rule of 5’ zone (see Table 5.4). 6c is very close to the cLogP cut-off and is 
considered too large for an oral drug. Additionally, 6c is consistently < 0.3 in both LE 
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and LLEAT across all the SCs, whereas the other compounds have a LLEAT > 0.3 despite 
some having a LE ranging from 0.22–0.40.  
 
5.3.2 THC-derivatives do not block the hPCNA/p21 interaction 
The overall structural similarity between bacterial SCs and the human homologue, 
hPCNA (section 3.3.7.1), is an important consideration in designing antibiotics 
targeting the SC. There is a possibility that the THC-derivatives can inhibit the 
hPCNA-binding pocket, as the interaction requires halogen and H-bonding to the 
peptide backbone of the pocket residues (see section 5.3.1). Therefore, the THC-derived 
compounds were tested for interaction with hPCNA. Dr John Bruning from the 
University of Adelaide kindly donated hPCNA and two peptides from the PIP-box of its 
tightest known binding partner, p21 (QTSMTDFY).181 p21 is a member of a family of 
cdk-inhibitory proteins that are able to directly inhibit DNA replication through a tight 
interaction with hPCNA via its C-terminus that makes it distinct from other 
cdk-inhibitors.101,263,264 This interaction results in G1 and G2 cell cycle arrest.265 
5.3.2.1 hPCNA-p21 competition assays with THC-derivatives 
The FP assay had to be optimised for the p21/hPCNA interaction. The two peptides, 
p21-WT and p21s differ in length. P21s is the shortest region of the p21-WT peptide 
that can functionally bind to the pocket of hPCNA.226 The fluorophore-labelled peptide 
p21s (5FAM-p21s) was used as the tracer in the assay and hPCNA was serially diluted 
to measure the binding affinities (Figure 5.4). The KD of the interaction was determined 
to be 214 nM, similar to the reported KD of 121 nM.181,266 
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Figure 5.4: Interaction between 5FAM-p21s and hPCNA, determined by FP. Assay 
conducted in quadruplicates, with error bars indicating the standard error of the mean.  
 
 
To design the competition assays, acetylated p21-WT and p21s peptides were used as 
inhibitors of the hPCNA-binding pocket. The p21-WT had an IC50 of 284 nM 
(corresponding to a KD of 60.4 nM using eq. 7), which is in good agreement with 
previous studies.226,228 The p21s peptide was a slightly weaker binder with an IC50 of 
750 nM. The corresponding KD is 160 nM, which is similar to the affinity of 
5FAM-p21s for hPCNA. The THC-derivatives were used in the same competition 
assay, and the same concentration range. There was no inhibition of the hPCNA binding 




5.3.2.2 Binding modes of consensus peptides to hPCNA and bacterial SCs are different 
The structural differences between hPCNA and the SCs include the number of 
monomers and the number of domains within each monomer (see section 3.3.7.1); 
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Figure 5.5: Inhibition of hPCNA-5FAM-p21s interaction, as determined by FP. Data 
points and curves are: p21-WT ( ), p21s ( ), 1e ( ), 5a ( ), 5b ( ), 5l ( ), and 5m (
). Conducted in duplicates with error bars indicating the standard error of the mean. 
 
 
however, the organisation of each domain is similar despite a low sequence identity 
(~10% between hPCNA and SCEco). Similarities lie at the protein-protein binding 
interface: both proteins recognise a consensus sequence in binding partners that 
interacts in a hydrophobic groove in the C-terminal domain. The p21-PIP box of the 
p21-WT peptide was found to bind specifically to a hydrophobic groove (Figure 5.6a) 
while the rest of the peptide runs along the interconnecting domain loop towards the 
N-terminus of the monomer, forming a two stranded !-sheet with the loop. The 
N-terminal pentapeptide motif, GRKRR, was disordered in the crystal structure but 
thought to form salt bridges with the residues 256-EDEEGS-261 of hPCNA.101  
A study from Zheleva and co-workers aimed to identify the smallest region of the 
p21-WT peptide that can inhibit PCNA activity by using fluorimeter-based competition 
assays.226 The smallest peptide needed for inhibition of the interaction between p21-WT 
and hPCNA was KRRQTSMTDFYH.  The PIP-box peptide alone showed no 
inhibition. Thus it appears that both occupation of the hydrophobic pocket and the 
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positively charged motif are required for the interaction. The PIP-box residues that are 
vital for the interaction are Q144, M147, F150 and Y151, as mutating any to alanine 
abolishes or attenuates binding to hPCNA.226,266 Furthermore, the K141, R142 and 
R143 residues of the pentapeptide motif are vital for the interaction, suggesting that salt 
bridges with the protein must be important for p21 interaction. Much like the LM-SC 
interaction, the Q144 residue of the PIP-box requires a water-mediated H-bonding 
network for it to remain buried in the hydrophobic pocket (Figure 5.6b,c).101 However, 
unlike the LM-SC interaction, the Y151 residue requires a water-mediated H-bonding 
network in the hydrophobic groove (Figure 5.6b). Mutating Y151 to phenylalanine saw 
a 3-fold decrease in Ki for the hPCNA in the p21-WT peptide.266 The hydroxyl group of 
the tyrosine is needed to participate in the water-mediated H-bonding interactions but 
the residue also establishes hydrophobic, electrostatic and van der Waals interactions 
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Figure 5.6: p21-PIP box peptide interaction compared to SCEco and LM interaction. (a) 
PIP-box, QTSMTDFYH, bound into hPCNA binding pocket (PDB entry 1AXC).101 
This interaction is located between the two domains of the hPCNA monomer. (b) 
Schematic of contacts between the p21s peptide and hPCNA and (c) SCEco and LM, 
QLDLF. Residues of the peptides are shown in vertical letters. The residues in the gray 
box in (b) are those that are thought to have salt bridge interactions with the protein. 
Residues in the black boxes indicate hydrophobic interactions. Blue circles show water-
mediated interactions. O and N at the end of the residues indicate either carbonyl or 
amine interaction, respectively, with the peptide backbone.  
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5.4 CONCLUSIONS 
 
A series of THC-based compounds have been identified as inhibitors of ESKAPE SC 
protein-binding pockets. The similarities of the binding pocket and the DB-loop of the 
ESKAPE SCs subset to the SCEco suggest a similar mechanism of interaction with 
inhibitors. Furthermore, the compounds appear to bind to bacterial SCs, and do not 
inhibit the interactions that the human homologue, hPCNA, makes with relevant 
binding partners. Also, differences in the structure of the binding pockets, consensus 
sequence of bound peptides and mode of peptide binding between the bacterial and 
human homologues further suggest that inhibitors developed for the bacterial SCs 
binding pocket should not inhibit the hPCNA binding pocket. These inhibitors are 
promising scaffolds for further generations of broad-spectrum SC inhibitors. 
Research is now underway to identify functional groups to extend the phenylalanine 
group of 5m to fully occupy sub-site III and ultimately extending the compound into 
sub-site II so as to completely inhibit the pocket. Ideally, the inhibitor should be more 
potent than the binding partners (KD ~ 1 µM).  
As many essential cellular proteins interact in this pocket by the same mechanism, 
blocking the pocket doesn’t inhibit the function of just the SC protein, but at least ten 
other proteins, conferring inhibition to DNA replication and repair, leading to eventual 
cell death. What makes this an attractive target is that if the bacteria were to survive by 
mutations in the binding site, it would need to have simultaneous complementary 
mutations in all binding partners, which is statistically highly unlikely. There is a 
relatively low abundance of SCs in the cell at any given time, between 300 and 
600,94,154 indicating that there does not need to be much compound for inhibition of all 
SCs thereby decreasing the potential of off-target affects. The data presented here 
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strongly suggest that THC-based SC inhibitors will not inhibit hPCNA/p21 interactions. 
Therefore, the THC-derived inhibitors are unlikely to interfere with the human DNA 
replication and repair and cell cycle control. 






CHAPTER 6.     
CONCLUDING REMARKS AND FUTURE 
OUTLOOKS
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The findings described in this Thesis contribute to the understanding of the structure 
and function of SCs from pathogenic bacteria. In Chapter 3 the structures of members 
of the ESKAPE SCs determined by X-ray crystallography were described. They were 
shown to be conserved with respect to previously determined SC structures despite 
variable sequence identity. Furthermore, the subunit exchange dynamics of the SCs, as 
assessed by mass spectrometry, highlighted the interactions required for dimerization of 
SCs. Chapter 4 explored the relationship between the structure of the protein binding 
pocket and binding functionality with respect to the consensus LM sequence. The 
mechanism of LM binding was proposed to be identical to SCEco, with the same vital 
interactions observed in the binding pockets. Chapter 5 investigated the question of 
whether these protein-binding pockets could be targeted for the development of a 
broad-spectrum inhibitor. Based on their affinities for the representative SCs and the 
unobserved interaction with the human homologue hPCNA, THC-derivatives appear to 
be excellent candidates for the development of broad-spectrum antimicrobials.  
The overall structure of the ESKAPE SCs subset is highly conserved. Some differences 
were observed in the overall shape of the inner channel: Gram-negative SCs studied 
have a circular channel and the Gram-positive SCs channel tends to be elliptical. In 
subunit exchange experiments, the formation of heterodimers was observed only 
between the Gram-negative SCs and SCEco and not with the SCEfu-His6. Possible reasons 
for the latter include differences in structures and sequences at interface regions 
between Gram-positive and Gram-negative SCs. The interactions of Gram-positive SCs 
could be probed with subunit exchange experiments with, for example, SCEfu-His6 and 
SCBsu (where the domains and chemical and structural arrangement at the SCBsu dimer 
interface is similar to SCEfu-His6). The formation of heterodimers between the SCs 
suggest conservation of the interface structures and residues, as well as the existence of 
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SCs as open dimers in solution, like SCEco.189 The dynamics and ability to exchange 
subunits of SCs could be further explored by assessing wild type and His6 tagged 
variants of the same bacterial SC for formation of heterodimers in the concentration 
range used. Consequencely, the dimer interface can be targeted for small-molecule 
inhibitors due to the conservation of the monomer interactions. Preventing the 
dimersation of the SC abolishes the function of the SC as a processivity factor and 
protein anchor to DNA, due to monomeric SC not able to remain interacting with the 
DNA.60,79 
The LM interaction in the protein-binding pocket appear similar amongst the ESKAPE 
SCs modelled and SCEco; and despite the substitution M362T in SCEfu-His6, it showed 
similar LM-binding characteristics to SCEco. It would be interesting to conduct the Ala 
scan on LM-binding to the Gram-positive SCs, particularly those where the 
corresponding residue to M362 is either a Leu or Val (e.g. SCBsu and SCSau). This would 
assist in determining if the same anchor-based mechanism is conserved, especially 
given that the Gram-positive LMs are similar to Gram-negative LMs. Employing these 
fluorescence polarisation-based binding and competition assays with putative LMs from 
respective protein partners would (i) provide insight into the hierarchy of the proteins 
interacting at the binding pocket of the ESKAPE subset SCs and, (ii) discern whether 
these interactions and affinities are conserved. Furthermore, the putative LMs could be 
cross-measured amongst the different SCs (e.g. the LM of E. coli " subunit with all the 
SCs), to greater assess the conserved nature of the different SC pockets and explore the 
apparent difference in LM-binding between Gram-negative and Gram-positive SCs. 
Of the THC-derivatives, 5m was found to be the most promising inhibitor with 
broad-spectrum activity. It bound with similar affinity to the ESKAPE SCs tested and, 
due to the high conservation of the binding pocket, appears likely to have the same 
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binding conformation. Furthermore, no interaction of 5m with hPCNA was detected. 
Research is currently underway to find suitable functional groups at the meta-position 
of the phenyl ring to fully occupy sub-site III, which may lead to an increase in potency.  
Affinity for a protein target is not the only parameter that should influence the potency 
of a drug. Another parameter is the inhibitors residence time, in other words the period 
of time the inhibitor remains bound to the target.267 This is dependent on the association 
rate and, more significantly, the dissociation rate. Dissociation rates can be measured 
effectively through off-rate screening with the surface plasmon resonance (SPR) 
techniques.267-269 Briefly, this technique detects a change in mass on a surface in real 
time to capture the binding association and dissociation events, and from this the 
affinity of the interaction can be calculated. The dissociation rates can vary from fast 
(e.g. transient interactions) to immeasurably slow (e.g. stable covalent complexes).  For 
the SCs binding pocket, an inhibitor with a slow dissociation rate has a high chance of 
preventing the re-association of protein partners. The interactions in the SC binding 
pocket are dynamic and transient – every protein that interacts here has fast-on/fast-off 
kinetics.203 Therefore, producing an inhibitor that has fast-on/slow-off kinetics and a KD 
< 10 µM will out-compete protein partners for binding to the pocket. As an example, the 
Pol III " subunit of the catalytic core has the ability to synthesise DNA in the absence 
of the SC, however, it will dissociate from the DNA after ~20 nucleotides.58 As the 
whole E. coli genome is 4.6 Mbp,30 the catalytic core will not be able to efficiently 
replicate the genome in isolation, attenuating DNA replication, and the bacteria as a 
result cannot enter the cell division phase to produce daughter cells. Blocking the 
binding pocket with an inhibitor will prevent the interaction between the Pol III " 
subunit and the SC leading to the arrest in DNA replication.  
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Along with SPR, another technique that could be utilised to study SC inhibitor 
interactions is isothermal titration calorimetry (ITC). This technique directly measures 
the thermodynamic properties of an interaction and can be used to determine the 
enthalpic and entropic contributions of binding free energy.270-272 As inhibitor binding 
affinity is a function of the binding enthalpy and entropy, high affinity cannot be 
achieved unless both the binding enthalpy and entropy are optimised.270 ITC is popular 
for use in drug design and has been utilised during the optimisation of the THC-
derivatives.72,73 The advantage of this technique compared to FP is that the inhibitors 
binding to the target can be directly measured, and can be used in competition assays. 
Additionally, SPR and ITC can be used for the interaction with the hPCNA to confirm 
the results obtained with FP, and address the whether the compound interacts at other 
positions on the hPCNA. 
Further experiments are needed to test the effects of inhibitors on both Gram-negative 
and Gram-positive bacteria for antibacterial activity by determining the minimum 
concentrations that can prevent bacterial growth (minimum inhibitory concentrations). 
These experiments involve the drug permeating the bacterial cell wall and locating the 
drug target to eventually cause cell death. Of the THC-derivatives used in this thesis, 
compound 1e is the only one tested for antibacterial activity against E. coli, A. baylyi, B. 
subtilis and S. aureus and was found to be active against all four species.72 This 
indicates that the THC-scaffold is able to permeate the cells of Gram-negative and 
positive bacteria. Gram-negative bacteria have an outer membrane that creates an 
additional permeability barrier that generally impedes access of drugs to intracellular 
targets, while Gram-positive bacteria do not have this outer membrane but have a 
thicker peptidoglycan layer compared to Gram-negative bacteria.16,273,274 One reason for 
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the higher prevalence of resistant Gram-negative bacteria, compared to Gram-positive, 
is the outer membrane.274  
Once the binding characterisation and bactericidal affects have been established through 
the experiments mentioned previously, the antibiotic resistance mechanism of the lead 
compounds can be explored. In an elegant study by Kling and colleagues74, a natural 
product, griselimycin,  was found to be an inhibitor of SCMtu and SCMsm. This was 
identified after culturing the bacteria in the presence of increasing concentrations of 
griselimycin, sequencing the chromosome and uncovering the amplification of the dnaN 
gene (encoding the SC). This then led to SPR and crystallisation studies of SCMtu and 
SCMsm with the griselimycin to confirm the inhibition of SC binding pocket in 
Mycobacteria. The project explored in this Thesis would eventually require a similar 
experimental procedure with the THC-derivatives and ESKAPE pathogens to identify 
(i) the resistance rate and (ii) the mechanism of resistance.  
Finally, while LE metrics are helpful in predicting a compound’s propensity for off-
target effects during lead optimisation, cytotoxicity assays with human cell lines is an 
experimental means of measuring this. Briefly, the compound is titrated against the 
human cells and incubated for a period of time (e.g. 72 h) before the assay is developed 
with a metabolic dye (e.g. Alamar Blue, MTT).275–278 The assay is usually 
colourimetric, with the dye being a different colour for metabolically dead and intact 
cells, assessing cell viability. As such, the absorbance can be measured to provide a 
numerical value through which the percentage of non-viable cells, and subsequently the 
IC50, can be calculated. 
While protein-protein interactions are considered difficult targets for the discovery of 
effective inhibitors,193 the conserved nature of these interactions and the importance of 
the SC for bacterial cell survival makes the SC an attractive target for the development 
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of broad-spectrum antibacterial agents.  The work in this thesis has contributed to the 
knowledge of how the ESKAPE SCs function in their respective bacterium, by 
determining the structure-function relationship with the consensus LM and identifying a 
new series of inhibitors that interact similarly in the conserved bacterial protein binding 
pockets. These inhibitors are promising scaffolds for further generations of a compound 
to potentially fully occupy sub-sites I, II and III in SCEco, and a high possibility for the 
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Table A.1: Primers used for construction of expression vectors. 
Primer Oligonucleotide Sequence (5$ to 3$) Plasmid Used 
pJ434_F CTCGAAAATAATAAAGGGAAAATCAG pJ434 plasmids 
PCR 
pJ434_R TGGTAGTGTGGGGACTC pJ434 plasmids 
PCR 
NED640 TCCTGAAGAACGTCATCGCCCAG pJ434:82302 
colony PCR 
NED641 TGGGCGATGACGTTCTTCAGGAC pJ434:82302 
colony PCR 
NED642 CTATTGATCGTGCGAGCCTGCTG pJ434:82302 
colony PCR 
NED643 CAGCAGGCTCGCACGATCAATAG pJ434:82302 





NED675 CGAAAGGATCAGTCGAAAGACTGG pJ251:114400 
PCR 
P3 CGACTCACTATAGGGAGACCACAAC   pETMSCIII F 
P4 CCTTTCGGGCTTTGTTAGCAG   pETMSCIII R 
P9 GGCAGCATTCAAAGCAGAAG pND706 F 
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Table A.2: List of plasmids constructed in this work. 
Gene Parental Vector Expression Vector Plasmid 
A. baumannii dnaN Genomic DNA pETMSCIII apFD1596 
pFD1596 pND706 pAM2170 
A. baylyi dnaN Genomic DNA pETMSCIII bpAR1349 
 pAR1349 pND706 pAM2169 
P. aeruginosa dnaN pJ434:114402 pND706 pAM2118 
E. cloacae dnaN pJ434:114401 pND706 pAM2119 
E. faecium dnaN pJ251:114400 pETMSCIII pAM2203 
S. aureus dnaN pJ434:82302 pND706 pAM2120 
 pAM2120 pETMSCIII pAM2194 
aConstructed by Dr Fay Dawes 
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Figure B.1: Schematic of the monomer structural arrangement of (a) SCAbm-His6, (b) 
SCPae, (c) SCEcl, and (d) SCEfu-His6. The secondary structural elements of "-helices are 
shown as circles and !-strands as arrows, with the direction shown. Differences 
compared to SCEco are highlighted in red. N- and C-terminus are labelled with N and C 
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Figure C.1: Native state mass spectra of the SCs used in the subunit exchange 
experiments. Relative abundance as a percentage on the Y-axis and m/z on the X-axis. 
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Figure D.1: Subunit exchange in 1 M NaCl between SCEco-His6 (grey circles) and SCAbm 
(magenta circles). Equimolar concentrations of SC (2.5 µM) were mixed and dialysed in 
30 mM Tris-HCl pH 7.6, 1 M NaCl, 10 mM MgCl2, 1 mM DTT at 30 °C. Samples of 
50 µL were taken at specified time points and dialysed extensively in 200 mM 
ammonium acetate pH 7.6, 1 mM DTT at 4 °C. From this, 3 µL aliquots were 
withdrawn and analysed by positive ion nanoESI-MS. Yellow circles indicate the peaks 
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Figure D.2: Subunit exchange in 1 M NaCl between SCEco-His6 (grey circles) and SCAby 
(orange circles). Equimolar concentrations of SC (2.5 µM) were mixed and dialysed in 
30 mM Tris-HCl pH 7.6, 1 M NaCl, 10 mM MgCl2, 1 mM DTT at 30 °C. Samples of 
50 µL were taken at specified time points and dialysed extensively in 200 mM 
ammonium acetate pH 7.6, 1 mM DTT at 4 °C. From this, 3 µL aliquots were 
withdrawn and analysed by positive ion nanoESI-MS. Yellow circles indicate the peaks 
corresponding to the heterodimer. The three most abundant charge states are shown. 
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Figure D.3: Subunit exchange in 1 M NaCl between SCEco-His6 (grey circles) and SCPae 
(green circles). Equimolar concentrations of SC (2.5 µM) were mixed and dialysed in 30 
mM Tris-HCl pH 7.6, 1 M NaCl, 10 mM MgCl2, 1 mM DTT at 30 °C. Samples of 50 
µL were taken at specified time points and dialysed extensively in 200 mM ammonium 
acetate pH 7.6, 1 mM DTT at 4 °C. From this, 3 µL aliquots were withdrawn and 
analysed by positive ion nanoESI-MS. Yellow circles indicate the peaks corresponding 
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Figure D.4: Subunit exchange in 1 M NaCl between SCEco-His6 (grey circles) and SCEcl 
(purple circles). Equimolar concentrations of SC (2.5 µM) were mixed and dialysed in 
30 mM Tris-HCl pH 7.6, 1 M NaCl, 10 mM MgCl2, 1 mM DTT at 30 °C. Samples of 
50 µL were taken at specified time points and dialysed extensively in 200 mM 
ammonium acetate pH 7.6, 1 mM DTT at 4 °C. From this, 3 µL aliquots were 
withdrawn and analysed by positive ion nanoESI-MS. Yellow circles indicate the peaks 
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Figure D.5: Subunit exchange in 1 M NaCl between SCEco (grey circles) and SCEfu-His6 
(blue). Equimolar concentrations of SC (2.5 µM) were mixed and dialysed in 30 mM 
Tris-HCl pH 7.6, 1 M NaCl, 10 mM MgCl2, 1 mM DTT at 30 °C. Samples of 50 µL 
were taken at specified time points and dialysed extensively in 200 mM ammonium 
acetate pH 7.6, 1 mM DTT at 4 °C. From this, 3 µL aliquots were withdrawn and 
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Figure E.1: Sequence alignment of ESKAPE SCs. The residues highlighted DB-loop 
(green), sub-site I (yellow), sub-site II residues (red), bordering residues (orange), 
dimeric interface residues (blue). The numbers refer to the SCAbm sequence.  
